{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "9f492008",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Primary Outcome Measures</th>\n",
       "      <th>Secondary Outcome Measures</th>\n",
       "      <th>Other Outcome Measures</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00080951</td>\n",
       "      <td>Irinotecan, Fluorouracil, Leucovorin, and Oxal...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>tumor response rate, Up to 5 years</td>\n",
       "      <td>time to progression, Up to 5 years|overall sur...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT02495051</td>\n",
       "      <td>Esophageal Atresia: Metaplasia, Barrett</td>\n",
       "      <td>The frequency of Barrett's esophagus (BE) has ...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Gastroesophageal Reflux|Esophagus, Barrett</td>\n",
       "      <td>presence of gastric and / or intestinal metapl...</td>\n",
       "      <td>presence of esophagitis or anomalies at the an...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00023751</td>\n",
       "      <td>Surgery With or Without Chemotherapy and Radia...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>disease-free survival, Up to 5 years</td>\n",
       "      <td>overall survival, Up to 5 years|colostomy-free...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00017212</td>\n",
       "      <td>DX-8951f in Treating Patients With Metastatic ...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Esophageal Cancer|Gastric Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01288612</td>\n",
       "      <td>Comparative Effectiveness of Endoscopic Assess...</td>\n",
       "      <td>The hypothesis of this study was that the comp...</td>\n",
       "      <td>YES</td>\n",
       "      <td>Barrett's Esophagus</td>\n",
       "      <td>Percentage of Subjects Who Agreed to Participa...</td>\n",
       "      <td>Rate of Successful Intubation, The rate of suc...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT00080951  Irinotecan, Fluorouracil, Leucovorin, and Oxal...   \n",
       "1  NCT02495051            Esophageal Atresia: Metaplasia, Barrett   \n",
       "2  NCT00023751  Surgery With or Without Chemotherapy and Radia...   \n",
       "3  NCT00017212  DX-8951f in Treating Patients With Metastatic ...   \n",
       "4  NCT01288612  Comparative Effectiveness of Endoscopic Assess...   \n",
       "\n",
       "                                       Brief Summary Study Results  \\\n",
       "0  RATIONALE: Drugs used in chemotherapy, such as...            NO   \n",
       "1  The frequency of Barrett's esophagus (BE) has ...            NO   \n",
       "2  RATIONALE: Drugs used in chemotherapy use diff...            NO   \n",
       "3  RATIONALE: Drugs used in chemotherapy use diff...            NO   \n",
       "4  The hypothesis of this study was that the comp...           YES   \n",
       "\n",
       "                                   Conditions  \\\n",
       "0                           Colorectal Cancer   \n",
       "1  Gastroesophageal Reflux|Esophagus, Barrett   \n",
       "2                           Colorectal Cancer   \n",
       "3            Esophageal Cancer|Gastric Cancer   \n",
       "4                         Barrett's Esophagus   \n",
       "\n",
       "                            Primary Outcome Measures  \\\n",
       "0                 tumor response rate, Up to 5 years   \n",
       "1  presence of gastric and / or intestinal metapl...   \n",
       "2               disease-free survival, Up to 5 years   \n",
       "3                                                NaN   \n",
       "4  Percentage of Subjects Who Agreed to Participa...   \n",
       "\n",
       "                          Secondary Outcome Measures Other Outcome Measures  \n",
       "0  time to progression, Up to 5 years|overall sur...                    NaN  \n",
       "1  presence of esophagitis or anomalies at the an...                    NaN  \n",
       "2  overall survival, Up to 5 years|colostomy-free...                    NaN  \n",
       "3                                                NaN                    NaN  \n",
       "4  Rate of Successful Intubation, The rate of suc...                    NaN  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Importing modules\n",
    "import gensim\n",
    "from gensim.utils import simple_preprocess\n",
    "from gensim.parsing.preprocessing import STOPWORDS\n",
    "from nltk.stem import WordNetLemmatizer, SnowballStemmer\n",
    "from nltk.stem.porter import *\n",
    "import numpy as np\n",
    "np.random.seed(2018)\n",
    "import nltk\n",
    "import pandas as pd\n",
    "import os\n",
    "import openai \n",
    "\n",
    "os.chdir('../../..')\n",
    "\n",
    "# Read data into papers. Please change directory to re-run\n",
    "papers = pd.read_csv('C:/Users/PC/Downloads/lab_sessions/lab6/data_expanded.csv')\n",
    "\n",
    "# Print head\n",
    "papers.head()\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "8c18c978",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Primary Outcome Measures</th>\n",
       "      <th>Secondary Outcome Measures</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00080951</td>\n",
       "      <td>Irinotecan, Fluorouracil, Leucovorin, and Oxal...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>tumor response rate, Up to 5 years</td>\n",
       "      <td>time to progression, Up to 5 years|overall sur...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT02495051</td>\n",
       "      <td>Esophageal Atresia: Metaplasia, Barrett</td>\n",
       "      <td>The frequency of Barrett's esophagus (BE) has ...</td>\n",
       "      <td>Gastroesophageal Reflux|Esophagus, Barrett</td>\n",
       "      <td>presence of gastric and / or intestinal metapl...</td>\n",
       "      <td>presence of esophagitis or anomalies at the an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00023751</td>\n",
       "      <td>Surgery With or Without Chemotherapy and Radia...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>disease-free survival, Up to 5 years</td>\n",
       "      <td>overall survival, Up to 5 years|colostomy-free...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00017212</td>\n",
       "      <td>DX-8951f in Treating Patients With Metastatic ...</td>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n",
       "      <td>Esophageal Cancer|Gastric Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01288612</td>\n",
       "      <td>Comparative Effectiveness of Endoscopic Assess...</td>\n",
       "      <td>The hypothesis of this study was that the comp...</td>\n",
       "      <td>Barrett's Esophagus</td>\n",
       "      <td>Percentage of Subjects Who Agreed to Participa...</td>\n",
       "      <td>Rate of Successful Intubation, The rate of suc...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT00080951  Irinotecan, Fluorouracil, Leucovorin, and Oxal...   \n",
       "1  NCT02495051            Esophageal Atresia: Metaplasia, Barrett   \n",
       "2  NCT00023751  Surgery With or Without Chemotherapy and Radia...   \n",
       "3  NCT00017212  DX-8951f in Treating Patients With Metastatic ...   \n",
       "4  NCT01288612  Comparative Effectiveness of Endoscopic Assess...   \n",
       "\n",
       "                                       Brief Summary  \\\n",
       "0  RATIONALE: Drugs used in chemotherapy, such as...   \n",
       "1  The frequency of Barrett's esophagus (BE) has ...   \n",
       "2  RATIONALE: Drugs used in chemotherapy use diff...   \n",
       "3  RATIONALE: Drugs used in chemotherapy use diff...   \n",
       "4  The hypothesis of this study was that the comp...   \n",
       "\n",
       "                                   Conditions  \\\n",
       "0                           Colorectal Cancer   \n",
       "1  Gastroesophageal Reflux|Esophagus, Barrett   \n",
       "2                           Colorectal Cancer   \n",
       "3            Esophageal Cancer|Gastric Cancer   \n",
       "4                         Barrett's Esophagus   \n",
       "\n",
       "                            Primary Outcome Measures  \\\n",
       "0                 tumor response rate, Up to 5 years   \n",
       "1  presence of gastric and / or intestinal metapl...   \n",
       "2               disease-free survival, Up to 5 years   \n",
       "3                                                NaN   \n",
       "4  Percentage of Subjects Who Agreed to Participa...   \n",
       "\n",
       "                          Secondary Outcome Measures  \n",
       "0  time to progression, Up to 5 years|overall sur...  \n",
       "1  presence of esophagitis or anomalies at the an...  \n",
       "2  overall survival, Up to 5 years|colostomy-free...  \n",
       "3                                                NaN  \n",
       "4  Rate of Successful Intubation, The rate of suc...  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Remove the columns\n",
    "papers = papers.drop(columns=['Study Results','Other Outcome Measures'], axis=1)\n",
    "\n",
    "# Print out the first rows of papers\n",
    "papers.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9e23a2ff",
   "metadata": {},
   "outputs": [],
   "source": [
    "papers2 = pd.DataFrame()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "d13a3a9c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the regular expression library this process is for data cleaning \n",
    "import re\n",
    "\n",
    "# Fill NA values and ensure all values are treated as strings\n",
    "papers2['1st_Outcomes'] = papers['Primary Outcome Measures'].fillna('').astype(str)\n",
    "papers2['2nd_Outcomes'] = papers['Secondary Outcome Measures'].fillna('').astype(str)\n",
    "papers2['Condition'] = papers['Conditions'].fillna('').astype(str)\n",
    "papers2['Summary'] = papers['Brief Summary'].fillna('').astype(str)\n",
    "papers2['Titles'] = papers['Study Title'].fillna('').astype(str)\n",
    "\n",
    "# Remove punctuation\n",
    "papers2['1st_Outcomes'] = papers2['1st_Outcomes'].map(lambda x: re.sub('[,\\.!?]', '', x))\n",
    "papers2['2nd_Outcomes'] = papers2['2nd_Outcomes'].map(lambda x: re.sub('[,\\.!?]', '', x))\n",
    "papers2['Condition'] = papers2['Condition'].map(lambda x: re.sub('[,\\.!?]', '', x))\n",
    "papers2['Summary'] = papers2['Summary'].map(lambda x: re.sub('[,\\.!?]', '', x))\n",
    "papers2['Titles'] = papers2['Titles'].map(lambda x: re.sub('[,\\.!?]', '', x))\n",
    "\n",
    "# Convert the titles to lowercase\n",
    "papers2['1st_Outcomes'] = papers2['1st_Outcomes'].map(lambda x: x.lower())\n",
    "papers2['2nd_Outcomes'] = papers2['2nd_Outcomes'].map(lambda x: x.lower())\n",
    "papers2['Condition'] = papers2['Condition'].map(lambda x: x.lower())\n",
    "papers2['Summary'] = papers2['Summary'].map(lambda x: x.lower())\n",
    "papers2['Titles'] = papers2['Titles'].map(lambda x: x.lower())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "bf9306e8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1st_Outcomes</th>\n",
       "      <th>2nd_Outcomes</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Titles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>tumor response rate up to 5 years</td>\n",
       "      <td>time to progression up to 5 years|overall surv...</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>rationale: drugs used in chemotherapy such as ...</td>\n",
       "      <td>irinotecan fluorouracil leucovorin and oxalipl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>presence of gastric and / or intestinal metapl...</td>\n",
       "      <td>presence of esophagitis or anomalies at the an...</td>\n",
       "      <td>gastroesophageal reflux|esophagus barrett</td>\n",
       "      <td>the frequency of barrett's esophagus (be) has ...</td>\n",
       "      <td>esophageal atresia: metaplasia barrett</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>disease-free survival up to 5 years</td>\n",
       "      <td>overall survival up to 5 years|colostomy-free ...</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>rationale: drugs used in chemotherapy use diff...</td>\n",
       "      <td>surgery with or without chemotherapy and radia...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>esophageal cancer|gastric cancer</td>\n",
       "      <td>rationale: drugs used in chemotherapy use diff...</td>\n",
       "      <td>dx-8951f in treating patients with metastatic ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>percentage of subjects who agreed to participa...</td>\n",
       "      <td>rate of successful intubation the rate of succ...</td>\n",
       "      <td>barrett's esophagus</td>\n",
       "      <td>the hypothesis of this study was that the comp...</td>\n",
       "      <td>comparative effectiveness of endoscopic assess...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        1st_Outcomes  \\\n",
       "0                  tumor response rate up to 5 years   \n",
       "1  presence of gastric and / or intestinal metapl...   \n",
       "2                disease-free survival up to 5 years   \n",
       "3                                                      \n",
       "4  percentage of subjects who agreed to participa...   \n",
       "\n",
       "                                        2nd_Outcomes  \\\n",
       "0  time to progression up to 5 years|overall surv...   \n",
       "1  presence of esophagitis or anomalies at the an...   \n",
       "2  overall survival up to 5 years|colostomy-free ...   \n",
       "3                                                      \n",
       "4  rate of successful intubation the rate of succ...   \n",
       "\n",
       "                                   Condition  \\\n",
       "0                          colorectal cancer   \n",
       "1  gastroesophageal reflux|esophagus barrett   \n",
       "2                          colorectal cancer   \n",
       "3           esophageal cancer|gastric cancer   \n",
       "4                        barrett's esophagus   \n",
       "\n",
       "                                             Summary  \\\n",
       "0  rationale: drugs used in chemotherapy such as ...   \n",
       "1  the frequency of barrett's esophagus (be) has ...   \n",
       "2  rationale: drugs used in chemotherapy use diff...   \n",
       "3  rationale: drugs used in chemotherapy use diff...   \n",
       "4  the hypothesis of this study was that the comp...   \n",
       "\n",
       "                                              Titles  \n",
       "0  irinotecan fluorouracil leucovorin and oxalipl...  \n",
       "1             esophageal atresia: metaplasia barrett  \n",
       "2  surgery with or without chemotherapy and radia...  \n",
       "3  dx-8951f in treating patients with metastatic ...  \n",
       "4  comparative effectiveness of endoscopic assess...  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers2.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "634e541d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4763"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(papers2['Summary'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "084e7765",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize the WordNet Lemmatizer\n",
    "lemmatizer = WordNetLemmatizer()\n",
    "\n",
    "# Function to lemmatize a given text\n",
    "def lemmatize_stemming(text):\n",
    "    return lemmatizer.lemmatize(text)\n",
    "\n",
    "# Function to preprocess a given text\n",
    "def preprocess(text):\n",
    "    result = []\n",
    "    for token in gensim.utils.simple_preprocess(text):\n",
    "        if token not in gensim.parsing.preprocessing.STOPWORDS and len(token) > 3:\n",
    "            result.append(lemmatize_stemming(token))\n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "2b97132a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "original Summary: \n",
      "['the', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'defecatory', 'function', 'when', 'nerve', 'fibers', 'around', 'the', 'inferior', 'mesenteric', 'artery(ima)', 'and', 'left', 'colic', 'artery(lca)', 'are', 'preserved(so', 'called', 'low', 'ligation', ')', 'or', 'not(high', 'ligation)', 'in', 'the', 'rectosigmoid', 'and', 'rectal', 'cancer', 'surgery']\n",
      "\n",
      "\n",
      " tokenized and lemmatized Summary: \n",
      "['purpose', 'study', 'evaluate', 'defecatory', 'function', 'nerve', 'fiber', 'inferior', 'mesenteric', 'artery', 'left', 'colic', 'artery', 'preserved', 'called', 'ligation', 'high', 'ligation', 'rectosigmoid', 'rectal', 'cancer', 'surgery']\n"
     ]
    }
   ],
   "source": [
    "doc_sample = papers2.loc[5, 'Summary']\n",
    "\n",
    "print('original Summary: ')\n",
    "words = []\n",
    "for word in doc_sample.split(' '):\n",
    "    words.append(word)\n",
    "print(words)\n",
    "\n",
    "print('\\n\\n tokenized and lemmatized Summary: ')\n",
    "print(preprocess(doc_sample))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "ae5ff0b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "#processes and cleans all data columns\n",
    "processed_summary=papers2['Summary'].map(preprocess)\n",
    "processed_1_outcome=papers2['1st_Outcomes'].map(preprocess)\n",
    "processed_2_outcome=papers2['2nd_Outcomes'].map(preprocess)\n",
    "processed_titles=papers2['Titles'].map(preprocess)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "91517012",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       [rationale, drug, chemotherapy, irinotecan, fl...\n",
       "1       [frequency, barrett, esophagus, increased, adu...\n",
       "2       [rationale, drug, chemotherapy, different, way...\n",
       "3       [rationale, drug, chemotherapy, different, way...\n",
       "4       [hypothesis, study, comparative, effectiveness...\n",
       "                              ...                        \n",
       "4758    [clinical, trial, hypothesize, microbiota, bac...\n",
       "4759    [nonpolypoid, colorectal, neoplasm, crns, rela...\n",
       "4760    [chemotherapy, given, standard, treat, cancer,...\n",
       "4761    [single, study, ass, resection, rate, liver, m...\n",
       "4762    [multicenter, phase, randomized, active, contr...\n",
       "Name: Summary, Length: 4763, dtype: object"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "processed_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "39e4ff97",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---- this is summaries----\n",
      "0 cell\n",
      "1 chemotherapy\n",
      "2 colorectal\n",
      "3 combination\n",
      "4 combining\n",
      "5 different\n",
      "6 dividing\n",
      "7 drug\n",
      "8 effectiveness\n",
      "9 fluorouracil\n",
      "10 growing\n"
     ]
    }
   ],
   "source": [
    "print('----Start of Dictionary for LDA ----')\n",
    "# Create a dictionary from the processed_summary\n",
    "dictionary_summary = gensim.corpora.Dictionary(processed_summary)\n",
    "\n",
    "# Initialize a count variable\n",
    "count = 0\n",
    "# Filter the dictionary by removing extremes\n",
    "dictionary_summary.filter_extremes(no_below=15, no_above=0.5, keep_n=100000)\n",
    "\n",
    "# Iterate over the items in the dictionary\n",
    "for k, v in dictionary_summary.iteritems():\n",
    "    print(k, v)\n",
    "    count += 1\n",
    "    if count > 10:\n",
    "        break\n",
    "        \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "3dcc7f2c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a Bag-of-Words (BoW) representation of the summary corpus\n",
    "bow_corpus_summary = [dictionary_summary.doc2bow(doc) for doc in processed_summary]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "e59b3bbb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Word 18 (\"purpose\") appears 1 time.\n",
      "Word 72 (\"high\") appears 1 time.\n",
      "Word 76 (\"rectal\") appears 1 time.\n",
      "Word 79 (\"surgery\") appears 1 time.\n",
      "Word 87 (\"artery\") appears 2 time.\n",
      "Word 88 (\"called\") appears 1 time.\n",
      "Word 89 (\"evaluate\") appears 1 time.\n",
      "Word 90 (\"function\") appears 1 time.\n",
      "Word 91 (\"inferior\") appears 1 time.\n",
      "Word 92 (\"left\") appears 1 time.\n",
      "Word 93 (\"nerve\") appears 1 time.\n"
     ]
    }
   ],
   "source": [
    "# Select the Bag-of-Words representation for a specific document (index 5)\n",
    "bow_doc = bow_corpus_summary[5]\n",
    "# Iterate over each item in the Bag-of-Words representation\n",
    "for i in range(len(bow_doc)):\n",
    "    print(\"Word {} (\\\"{}\\\") appears {} time.\".format(bow_doc[i][0], \n",
    "                                               dictionary_summary[bow_doc[i][0]], \n",
    "bow_doc[i][1]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "7c6847cc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[(0, 0.24574561295855715),\n",
      " (1, 0.21005222631406456),\n",
      " (2, 0.08230301124716685),\n",
      " (3, 0.1399743890823888),\n",
      " (4, 0.24529621077294597),\n",
      " (5, 0.15061463590661664),\n",
      " (6, 0.18791658243231862),\n",
      " (7, 0.2868533765348094),\n",
      " (8, 0.17126347178031678),\n",
      " (9, 0.21042996357535607),\n",
      " (10, 0.21447957819590424),\n",
      " (11, 0.20683884403617328),\n",
      " (12, 0.19656106276617302),\n",
      " (13, 0.24322877703853832),\n",
      " (14, 0.19211372927681555),\n",
      " (15, 0.12748362371199942),\n",
      " (16, 0.19526312422344508),\n",
      " (17, 0.10664363605677096),\n",
      " (18, 0.08943013297696623),\n",
      " (19, 0.15870067707792096),\n",
      " (20, 0.339754247664755),\n",
      " (21, 0.13249059890840834),\n",
      " (22, 0.15204299692560141),\n",
      " (23, 0.09481311337937268),\n",
      " (24, 0.2063853617337529),\n",
      " (25, 0.17843864820315505),\n",
      " (26, 0.18194302836847615)]\n"
     ]
    }
   ],
   "source": [
    "from gensim import corpora, models\n",
    "# Create a TF-IDF model from the Bag-of-Words summary corpus\n",
    "tfidf_summary = models.TfidfModel(bow_corpus_summary)\n",
    "\n",
    "# Apply TF-IDF transformation to the entire summary corpus\n",
    "corpus_tfidf_summary = tfidf_summary[bow_corpus_summary]\n",
    "\n",
    "# Iterate over the transformed corpus and print the first document\n",
    "from pprint import pprint\n",
    "for doc in corpus_tfidf_summary:\n",
    "    pprint(doc)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "e45e7b3b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Topic: 0 \n",
      "Words: 0.032*\"treatment\" + 0.014*\"gastric\" + 0.012*\"response\" + 0.012*\"tumor\" + 0.012*\"chemotherapy\" + 0.011*\"clinical\" + 0.010*\"advanced\" + 0.010*\"colorectal\" + 0.008*\"combination\" + 0.008*\"primary\"\n",
      "Topic: 1 \n",
      "Words: 0.023*\"surgery\" + 0.019*\"group\" + 0.018*\"treatment\" + 0.014*\"colorectal\" + 0.014*\"respiratory\" + 0.014*\"pulmonary\" + 0.014*\"compare\" + 0.013*\"postoperative\" + 0.012*\"performed\" + 0.012*\"participant\"\n",
      "Topic: 2 \n",
      "Words: 0.018*\"treatment\" + 0.017*\"gastric\" + 0.015*\"screening\" + 0.014*\"disease\" + 0.011*\"immune\" + 0.010*\"objective\" + 0.010*\"tumor\" + 0.010*\"related\" + 0.009*\"clinical\" + 0.009*\"great\"\n",
      "Topic: 3 \n",
      "Words: 0.052*\"care\" + 0.036*\"palliative\" + 0.029*\"week\" + 0.027*\"treatment\" + 0.018*\"placebo\" + 0.015*\"randomized\" + 0.014*\"receive\" + 0.013*\"standard\" + 0.012*\"visit\" + 0.011*\"oral\"\n",
      "Topic: 4 \n",
      "Words: 0.036*\"cell\" + 0.035*\"tumor\" + 0.027*\"stage\" + 0.018*\"treatment\" + 0.018*\"colorectal\" + 0.010*\"growth\" + 0.010*\"test\" + 0.009*\"associated\" + 0.009*\"blood\" + 0.008*\"therapy\"\n",
      "Topic: 5 \n",
      "Words: 0.028*\"cell\" + 0.027*\"rectal\" + 0.024*\"score\" + 0.023*\"lars\" + 0.023*\"cetuximab\" + 0.018*\"vegfr\" + 0.017*\"egfr\" + 0.014*\"receptor\" + 0.014*\"factor\" + 0.013*\"blood\"\n",
      "Topic: 6 \n",
      "Words: 0.018*\"sample\" + 0.016*\"treatment\" + 0.012*\"imaging\" + 0.011*\"rectal\" + 0.011*\"biopsy\" + 0.011*\"colon\" + 0.011*\"disease\" + 0.008*\"information\" + 0.008*\"resection\" + 0.008*\"surgery\"\n",
      "Topic: 7 \n",
      "Words: 0.015*\"chemotherapy\" + 0.014*\"tumor\" + 0.014*\"drug\" + 0.013*\"phase\" + 0.013*\"treatment\" + 0.012*\"gastric\" + 0.012*\"factor\" + 0.011*\"randomized\" + 0.010*\"participant\" + 0.010*\"recurrence\"\n",
      "Topic: 8 \n",
      "Words: 0.029*\"based\" + 0.021*\"unresectable\" + 0.019*\"colorectal\" + 0.017*\"stage\" + 0.017*\"treatment\" + 0.017*\"volume\" + 0.016*\"safety\" + 0.016*\"subject\" + 0.015*\"drug\" + 0.015*\"antibody\"\n",
      "Topic: 9 \n",
      "Words: 0.022*\"treatment\" + 0.021*\"cell\" + 0.016*\"tumor\" + 0.016*\"death\" + 0.015*\"colorectal\" + 0.013*\"cause\" + 0.012*\"disease\" + 0.011*\"prognostic\" + 0.011*\"bevacizumab\" + 0.010*\"year\"\n",
      "Topic: 10 \n",
      "Words: 0.030*\"irinotecan\" + 0.023*\"leucovorin\" + 0.022*\"combination\" + 0.021*\"drug\" + 0.018*\"fluorouracil\" + 0.017*\"dose\" + 0.016*\"colorectal\" + 0.015*\"calcium\" + 0.014*\"folfiri\" + 0.014*\"cell\"\n",
      "Topic: 11 \n",
      "Words: 0.042*\"gastric\" + 0.028*\"stomach\" + 0.026*\"acid\" + 0.016*\"treatment\" + 0.015*\"event\" + 0.013*\"cell\" + 0.013*\"lining\" + 0.012*\"effect\" + 0.011*\"progression\" + 0.011*\"colonic\"\n",
      "Topic: 12 \n",
      "Words: 0.025*\"treatment\" + 0.014*\"individual\" + 0.014*\"investigator\" + 0.014*\"chemotherapy\" + 0.011*\"outcome\" + 0.011*\"care\" + 0.010*\"improve\" + 0.010*\"time\" + 0.010*\"surgical\" + 0.010*\"colon\"\n",
      "Topic: 13 \n",
      "Words: 0.033*\"colorectal\" + 0.032*\"investigator\" + 0.029*\"screening\" + 0.019*\"effective\" + 0.018*\"determine\" + 0.017*\"unresectable\" + 0.017*\"treatment\" + 0.017*\"purpose\" + 0.017*\"phone\" + 0.016*\"health\"\n",
      "Topic: 14 \n",
      "Words: 0.031*\"gastric\" + 0.021*\"diagnosis\" + 0.020*\"primary\" + 0.020*\"tissue\" + 0.019*\"upper\" + 0.018*\"screening\" + 0.015*\"objective\" + 0.014*\"rate\" + 0.014*\"colorectal\" + 0.013*\"detection\"\n",
      "Topic: 15 \n",
      "Words: 0.039*\"colorectal\" + 0.018*\"group\" + 0.017*\"outcome\" + 0.016*\"compare\" + 0.014*\"surgery\" + 0.014*\"anastomosis\" + 0.013*\"purpose\" + 0.013*\"quality\" + 0.012*\"hereditary\" + 0.011*\"surgical\"\n",
      "Topic: 16 \n",
      "Words: 0.030*\"surgery\" + 0.018*\"rectal\" + 0.012*\"local\" + 0.011*\"rate\" + 0.011*\"abdominal\" + 0.010*\"resection\" + 0.010*\"pain\" + 0.010*\"western\" + 0.009*\"postoperative\" + 0.009*\"therapy\"\n",
      "Topic: 17 \n",
      "Words: 0.022*\"screening\" + 0.022*\"group\" + 0.017*\"outcome\" + 0.015*\"surgery\" + 0.015*\"year\" + 0.014*\"data\" + 0.014*\"recovery\" + 0.013*\"colonoscopy\" + 0.012*\"hospital\" + 0.011*\"method\"\n",
      "Topic: 18 \n",
      "Words: 0.030*\"treatment\" + 0.021*\"polyp\" + 0.019*\"diagnosis\" + 0.017*\"optical\" + 0.016*\"phase\" + 0.014*\"mcrc\" + 0.012*\"open\" + 0.011*\"chemotherapy\" + 0.011*\"trial\" + 0.011*\"cell\"\n",
      "Topic: 19 \n",
      "Words: 0.024*\"treatment\" + 0.023*\"sunitinib\" + 0.023*\"gist\" + 0.021*\"regorafenib\" + 0.020*\"tumor\" + 0.019*\"kinase\" + 0.019*\"purpose\" + 0.018*\"advanced\" + 0.017*\"imatinib\" + 0.015*\"therapy\"\n",
      "Topic: 20 \n",
      "Words: 0.024*\"colorectal\" + 0.020*\"subject\" + 0.018*\"primary\" + 0.015*\"treatment\" + 0.014*\"anal\" + 0.013*\"combination\" + 0.013*\"stage\" + 0.012*\"chemotherapy\" + 0.012*\"response\" + 0.012*\"evaluate\"\n",
      "Topic: 21 \n",
      "Words: 0.040*\"tumor\" + 0.030*\"cell\" + 0.028*\"growth\" + 0.025*\"trial\" + 0.025*\"erlotinib\" + 0.023*\"oxaliplatin\" + 0.022*\"effectiveness\" + 0.020*\"capecitabine\" + 0.019*\"phase\" + 0.019*\"interfere\"\n",
      "Topic: 22 \n",
      "Words: 0.020*\"node\" + 0.020*\"lymph\" + 0.018*\"surgery\" + 0.015*\"trial\" + 0.014*\"clinical\" + 0.014*\"colorectal\" + 0.014*\"treatment\" + 0.014*\"cell\" + 0.013*\"randomized\" + 0.013*\"follow\"\n",
      "Topic: 23 \n",
      "Words: 0.055*\"care\" + 0.016*\"colorectal\" + 0.014*\"disease\" + 0.013*\"pain\" + 0.013*\"physician\" + 0.012*\"health\" + 0.011*\"life\" + 0.011*\"undergoing\" + 0.011*\"purpose\" + 0.011*\"palliative\"\n",
      "Topic: 24 \n",
      "Words: 0.024*\"endpoint\" + 0.020*\"treatment\" + 0.019*\"secondary\" + 0.014*\"symptom\" + 0.012*\"chemotherapy\" + 0.012*\"radiotherapy\" + 0.011*\"procedure\" + 0.010*\"surgery\" + 0.010*\"primary\" + 0.009*\"survival\"\n",
      "Topic: 25 \n",
      "Words: 0.022*\"chemotherapy\" + 0.017*\"gastric\" + 0.017*\"tumor\" + 0.016*\"treatment\" + 0.015*\"purpose\" + 0.013*\"esophageal\" + 0.012*\"colorectal\" + 0.012*\"metastatic\" + 0.011*\"dose\" + 0.011*\"folfiri\"\n",
      "Topic: 26 \n",
      "Words: 0.028*\"treatment\" + 0.021*\"gastric\" + 0.017*\"chemotherapy\" + 0.016*\"esophageal\" + 0.014*\"effect\" + 0.013*\"stage\" + 0.013*\"safety\" + 0.013*\"adjuvant\" + 0.012*\"phase\" + 0.012*\"capecitabine\"\n",
      "Topic: 27 \n",
      "Words: 0.039*\"drug\" + 0.034*\"tumor\" + 0.030*\"cell\" + 0.022*\"treatment\" + 0.019*\"chemotherapy\" + 0.013*\"stop\" + 0.012*\"growth\" + 0.010*\"trial\" + 0.010*\"capecitabine\" + 0.010*\"everolimus\"\n",
      "Topic: 28 \n",
      "Words: 0.018*\"cell\" + 0.017*\"tumor\" + 0.016*\"trial\" + 0.014*\"screening\" + 0.014*\"group\" + 0.013*\"bowel\" + 0.012*\"investigator\" + 0.010*\"stent\" + 0.010*\"colorectal\" + 0.009*\"esophageal\"\n",
      "Topic: 29 \n",
      "Words: 0.030*\"chemotherapy\" + 0.024*\"purpose\" + 0.021*\"trial\" + 0.021*\"receiving\" + 0.018*\"phase\" + 0.017*\"combination\" + 0.016*\"advanced\" + 0.015*\"blood\" + 0.015*\"tumor\" + 0.013*\"efficacy\"\n",
      "Topic: 30 \n",
      "Words: 0.066*\"plus\" + 0.061*\"oxaliplatin\" + 0.030*\"advanced\" + 0.021*\"regimen\" + 0.021*\"capsule\" + 0.020*\"capecitabine\" + 0.019*\"perioperative\" + 0.018*\"chemotherapy\" + 0.017*\"gastric\" + 0.016*\"therapy\"\n",
      "Topic: 31 \n",
      "Words: 0.021*\"risk\" + 0.017*\"esophageal\" + 0.017*\"molecular\" + 0.017*\"barrett\" + 0.014*\"anal\" + 0.014*\"colorectal\" + 0.013*\"investigator\" + 0.013*\"treatment\" + 0.012*\"imaging\" + 0.011*\"esophagus\"\n",
      "Topic: 32 \n",
      "Words: 0.041*\"therapy\" + 0.037*\"radiation\" + 0.027*\"purpose\" + 0.024*\"neck\" + 0.024*\"head\" + 0.020*\"trial\" + 0.018*\"phase\" + 0.016*\"mucositis\" + 0.015*\"randomized\" + 0.013*\"preventing\"\n",
      "Topic: 33 \n",
      "Words: 0.030*\"received\" + 0.025*\"therapy\" + 0.017*\"survival\" + 0.017*\"rate\" + 0.016*\"resection\" + 0.016*\"treatment\" + 0.012*\"surgical\" + 0.012*\"year\" + 0.012*\"efficacy\" + 0.012*\"primary\"\n",
      "Topic: 34 \n",
      "Words: 0.029*\"colorectal\" + 0.027*\"blood\" + 0.020*\"screening\" + 0.018*\"gene\" + 0.016*\"tumor\" + 0.016*\"mutation\" + 0.015*\"sample\" + 0.014*\"cell\" + 0.012*\"drug\" + 0.012*\"laboratory\"\n",
      "Topic: 35 \n",
      "Words: 0.026*\"therapy\" + 0.019*\"pemetrexed\" + 0.017*\"gastric\" + 0.017*\"factor\" + 0.014*\"cisplatin\" + 0.014*\"chemoradiation\" + 0.012*\"tumor\" + 0.012*\"response\" + 0.012*\"mucositis\" + 0.011*\"oral\"\n",
      "Topic: 36 \n",
      "Words: 0.032*\"imatinib\" + 0.029*\"tumor\" + 0.026*\"gist\" + 0.018*\"treatment\" + 0.017*\"colonoscopy\" + 0.014*\"high\" + 0.013*\"month\" + 0.011*\"cell\" + 0.011*\"day\" + 0.011*\"following\"\n",
      "Topic: 37 \n",
      "Words: 0.045*\"treatment\" + 0.032*\"capecitabine\" + 0.028*\"combination\" + 0.026*\"drug\" + 0.025*\"approved\" + 0.023*\"colorectal\" + 0.022*\"irinotecan\" + 0.022*\"standard\" + 0.022*\"improve\" + 0.019*\"metastatic\"\n",
      "Topic: 38 \n",
      "Words: 0.041*\"life\" + 0.040*\"quality\" + 0.031*\"colorectal\" + 0.021*\"purpose\" + 0.019*\"related\" + 0.018*\"folfox\" + 0.016*\"determine\" + 0.016*\"older\" + 0.015*\"adult\" + 0.015*\"therapy\"\n",
      "Topic: 39 \n",
      "Words: 0.049*\"gastric\" + 0.034*\"postoperative\" + 0.030*\"nutrition\" + 0.022*\"complication\" + 0.018*\"colorectal\" + 0.018*\"survival\" + 0.018*\"ass\" + 0.013*\"year\" + 0.012*\"surveillance\" + 0.012*\"undergoing\"\n",
      "Topic: 40 \n",
      "Words: 0.035*\"treatment\" + 0.019*\"colorectal\" + 0.017*\"safety\" + 0.014*\"clinical\" + 0.014*\"regorafenib\" + 0.013*\"effect\" + 0.012*\"prior\" + 0.012*\"phase\" + 0.011*\"efficacy\" + 0.011*\"evaluate\"\n",
      "Topic: 41 \n",
      "Words: 0.027*\"cohort\" + 0.024*\"advanced\" + 0.017*\"neoadjuvant\" + 0.015*\"based\" + 0.014*\"phase\" + 0.014*\"locally\" + 0.013*\"trial\" + 0.012*\"treated\" + 0.012*\"purpose\" + 0.011*\"chemotherapy\"\n",
      "Topic: 42 \n",
      "Words: 0.022*\"treatment\" + 0.018*\"chemotherapy\" + 0.017*\"risk\" + 0.013*\"model\" + 0.012*\"based\" + 0.011*\"ass\" + 0.011*\"mucositis\" + 0.011*\"dose\" + 0.010*\"high\" + 0.010*\"radiotherapy\"\n",
      "Topic: 43 \n",
      "Words: 0.020*\"treatment\" + 0.019*\"endoscopic\" + 0.018*\"acid\" + 0.017*\"esophagus\" + 0.017*\"gastric\" + 0.014*\"barrett\" + 0.013*\"lesion\" + 0.013*\"response\" + 0.012*\"investigator\" + 0.010*\"resection\"\n",
      "Topic: 44 \n",
      "Words: 0.025*\"test\" + 0.024*\"screening\" + 0.023*\"colorectal\" + 0.019*\"avastin\" + 0.014*\"evaluate\" + 0.014*\"objective\" + 0.012*\"treatment\" + 0.011*\"colonoscopy\" + 0.010*\"disease\" + 0.009*\"investigator\"\n",
      "Topic: 45 \n",
      "Words: 0.025*\"surgery\" + 0.024*\"diet\" + 0.021*\"subject\" + 0.020*\"week\" + 0.017*\"colorectal\" + 0.012*\"liver\" + 0.012*\"exercise\" + 0.012*\"resection\" + 0.010*\"blood\" + 0.010*\"program\"\n",
      "Topic: 46 \n",
      "Words: 0.037*\"surgery\" + 0.020*\"gastric\" + 0.018*\"laparoscopic\" + 0.015*\"surgical\" + 0.013*\"treatment\" + 0.010*\"standard\" + 0.010*\"survival\" + 0.010*\"rectal\" + 0.010*\"rate\" + 0.009*\"therapy\"\n",
      "Topic: 47 \n",
      "Words: 0.026*\"colorectal\" + 0.022*\"combination\" + 0.017*\"advanced\" + 0.016*\"tumor\" + 0.015*\"chemotherapy\" + 0.014*\"metastatic\" + 0.013*\"colonoscopy\" + 0.013*\"cell\" + 0.012*\"trial\" + 0.012*\"paclitaxel\"\n",
      "Topic: 48 \n",
      "Words: 0.078*\"tumor\" + 0.073*\"cell\" + 0.032*\"growth\" + 0.029*\"stop\" + 0.026*\"chemotherapy\" + 0.023*\"treating\" + 0.023*\"kill\" + 0.022*\"therapy\" + 0.021*\"work\" + 0.021*\"different\"\n",
      "Topic: 49 \n",
      "Words: 0.023*\"risk\" + 0.020*\"polyp\" + 0.019*\"colonoscopy\" + 0.016*\"screening\" + 0.015*\"factor\" + 0.014*\"colorectal\" + 0.013*\"treatment\" + 0.012*\"survival\" + 0.012*\"folfox\" + 0.011*\"test\"\n",
      "Topic: 50 \n",
      "Words: 0.034*\"dose\" + 0.026*\"evaluate\" + 0.025*\"objective\" + 0.025*\"safety\" + 0.020*\"response\" + 0.019*\"tumor\" + 0.015*\"advanced\" + 0.015*\"determine\" + 0.014*\"phase\" + 0.013*\"treatment\"\n",
      "Topic: 51 \n",
      "Words: 0.020*\"colorectal\" + 0.018*\"procedure\" + 0.017*\"device\" + 0.016*\"evaluate\" + 0.016*\"rate\" + 0.013*\"gastric\" + 0.012*\"safety\" + 0.012*\"time\" + 0.011*\"purpose\" + 0.010*\"high\"\n",
      "Topic: 52 \n",
      "Words: 0.062*\"chemotherapy\" + 0.039*\"tumor\" + 0.033*\"stop\" + 0.033*\"cell\" + 0.028*\"drug\" + 0.025*\"therapy\" + 0.022*\"radiation\" + 0.020*\"trial\" + 0.020*\"treating\" + 0.020*\"purpose\"\n",
      "Topic: 53 \n",
      "Words: 0.027*\"peptide\" + 0.025*\"tumor\" + 0.023*\"stop\" + 0.021*\"phase\" + 0.020*\"drug\" + 0.019*\"purpose\" + 0.018*\"cell\" + 0.016*\"treating\" + 0.016*\"trial\" + 0.015*\"gastric\"\n",
      "Topic: 54 \n",
      "Words: 0.025*\"treatment\" + 0.021*\"chemotherapy\" + 0.018*\"colon\" + 0.018*\"tumour\" + 0.017*\"combination\" + 0.012*\"cell\" + 0.011*\"tumor\" + 0.011*\"effect\" + 0.010*\"drug\" + 0.010*\"rectal\"\n",
      "Topic: 55 \n",
      "Words: 0.020*\"colon\" + 0.014*\"colorectal\" + 0.012*\"early\" + 0.012*\"therapy\" + 0.011*\"procedure\" + 0.010*\"pain\" + 0.010*\"metastatic\" + 0.009*\"advanced\" + 0.009*\"treatment\" + 0.009*\"irinotecan\"\n",
      "Topic: 56 \n",
      "Words: 0.027*\"treatment\" + 0.021*\"gastric\" + 0.017*\"level\" + 0.016*\"acid\" + 0.013*\"tumor\" + 0.010*\"safety\" + 0.009*\"response\" + 0.009*\"dosing\" + 0.009*\"physical\" + 0.009*\"rectal\"\n",
      "Topic: 57 \n",
      "Words: 0.034*\"tumor\" + 0.018*\"endoscopic\" + 0.015*\"phase\" + 0.014*\"rate\" + 0.013*\"submucosal\" + 0.012*\"cell\" + 0.012*\"trial\" + 0.012*\"advanced\" + 0.012*\"purpose\" + 0.011*\"chemotherapy\"\n",
      "Topic: 58 \n",
      "Words: 0.013*\"clinical\" + 0.012*\"trial\" + 0.012*\"treatment\" + 0.010*\"high\" + 0.009*\"effect\" + 0.009*\"colorectal\" + 0.009*\"approach\" + 0.009*\"rate\" + 0.009*\"purpose\" + 0.008*\"surgical\"\n",
      "Topic: 59 \n",
      "Words: 0.029*\"safety\" + 0.021*\"phase\" + 0.018*\"combination\" + 0.017*\"advanced\" + 0.017*\"dose\" + 0.015*\"tumor\" + 0.014*\"line\" + 0.013*\"cetuximab\" + 0.011*\"evaluate\" + 0.011*\"progression\"\n",
      "Topic: 60 \n",
      "Words: 0.047*\"screening\" + 0.024*\"colorectal\" + 0.022*\"colonoscopy\" + 0.013*\"effective\" + 0.013*\"health\" + 0.013*\"fobt\" + 0.012*\"risk\" + 0.012*\"cost\" + 0.011*\"colon\" + 0.010*\"based\"\n",
      "Topic: 61 \n",
      "Words: 0.032*\"gastric\" + 0.026*\"colorectal\" + 0.024*\"purpose\" + 0.023*\"screening\" + 0.015*\"biomarkers\" + 0.013*\"group\" + 0.013*\"test\" + 0.013*\"efficacy\" + 0.012*\"surgery\" + 0.012*\"recovery\"\n",
      "Topic: 62 \n",
      "Words: 0.024*\"colorectal\" + 0.019*\"rate\" + 0.019*\"detection\" + 0.018*\"screening\" + 0.017*\"colonoscopy\" + 0.016*\"node\" + 0.013*\"adenoma\" + 0.013*\"treatment\" + 0.011*\"response\" + 0.009*\"lymph\"\n",
      "Topic: 63 \n",
      "Words: 0.073*\"cell\" + 0.069*\"tumor\" + 0.034*\"growth\" + 0.027*\"work\" + 0.024*\"chemotherapy\" + 0.024*\"stop\" + 0.023*\"treating\" + 0.022*\"different\" + 0.021*\"colorectal\" + 0.020*\"way\"\n",
      "Topic: 64 \n",
      "Words: 0.032*\"evaluate\" + 0.025*\"capsule\" + 0.023*\"purpose\" + 0.022*\"allow\" + 0.022*\"safety\" + 0.021*\"efficacy\" + 0.019*\"treatment\" + 0.019*\"swallowing\" + 0.017*\"neoplasm\" + 0.017*\"unresectable\"\n",
      "Topic: 65 \n",
      "Words: 0.025*\"colorectal\" + 0.014*\"tumor\" + 0.013*\"surgery\" + 0.013*\"colon\" + 0.012*\"high\" + 0.011*\"purpose\" + 0.010*\"size\" + 0.010*\"imatinib\" + 0.009*\"number\" + 0.009*\"following\"\n",
      "Topic: 66 \n",
      "Words: 0.050*\"participant\" + 0.029*\"combination\" + 0.027*\"screening\" + 0.022*\"receive\" + 0.016*\"safety\" + 0.015*\"survey\" + 0.015*\"pembrolizumab\" + 0.014*\"purpose\" + 0.014*\"efficacy\" + 0.014*\"week\"\n",
      "Topic: 67 \n",
      "Words: 0.046*\"screening\" + 0.023*\"intervention\" + 0.022*\"rate\" + 0.021*\"care\" + 0.021*\"health\" + 0.021*\"group\" + 0.020*\"clinic\" + 0.019*\"colorectal\" + 0.012*\"community\" + 0.011*\"physician\"\n",
      "Topic: 68 \n",
      "Words: 0.034*\"lesion\" + 0.023*\"colonoscope\" + 0.023*\"device\" + 0.016*\"greater\" + 0.016*\"therapeutic\" + 0.015*\"performed\" + 0.015*\"histological\" + 0.014*\"physician\" + 0.013*\"effect\" + 0.013*\"polyp\"\n",
      "Topic: 69 \n",
      "Words: 0.029*\"program\" + 0.023*\"colorectal\" + 0.022*\"screening\" + 0.021*\"group\" + 0.020*\"test\" + 0.016*\"individual\" + 0.013*\"life\" + 0.012*\"chemotherapy\" + 0.012*\"week\" + 0.011*\"control\"\n",
      "Topic: 70 \n",
      "Words: 0.028*\"colorectal\" + 0.028*\"cell\" + 0.023*\"factor\" + 0.020*\"survival\" + 0.014*\"phase\" + 0.014*\"treatment\" + 0.013*\"trial\" + 0.012*\"metastasis\" + 0.012*\"improve\" + 0.012*\"response\"\n",
      "Topic: 71 \n",
      "Words: 0.022*\"cell\" + 0.014*\"cycle\" + 0.013*\"treatment\" + 0.013*\"clinical\" + 0.012*\"tumor\" + 0.012*\"carcinoma\" + 0.011*\"acute\" + 0.011*\"data\" + 0.010*\"test\" + 0.009*\"colorectal\"\n",
      "Topic: 72 \n",
      "Words: 0.028*\"health\" + 0.024*\"intervention\" + 0.023*\"group\" + 0.021*\"colon\" + 0.020*\"exercise\" + 0.019*\"improve\" + 0.017*\"intensive\" + 0.016*\"treatment\" + 0.016*\"fitness\" + 0.015*\"survivor\"\n",
      "Topic: 73 \n",
      "Words: 0.031*\"colorectal\" + 0.029*\"safety\" + 0.028*\"treatment\" + 0.027*\"panitumumab\" + 0.026*\"phase\" + 0.025*\"metastatic\" + 0.025*\"surgery\" + 0.023*\"clinical\" + 0.020*\"leakage\" + 0.019*\"anastomotic\"\n",
      "Topic: 74 \n",
      "Words: 0.022*\"accuracy\" + 0.022*\"colonoscopy\" + 0.019*\"diagnostic\" + 0.017*\"result\" + 0.016*\"symptom\" + 0.014*\"imaging\" + 0.014*\"test\" + 0.012*\"lesion\" + 0.011*\"pathway\" + 0.010*\"value\"\n",
      "Topic: 75 \n",
      "Words: 0.022*\"colon\" + 0.020*\"surgery\" + 0.016*\"treatment\" + 0.016*\"procedure\" + 0.015*\"screening\" + 0.013*\"receive\" + 0.013*\"trial\" + 0.011*\"stage\" + 0.011*\"lesion\" + 0.010*\"intervention\"\n",
      "Topic: 76 \n",
      "Words: 0.025*\"immune\" + 0.020*\"surgery\" + 0.020*\"cell\" + 0.017*\"effect\" + 0.016*\"laparoscopic\" + 0.015*\"tumor\" + 0.015*\"gastric\" + 0.015*\"investigator\" + 0.015*\"recommendation\" + 0.014*\"analgesia\"\n",
      "Topic: 77 \n",
      "Words: 0.030*\"dose\" + 0.028*\"treatment\" + 0.024*\"effect\" + 0.016*\"survival\" + 0.014*\"cell\" + 0.013*\"safety\" + 0.012*\"disease\" + 0.012*\"purpose\" + 0.011*\"efficacy\" + 0.011*\"drug\"\n",
      "Topic: 78 \n",
      "Words: 0.026*\"colorectal\" + 0.017*\"scan\" + 0.017*\"primary\" + 0.017*\"resection\" + 0.015*\"intervention\" + 0.014*\"risk\" + 0.012*\"group\" + 0.012*\"survival\" + 0.012*\"tumor\" + 0.011*\"testing\"\n",
      "Topic: 79 \n",
      "Words: 0.034*\"colorectal\" + 0.028*\"preparation\" + 0.025*\"bowel\" + 0.021*\"cell\" + 0.018*\"cleansing\" + 0.015*\"quality\" + 0.015*\"regimen\" + 0.014*\"tumor\" + 0.012*\"sided\" + 0.012*\"left\"\n"
     ]
    }
   ],
   "source": [
    "# Train an LDA (Latent Dirichlet Allocation) model on the Bag-of-Words summary corpus\n",
    "lda_model1 = gensim.models.LdaMulticore(bow_corpus_summary, num_topics=80, id2word=dictionary_summary, passes=2, workers=2)\n",
    "\n",
    "# Initialize an empty list to store the LDA topics\n",
    "lda_list=[]\n",
    "\n",
    "\n",
    "# Iterate over the topics in the LDA model and print them\n",
    "for idx, topic in lda_model1.print_topics(-1):\n",
    "    print('Topic: {} \\nWords: {}'.format(idx, topic))\n",
    "    topic1_string='Topic: {} \\nWords: {}'.format(idx, topic)\n",
    "    lda_list.append(topic1_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "5640f548",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Topic: 0 \n",
      "Words: 0.014*\"laparoscopic\" + 0.012*\"surgery\" + 0.010*\"gastric\" + 0.009*\"comparing\" + 0.009*\"lymph\" + 0.008*\"recovery\" + 0.008*\"versus\" + 0.008*\"node\" + 0.008*\"type\" + 0.008*\"anal\"\n",
      "Topic: 1 \n",
      "Words: 0.019*\"safe\" + 0.017*\"gastric\" + 0.016*\"docetaxel\" + 0.015*\"cisplatin\" + 0.013*\"malignant\" + 0.011*\"oral\" + 0.011*\"caused\" + 0.010*\"small\" + 0.010*\"capecitabine\" + 0.010*\"effective\"\n",
      "Topic: 2 \n",
      "Words: 0.038*\"familial\" + 0.036*\"adenomatous\" + 0.030*\"polyposis\" + 0.021*\"monitor\" + 0.017*\"fluid\" + 0.015*\"observed\" + 0.010*\"surgery\" + 0.009*\"bevacizumab\" + 0.008*\"giving\" + 0.008*\"randomized\"\n",
      "Topic: 3 \n",
      "Words: 0.022*\"week\" + 0.021*\"administered\" + 0.021*\"cycle\" + 0.021*\"xeloda\" + 0.016*\"anticipated\" + 0.014*\"safety\" + 0.014*\"day\" + 0.014*\"time\" + 0.014*\"participant\" + 0.012*\"capecitabine\"\n",
      "Topic: 4 \n",
      "Words: 0.041*\"ramucirumab\" + 0.021*\"reconstruction\" + 0.017*\"clinic\" + 0.015*\"endpoint\" + 0.012*\"long\" + 0.012*\"response\" + 0.011*\"combined\" + 0.011*\"according\" + 0.010*\"standard\" + 0.010*\"regimen\"\n",
      "Topic: 5 \n",
      "Words: 0.021*\"stromal\" + 0.011*\"tumor\" + 0.010*\"malignancy\" + 0.009*\"gene\" + 0.009*\"biopsy\" + 0.009*\"mutation\" + 0.008*\"cell\" + 0.008*\"tissue\" + 0.008*\"targeting\" + 0.008*\"human\"\n",
      "Topic: 6 \n",
      "Words: 0.024*\"goal\" + 0.023*\"operative\" + 0.019*\"research\" + 0.012*\"relationship\" + 0.011*\"live\" + 0.011*\"help\" + 0.010*\"studied\" + 0.010*\"highest\" + 0.010*\"group\" + 0.008*\"clinical\"\n",
      "Topic: 7 \n",
      "Words: 0.017*\"palliative\" + 0.017*\"mucosa\" + 0.015*\"panitumumab\" + 0.012*\"dietary\" + 0.011*\"document\" + 0.011*\"capecitabine\" + 0.010*\"median\" + 0.010*\"neoplastic\" + 0.010*\"beam\" + 0.010*\"polyp\"\n",
      "Topic: 8 \n",
      "Words: 0.019*\"sorafenib\" + 0.019*\"child\" + 0.016*\"adding\" + 0.015*\"referral\" + 0.015*\"educational\" + 0.014*\"pathway\" + 0.010*\"clear\" + 0.010*\"nurse\" + 0.009*\"colon\" + 0.009*\"based\"\n",
      "Topic: 9 \n",
      "Words: 0.039*\"folfox\" + 0.018*\"wild\" + 0.015*\"type\" + 0.012*\"treatment\" + 0.012*\"mcrc\" + 0.011*\"sodium\" + 0.010*\"cetuximab\" + 0.010*\"panitumumab\" + 0.009*\"metastatic\" + 0.009*\"survey\"\n",
      "Topic: 10 \n",
      "Words: 0.026*\"colonoscope\" + 0.019*\"colonoscopy\" + 0.017*\"stoma\" + 0.016*\"sequence\" + 0.016*\"polyp\" + 0.014*\"device\" + 0.013*\"apatinib\" + 0.012*\"human\" + 0.012*\"factor\" + 0.011*\"efficacy\"\n",
      "Topic: 11 \n",
      "Words: 0.037*\"alfa\" + 0.025*\"epithelial\" + 0.022*\"infection\" + 0.022*\"probe\" + 0.020*\"respiratory\" + 0.018*\"subject\" + 0.018*\"interferon\" + 0.017*\"prognostic\" + 0.016*\"pulmonary\" + 0.013*\"series\"\n",
      "Topic: 12 \n",
      "Words: 0.011*\"polyposis\" + 0.011*\"tumor\" + 0.010*\"investigates\" + 0.010*\"effect\" + 0.009*\"cell\" + 0.009*\"good\" + 0.009*\"pilot\" + 0.008*\"simultaneous\" + 0.008*\"prospective\" + 0.007*\"mutation\"\n",
      "Topic: 13 \n",
      "Words: 0.023*\"stem\" + 0.014*\"transplantation\" + 0.013*\"cell\" + 0.012*\"peripheral\" + 0.011*\"multiple\" + 0.010*\"colon\" + 0.010*\"screening\" + 0.009*\"program\" + 0.008*\"navigation\" + 0.008*\"providing\"\n",
      "Topic: 14 \n",
      "Words: 0.020*\"surgery\" + 0.018*\"crohn\" + 0.018*\"stomach\" + 0.015*\"sentinel\" + 0.014*\"soft\" + 0.013*\"radiation\" + 0.011*\"tissue\" + 0.011*\"esophageal\" + 0.010*\"cell\" + 0.009*\"work\"\n",
      "Topic: 15 \n",
      "Words: 0.044*\"harming\" + 0.043*\"locate\" + 0.038*\"neuroendocrine\" + 0.035*\"deliver\" + 0.023*\"normal\" + 0.021*\"contrast\" + 0.020*\"active\" + 0.019*\"cell\" + 0.018*\"monoclonal\" + 0.016*\"tumor\"\n",
      "Topic: 16 \n",
      "Words: 0.019*\"demonstrate\" + 0.017*\"chemoradiation\" + 0.016*\"antigen\" + 0.012*\"prevalence\" + 0.011*\"determination\" + 0.010*\"therapy\" + 0.009*\"healing\" + 0.009*\"induction\" + 0.008*\"tested\" + 0.008*\"response\"\n",
      "Topic: 17 \n",
      "Words: 0.023*\"gastrectomy\" + 0.017*\"node\" + 0.017*\"lymph\" + 0.011*\"folfiri\" + 0.011*\"satisfaction\" + 0.011*\"dissection\" + 0.011*\"analgesia\" + 0.011*\"laparoscopic\" + 0.010*\"healthy\" + 0.009*\"near\"\n",
      "Topic: 18 \n",
      "Words: 0.016*\"previously\" + 0.014*\"respond\" + 0.011*\"muscle\" + 0.011*\"reflux\" + 0.011*\"treated\" + 0.010*\"health\" + 0.010*\"screening\" + 0.009*\"intervention\" + 0.009*\"examine\" + 0.009*\"moderate\"\n",
      "Topic: 19 \n",
      "Words: 0.030*\"completion\" + 0.024*\"young\" + 0.023*\"fixed\" + 0.016*\"subsequent\" + 0.014*\"strength\" + 0.013*\"incidence\" + 0.010*\"pelvic\" + 0.010*\"loss\" + 0.010*\"initiation\" + 0.010*\"muscle\"\n",
      "Topic: 20 \n",
      "Words: 0.024*\"investigate\" + 0.018*\"tool\" + 0.013*\"screening\" + 0.012*\"optical\" + 0.010*\"testing\" + 0.010*\"vaccine\" + 0.009*\"fobt\" + 0.009*\"group\" + 0.009*\"recent\" + 0.009*\"asian\"\n",
      "Topic: 21 \n",
      "Words: 0.029*\"celecoxib\" + 0.016*\"measuring\" + 0.015*\"exercise\" + 0.014*\"radiotherapy\" + 0.013*\"portion\" + 0.013*\"bacteria\" + 0.012*\"learning\" + 0.011*\"step\" + 0.010*\"influence\" + 0.010*\"rectal\"\n",
      "Topic: 22 \n",
      "Words: 0.019*\"collect\" + 0.015*\"sided\" + 0.015*\"sorafenib\" + 0.015*\"severe\" + 0.013*\"left\" + 0.012*\"tube\" + 0.012*\"endoscope\" + 0.011*\"peptide\" + 0.010*\"letter\" + 0.010*\"progression\"\n",
      "Topic: 23 \n",
      "Words: 0.035*\"gist\" + 0.031*\"imatinib\" + 0.021*\"mesylate\" + 0.018*\"label\" + 0.017*\"open\" + 0.012*\"stromal\" + 0.009*\"colectomy\" + 0.009*\"resection\" + 0.009*\"following\" + 0.008*\"regorafenib\"\n",
      "Topic: 24 \n",
      "Words: 0.020*\"anal\" + 0.015*\"mitomycin\" + 0.015*\"modulated\" + 0.014*\"failure\" + 0.014*\"light\" + 0.013*\"risk\" + 0.013*\"scope\" + 0.013*\"develop\" + 0.012*\"decision\" + 0.011*\"colonic\"\n",
      "Topic: 25 \n",
      "Words: 0.037*\"dose\" + 0.023*\"tolerated\" + 0.021*\"maximum\" + 0.019*\"combination\" + 0.018*\"determine\" + 0.016*\"irinotecan\" + 0.015*\"phase\" + 0.015*\"kras\" + 0.014*\"recommended\" + 0.014*\"concurrent\"\n",
      "Topic: 26 \n",
      "Words: 0.019*\"fatigue\" + 0.018*\"mfolfox\" + 0.015*\"bleeding\" + 0.014*\"symptom\" + 0.012*\"developing\" + 0.012*\"cancerous\" + 0.010*\"late\" + 0.010*\"protect\" + 0.009*\"identified\" + 0.009*\"woman\"\n",
      "Topic: 27 \n",
      "Words: 0.024*\"supportive\" + 0.015*\"swallowing\" + 0.014*\"depression\" + 0.013*\"best\" + 0.012*\"subject\" + 0.011*\"message\" + 0.011*\"care\" + 0.011*\"quantitative\" + 0.010*\"consent\" + 0.009*\"screening\"\n",
      "Topic: 28 \n",
      "Words: 0.017*\"water\" + 0.014*\"leak\" + 0.012*\"esophageal\" + 0.011*\"option\" + 0.010*\"examination\" + 0.010*\"anastomotic\" + 0.010*\"carcinoma\" + 0.009*\"treated\" + 0.009*\"histologically\" + 0.009*\"localized\"\n",
      "Topic: 29 \n",
      "Words: 0.039*\"vitamin\" + 0.030*\"pemetrexed\" + 0.025*\"esophagus\" + 0.020*\"barrett\" + 0.020*\"chemoprevention\" + 0.015*\"certain\" + 0.014*\"observe\" + 0.013*\"observation\" + 0.012*\"procedure\" + 0.011*\"finding\"\n",
      "Topic: 30 \n",
      "Words: 0.014*\"questionnaire\" + 0.012*\"modified\" + 0.012*\"life\" + 0.011*\"quality\" + 0.009*\"screening\" + 0.009*\"biological\" + 0.008*\"receiving\" + 0.007*\"syndrome\" + 0.007*\"allow\" + 0.007*\"vaccine\"\n",
      "Topic: 31 \n",
      "Words: 0.022*\"trastuzumab\" + 0.018*\"group\" + 0.015*\"positive\" + 0.010*\"anesthesia\" + 0.010*\"concentration\" + 0.009*\"activity\" + 0.009*\"female\" + 0.009*\"factor\" + 0.009*\"improvement\" + 0.008*\"gastric\"\n",
      "Topic: 32 \n",
      "Words: 0.020*\"designed\" + 0.020*\"stent\" + 0.016*\"obstruction\" + 0.011*\"obtain\" + 0.010*\"clinical\" + 0.010*\"characterize\" + 0.009*\"adjuvant\" + 0.009*\"peritoneal\" + 0.009*\"surgery\" + 0.009*\"oxaliplatin\"\n",
      "Topic: 33 \n",
      "Words: 0.018*\"everolimus\" + 0.012*\"navigator\" + 0.011*\"band\" + 0.011*\"care\" + 0.010*\"narrow\" + 0.010*\"white\" + 0.010*\"financial\" + 0.009*\"project\" + 0.009*\"disparity\" + 0.009*\"endomicroscopy\"\n",
      "Topic: 34 \n",
      "Words: 0.028*\"bowel\" + 0.028*\"preparation\" + 0.018*\"plan\" + 0.017*\"volume\" + 0.015*\"histology\" + 0.012*\"versus\" + 0.012*\"colonoscopy\" + 0.012*\"caused\" + 0.012*\"self\" + 0.011*\"perioperative\"\n",
      "Topic: 35 \n",
      "Words: 0.027*\"adenoma\" + 0.019*\"robotic\" + 0.015*\"detection\" + 0.013*\"underwent\" + 0.012*\"laparoscopic\" + 0.012*\"rate\" + 0.012*\"colonoscopy\" + 0.012*\"compare\" + 0.011*\"risk\" + 0.011*\"surgery\"\n",
      "Topic: 36 \n",
      "Words: 0.018*\"dysphagia\" + 0.016*\"monotherapy\" + 0.016*\"recurrent\" + 0.013*\"duodenal\" + 0.012*\"slow\" + 0.012*\"interfere\" + 0.012*\"device\" + 0.011*\"oesophagus\" + 0.010*\"rectal\" + 0.009*\"safety\"\n",
      "Topic: 37 \n",
      "Words: 0.023*\"esophagectomy\" + 0.018*\"newly\" + 0.017*\"vomiting\" + 0.015*\"nausea\" + 0.015*\"autologous\" + 0.014*\"planned\" + 0.012*\"diagnosed\" + 0.010*\"month\" + 0.010*\"evaluating\" + 0.010*\"receiving\"\n",
      "Topic: 38 \n",
      "Words: 0.034*\"gene\" + 0.029*\"braf\" + 0.018*\"vaccine\" + 0.018*\"vegfr\" + 0.016*\"mutant\" + 0.014*\"immune\" + 0.012*\"cell\" + 0.011*\"cetuximab\" + 0.011*\"blood\" + 0.011*\"papillomavirus\"\n",
      "Topic: 39 \n",
      "Words: 0.036*\"american\" + 0.032*\"african\" + 0.030*\"anastomotic\" + 0.022*\"screening\" + 0.019*\"leakage\" + 0.018*\"mailed\" + 0.017*\"invitation\" + 0.016*\"likely\" + 0.013*\"fewer\" + 0.011*\"intervention\"\n",
      "Topic: 40 \n",
      "Words: 0.031*\"gemcitabine\" + 0.028*\"counseling\" + 0.014*\"prevention\" + 0.013*\"program\" + 0.012*\"care\" + 0.011*\"cost\" + 0.011*\"thought\" + 0.010*\"session\" + 0.010*\"improves\" + 0.009*\"anterior\"\n",
      "Topic: 41 \n",
      "Words: 0.021*\"aimed\" + 0.014*\"pathological\" + 0.013*\"practice\" + 0.012*\"daily\" + 0.011*\"crcs\" + 0.010*\"retrospectively\" + 0.010*\"dysplasia\" + 0.010*\"multicentric\" + 0.009*\"retrospective\" + 0.009*\"gastric\"\n",
      "Topic: 42 \n",
      "Words: 0.027*\"observational\" + 0.013*\"oncologic\" + 0.013*\"participant\" + 0.013*\"ulcerative\" + 0.011*\"physician\" + 0.011*\"line\" + 0.011*\"bevacizumab\" + 0.010*\"verify\" + 0.010*\"fluid\" + 0.009*\"mcrc\"\n",
      "Topic: 43 \n",
      "Words: 0.027*\"choice\" + 0.022*\"outreach\" + 0.021*\"family\" + 0.019*\"screening\" + 0.013*\"service\" + 0.011*\"member\" + 0.011*\"presence\" + 0.009*\"cell\" + 0.009*\"plasma\" + 0.009*\"cetuximab\"\n",
      "Topic: 44 \n",
      "Words: 0.044*\"paclitaxel\" + 0.022*\"cisplatin\" + 0.022*\"second\" + 0.019*\"single\" + 0.018*\"line\" + 0.013*\"day\" + 0.011*\"week\" + 0.010*\"treatment\" + 0.009*\"panitumumab\" + 0.009*\"progression\"\n",
      "Topic: 45 \n",
      "Words: 0.015*\"junction\" + 0.012*\"lung\" + 0.011*\"product\" + 0.011*\"liver\" + 0.011*\"cell\" + 0.011*\"tablet\" + 0.011*\"weekly\" + 0.010*\"sample\" + 0.010*\"tumor\" + 0.009*\"severity\"\n",
      "Topic: 46 \n",
      "Words: 0.012*\"prediction\" + 0.010*\"movement\" + 0.010*\"define\" + 0.009*\"blood\" + 0.009*\"sampling\" + 0.009*\"risk\" + 0.009*\"invasive\" + 0.008*\"adjuvant\" + 0.008*\"screening\" + 0.008*\"model\"\n",
      "Topic: 47 \n",
      "Words: 0.041*\"stop\" + 0.039*\"cell\" + 0.033*\"tumor\" + 0.029*\"drug\" + 0.027*\"chemotherapy\" + 0.025*\"way\" + 0.024*\"treating\" + 0.024*\"different\" + 0.023*\"dividing\" + 0.023*\"growing\"\n",
      "Topic: 48 \n",
      "Words: 0.024*\"chemoradiation\" + 0.017*\"predict\" + 0.014*\"involves\" + 0.014*\"researcher\" + 0.012*\"polypectomy\" + 0.011*\"implementation\" + 0.011*\"response\" + 0.010*\"positive\" + 0.009*\"intervention\" + 0.009*\"research\"\n",
      "Topic: 49 \n",
      "Words: 0.014*\"inoperable\" + 0.012*\"gastric\" + 0.012*\"identify\" + 0.011*\"related\" + 0.011*\"advanced\" + 0.010*\"chemotherapy\" + 0.010*\"multicentre\" + 0.010*\"biomarkers\" + 0.010*\"combination\" + 0.009*\"locally\"\n",
      "Topic: 50 \n",
      "Words: 0.017*\"line\" + 0.015*\"nutrition\" + 0.013*\"solution\" + 0.013*\"evaluate\" + 0.012*\"metastatic\" + 0.011*\"folfox\" + 0.010*\"safety\" + 0.010*\"cleansing\" + 0.010*\"gastric\" + 0.010*\"therapy\"\n",
      "Topic: 51 \n",
      "Words: 0.032*\"preventing\" + 0.016*\"optimal\" + 0.014*\"untreated\" + 0.011*\"doctor\" + 0.010*\"screening\" + 0.010*\"confocal\" + 0.010*\"previously\" + 0.008*\"learn\" + 0.008*\"randomized\" + 0.008*\"colorectal\"\n",
      "Topic: 52 \n",
      "Words: 0.013*\"real\" + 0.011*\"octreotide\" + 0.010*\"supplement\" + 0.010*\"detecting\" + 0.010*\"half\" + 0.009*\"oncology\" + 0.007*\"screening\" + 0.007*\"efficacy\" + 0.007*\"methylation\" + 0.007*\"measurement\"\n",
      "Topic: 53 \n",
      "Words: 0.016*\"fluorescence\" + 0.013*\"extended\" + 0.012*\"subgroup\" + 0.010*\"flow\" + 0.009*\"blood\" + 0.009*\"malnutrition\" + 0.009*\"retrospective\" + 0.008*\"poor\" + 0.008*\"major\" + 0.007*\"detection\"\n",
      "Topic: 54 \n",
      "Words: 0.030*\"elderly\" + 0.019*\"imaging\" + 0.019*\"tomography\" + 0.018*\"ablation\" + 0.014*\"assisted\" + 0.014*\"submucosal\" + 0.013*\"computed\" + 0.013*\"correlation\" + 0.012*\"endoscopic\" + 0.011*\"xelox\"\n",
      "Topic: 55 \n",
      "Words: 0.013*\"folfiri\" + 0.012*\"artery\" + 0.012*\"resected\" + 0.012*\"tumour\" + 0.011*\"rectal\" + 0.010*\"treatment\" + 0.009*\"arm\" + 0.009*\"placebo\" + 0.008*\"surgery\" + 0.008*\"selection\"\n",
      "Topic: 56 \n",
      "Words: 0.021*\"induced\" + 0.015*\"screening\" + 0.011*\"folinic\" + 0.011*\"ass\" + 0.011*\"educational\" + 0.011*\"material\" + 0.009*\"adult\" + 0.009*\"determine\" + 0.008*\"rectum\" + 0.008*\"acid\"\n",
      "Topic: 57 \n",
      "Words: 0.035*\"platinum\" + 0.024*\"survivor\" + 0.020*\"physical\" + 0.019*\"relapsed\" + 0.019*\"elective\" + 0.015*\"breast\" + 0.013*\"disorder\" + 0.012*\"metabolic\" + 0.011*\"activity\" + 0.008*\"measure\"\n",
      "Topic: 58 \n",
      "Words: 0.029*\"stool\" + 0.022*\"diarrhea\" + 0.016*\"protein\" + 0.013*\"specificity\" + 0.013*\"vaccination\" + 0.011*\"vaccine\" + 0.010*\"existing\" + 0.010*\"lynch\" + 0.010*\"western\" + 0.010*\"sensitivity\"\n",
      "Topic: 59 \n",
      "Words: 0.013*\"capecitabine\" + 0.012*\"region\" + 0.010*\"survivor\" + 0.010*\"radiation\" + 0.009*\"tumor\" + 0.008*\"treated\" + 0.008*\"determine\" + 0.008*\"colorectal\" + 0.008*\"approved\" + 0.007*\"treatment\"\n",
      "Topic: 60 \n",
      "Words: 0.020*\"evaluates\" + 0.014*\"participant\" + 0.014*\"week\" + 0.014*\"vaccine\" + 0.013*\"beneficial\" + 0.013*\"radiation\" + 0.013*\"age\" + 0.011*\"injection\" + 0.010*\"asian\" + 0.010*\"score\"\n",
      "Topic: 61 \n",
      "Words: 0.023*\"prophylactic\" + 0.023*\"complication\" + 0.021*\"aflibercept\" + 0.014*\"panitumumab\" + 0.013*\"tolerance\" + 0.012*\"hospital\" + 0.012*\"university\" + 0.012*\"melanoma\" + 0.011*\"record\" + 0.010*\"regimen\"\n",
      "Topic: 62 \n",
      "Words: 0.035*\"diet\" + 0.023*\"pylorus\" + 0.019*\"predicting\" + 0.014*\"weight\" + 0.013*\"eradication\" + 0.010*\"serum\" + 0.009*\"therapy\" + 0.009*\"gastric\" + 0.008*\"acid\" + 0.008*\"arterial\"\n",
      "Topic: 63 \n",
      "Words: 0.014*\"regimen\" + 0.014*\"scan\" + 0.011*\"agent\" + 0.010*\"pancreatic\" + 0.010*\"adenocarcinoma\" + 0.009*\"esophagogastric\" + 0.009*\"anti\" + 0.009*\"angiogenesis\" + 0.009*\"possible\" + 0.009*\"rectum\"\n",
      "Topic: 64 \n",
      "Words: 0.021*\"intervention\" + 0.021*\"screening\" + 0.010*\"outcome\" + 0.009*\"bowel\" + 0.009*\"colonoscopy\" + 0.009*\"aim\" + 0.008*\"caregiver\" + 0.008*\"primary\" + 0.007*\"telephone\" + 0.007*\"related\"\n",
      "Topic: 65 \n",
      "Words: 0.024*\"objective\" + 0.022*\"refractory\" + 0.016*\"inhibitor\" + 0.016*\"survival\" + 0.013*\"rate\" + 0.012*\"free\" + 0.012*\"response\" + 0.011*\"secondary\" + 0.010*\"primary\" + 0.010*\"evaluate\"\n",
      "Topic: 66 \n",
      "Words: 0.020*\"postoperative\" + 0.016*\"surgery\" + 0.011*\"abdominal\" + 0.010*\"anesthesia\" + 0.009*\"pain\" + 0.008*\"complication\" + 0.008*\"expressing\" + 0.008*\"protocol\" + 0.008*\"gastric\" + 0.007*\"delivered\"\n",
      "Topic: 67 \n",
      "Words: 0.013*\"adenocarcinoma\" + 0.011*\"squamous\" + 0.011*\"pembrolizumab\" + 0.010*\"extension\" + 0.009*\"bevacizumab\" + 0.009*\"single\" + 0.009*\"elderly\" + 0.008*\"death\" + 0.008*\"expression\" + 0.008*\"group\"\n",
      "Topic: 68 \n",
      "Words: 0.039*\"sunitinib\" + 0.017*\"dosing\" + 0.012*\"interleukin\" + 0.012*\"magnetic\" + 0.010*\"intolerant\" + 0.010*\"resonance\" + 0.010*\"assessment\" + 0.009*\"single\" + 0.009*\"measured\" + 0.009*\"treatment\"\n",
      "Topic: 69 \n",
      "Words: 0.020*\"folfiri\" + 0.019*\"inflammation\" + 0.018*\"intestinal\" + 0.016*\"consecutive\" + 0.011*\"complete\" + 0.011*\"responder\" + 0.010*\"response\" + 0.010*\"undergoing\" + 0.010*\"week\" + 0.010*\"later\"\n",
      "Topic: 70 \n",
      "Words: 0.046*\"neck\" + 0.043*\"head\" + 0.032*\"mucositis\" + 0.017*\"mouth\" + 0.012*\"called\" + 0.012*\"lesion\" + 0.011*\"radiation\" + 0.009*\"nutritional\" + 0.009*\"medicine\" + 0.009*\"imatinib\"\n",
      "Topic: 71 \n",
      "Words: 0.035*\"growth\" + 0.031*\"cell\" + 0.024*\"tumor\" + 0.022*\"unresectable\" + 0.020*\"blocking\" + 0.020*\"stop\" + 0.019*\"enzyme\" + 0.018*\"work\" + 0.016*\"treating\" + 0.016*\"oxaliplatin\"\n",
      "Topic: 72 \n",
      "Words: 0.012*\"colonoscopy\" + 0.012*\"polyp\" + 0.011*\"routine\" + 0.010*\"rehabilitation\" + 0.010*\"care\" + 0.009*\"sedation\" + 0.008*\"screening\" + 0.007*\"starting\" + 0.007*\"diagnosis\" + 0.007*\"planning\"\n",
      "Topic: 73 \n",
      "Words: 0.025*\"intravenous\" + 0.024*\"confirmed\" + 0.022*\"maintenance\" + 0.017*\"consisting\" + 0.016*\"injection\" + 0.015*\"infusion\" + 0.013*\"enroll\" + 0.013*\"subject\" + 0.010*\"disease\" + 0.010*\"stromal\"\n",
      "Topic: 74 \n",
      "Words: 0.022*\"avastin\" + 0.019*\"xeloda\" + 0.013*\"screening\" + 0.012*\"image\" + 0.011*\"programme\" + 0.011*\"carboplatin\" + 0.011*\"bevacizumab\" + 0.010*\"endoscopists\" + 0.010*\"detection\" + 0.009*\"intention\"\n",
      "Topic: 75 \n",
      "Words: 0.035*\"cetuximab\" + 0.030*\"tumor\" + 0.025*\"cell\" + 0.024*\"block\" + 0.019*\"growth\" + 0.019*\"monoclonal\" + 0.018*\"spread\" + 0.017*\"work\" + 0.016*\"antibody\" + 0.016*\"killing\"\n",
      "Topic: 76 \n",
      "Words: 0.014*\"life\" + 0.014*\"anastomosis\" + 0.013*\"undergoing\" + 0.013*\"quality\" + 0.013*\"mucositis\" + 0.011*\"pain\" + 0.009*\"symptom\" + 0.009*\"older\" + 0.008*\"generation\" + 0.008*\"associated\"\n",
      "Topic: 77 \n",
      "Words: 0.032*\"neoadjuvant\" + 0.017*\"rectal\" + 0.016*\"tolerability\" + 0.016*\"gastric\" + 0.014*\"excision\" + 0.012*\"paclitaxel\" + 0.011*\"ultrasound\" + 0.011*\"mesorectal\" + 0.010*\"locally\" + 0.010*\"feasibility\"\n",
      "Topic: 78 \n",
      "Words: 0.034*\"placebo\" + 0.032*\"oral\" + 0.019*\"carcinoma\" + 0.019*\"double\" + 0.017*\"blind\" + 0.015*\"regorafenib\" + 0.013*\"receiving\" + 0.011*\"skin\" + 0.010*\"safety\" + 0.009*\"participant\"\n",
      "Topic: 79 \n",
      "Words: 0.036*\"training\" + 0.018*\"vessel\" + 0.018*\"radiofrequency\" + 0.016*\"performance\" + 0.014*\"heart\" + 0.013*\"ablation\" + 0.012*\"intestine\" + 0.012*\"disease\" + 0.011*\"indication\" + 0.011*\"outpatient\"\n"
     ]
    }
   ],
   "source": [
    "# Train an LDA (Latent Dirichlet Allocation) model on the TF-IDF summary corpus\n",
    "lda_model_tfidf = gensim.models.LdaMulticore(corpus_tfidf_summary, num_topics=80, id2word=dictionary_summary, passes=2, workers=4)\n",
    "\n",
    "# Initialize an empty list to store the LDA topics for the TF-IDF version\n",
    "tfidf_list=[]\n",
    "\n",
    "# Iterate over the topics in the LDA model and print them\n",
    "for idx, topic in lda_model_tfidf.print_topics(-1):\n",
    "    print('Topic: {} \\nWords: {}'.format(idx, topic))\n",
    "    topic_string='Topic: {} \\nWords: {}'.format(idx, topic)\n",
    "    tfidf_list.append(topic_string)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "4da71666",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Topic: 0.062*\"chemotherapy\" + 0.039*\"tumor\" + 0.033*\"stop\" + 0.033*\"cell\" + 0.028*\"drug\" + 0.025*\"therapy\" + 0.022*\"radiation\" + 0.020*\"trial\" + 0.020*\"treating\" + 0.020*\"purpose\"\n"
     ]
    }
   ],
   "source": [
    "# Iterate over the topics and for the first document in the summary corpus BOW model\n",
    "for index, score in sorted(lda_model1[bow_corpus_summary[0]], key=lambda tup: -1*tup[1]):\n",
    "    print(\"\\nTopic: {}\".format( lda_model1.print_topic(index, 10)))\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "3a4cdd03",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Topic: 0.026*\"colorectal\" + 0.022*\"combination\" + 0.017*\"advanced\" + 0.016*\"tumor\" + 0.015*\"chemotherapy\" + 0.014*\"metastatic\" + 0.013*\"colonoscopy\" + 0.013*\"cell\" + 0.012*\"trial\" + 0.012*\"paclitaxel\"\n"
     ]
    }
   ],
   "source": [
    "# Iterate over the topics for the first document in the summary corpus TF-IDF model\n",
    "for index, score in sorted(lda_model_tfidf[corpus_tfidf_summary[0]], key=lambda tup: -1*tup[1]):\n",
    "    print(\"\\nTopic: {}\".format(lda_model1.print_topic(index, 10)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "df1aa97a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[measurement of chemotherapy effectiveness, measurement of tumor response, measurement of cell response, measurement of drug efficacy, measurement of therapy outcomes, measurement of radiation impact, measurement of trial outcomes]\n"
     ]
    }
   ],
   "source": [
    "# Set the OpenAI API key make sure to use your own key, or the notebook will not work\n",
    "openai.api_key = ################################\n",
    "import requests\n",
    "# Create an empty list to store the scores\n",
    "list_of_scores=[]\n",
    "# Iterate over the topics and scores for the first document in the summary corpus\n",
    "for index, score in sorted(lda_model1[bow_corpus_summary[0]], key=lambda tup: -1*tup[1]):\n",
    "# Append the topic string to the list of scores\n",
    "    list_of_scores.append(lda_model1.print_topic(index))\n",
    "    break\n",
    "    \n",
    "# Define the user input query for the LLM \n",
    "input1=' give all of the measurements found without scores for the topics below: '\n",
    "\n",
    "# Define the URL for the OpenAI API\n",
    "URL = \"https://api.openai.com/v1/chat/completions\"\n",
    "\n",
    "# Construct the complete query by joining the list of scores\n",
    "query=(input1 + ', '.join(list_of_scores))\n",
    "\n",
    "# Construct the payload for the API request\n",
    "payload = {\n",
    "\"model\": \"gpt-3.5-turbo-16k\",\n",
    "\"messages\": [{'role': 'system','content':'you are a translation system. Your role is to get this type of input (Topic: 0.038* tumor  + 0.027*cell + 0.015*drug + 0.014*colorectal + 0.014*treatment + 0.013*growth + 0.013*screening + 0.010*bevacizumab + 0.009*chemotherapy + 0.009*therapy and reformat it into this type:[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]'},\n",
    "            {\"role\": \"user\", \"content\": query}],\n",
    "\"temperature\" : 0.8,\n",
    "\"top_p\":0.87,\n",
    "\"n\" : 1,\n",
    "\"stream\": False,\n",
    "\"presence_penalty\":0.03,\n",
    "\"frequency_penalty\":0.5,\n",
    "}\n",
    "\n",
    "headers = {\n",
    "\"Content-Type\": \"application/json\",\n",
    "\"Authorization\": f\"Bearer {openai.api_key}\"\n",
    "}\n",
    "# Send a POST request to the OpenAI API\n",
    "response = requests.post(URL, headers=headers, json=payload, stream=False)\n",
    "\n",
    "# Parse the response JSON\n",
    "response_json = response.json()\n",
    "\n",
    "# Extract the chatbot response\n",
    "chatbot_response = response_json['choices'][0]['message']['content']\n",
    "\n",
    "# Split the chatbot response into a list of individual measurements\n",
    "measurements_list = chatbot_response.strip().split('\\n')\n",
    "\n",
    "#Print the list of measurements\n",
    "for measurement in measurements_list:\n",
    "    print(measurement)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "2d603d89",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['[measurement of laparoscopic surgery, measurement of gastric surgery, measurement of comparing lymph recovery, measurement of versus node type, measurement of anal recovery]']\n",
      "['[measurement of safe use, measurement of gastric treatment, measurement of docetaxel treatment, measurement of cisplatin treatment, measurement of malignancy, measurement of oral treatment, measurement of causation, measurement of small size, measurement of capecitabine treatment, measurement of effectiveness]']\n",
      "['measurement of familial adenomatous polyposis', 'measurement of monitor', 'measurement of fluid', 'measurement of observed', 'measurement of surgery', 'measurement of bevacizumab', 'measurement of giving', 'measurement of randomized']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of bevacizumab impact', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "['measurement of stromal tumor malignancy', 'measurement of gene response', 'measurement of biopsy outcomes', 'measurement of mutation effects', 'measurement of cell response', 'measurement of tissue response', 'measurement of targeting efficacy', 'measurement of human response']\n",
      "['[measurement of goal achievement, measurement of operative outcomes, measurement of research impact, measurement of relationship effectiveness, measurement of live performance, measurement of assistance provided, measurement of studies conducted, measurement of highest group performance, measurement of clinical outcomes]']\n",
      "['measurement of palliative effect', 'measurement of mucosa response', 'measurement of panitumumab efficacy', 'measurement of dietary impact', 'measurement of document analysis', 'measurement of capecitabine effectiveness', 'measurement of median outcomes', 'measurement of neoplastic response', 'measurement of beam impact', 'measurement of polyp size']\n",
      "['[measurement of sorafenib effectiveness, measurement of child response, measurement of adding impact, measurement of referral effectiveness, measurement of educational outcomes, measurement of pathway effectiveness, measurement of clear outcomes, measurement of nurse effectiveness, measurement of colon-based outcomes]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[measurement of colonoscopy, measurement of colonoscopy, measurement of stoma, measurement of sequence, measurement of polyp, measurement of device, measurement of apatinib, measurement of human, measurement of factor, measurement of efficacy]']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['measurement of tumor growth, measurement of investigates, measurement of effect, measurement of cell, measurement of good, measurement of pilot, measurement of simultaneous, measurement of prospective, measurement of mutation']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of program effectiveness, measurement of navigation impact, measurement of providing effectiveness']\n",
      "[\"[measurement of surgery outcomes, measurement of crohn's treatment, measurement of stomach treatment, measurement of sentinel effectiveness, measurement of soft treatment, measurement of radiation treatment, measurement of tissue response, measurement of esophageal treatment, measurement of cell response, measurement of work effectiveness]\"]\n",
      "['[measurement of tumor growth, measurement of cell response]']\n",
      "['[measurement of demonstration, measurement of chemoradiation, measurement of antigen, measurement of prevalence, measurement of determination, measurement of therapy, measurement of healing, measurement of induction, measurement of tested, measurement of response]']\n",
      "['measurement of gastrectomy', 'measurement of node', 'measurement of lymph', 'measurement of folfir', 'measurement of satisfaction', 'measurement of dissection', 'measurement of analgesia', 'measurement of laparoscopic', 'measurement of healthy', 'measurement of near']\n",
      "['[measurement of previously responded muscle reflux treated health screening intervention examine moderate]']\n",
      "['measurement of completion', 'measurement of young', 'measurement of fixed', 'measurement of subsequent', 'measurement of strength', 'measurement of incidence', 'measurement of pelvic', 'measurement of loss', 'measurement of initiation', 'measurement of muscle']\n",
      "['[measurement of investigate, measurement of tool, measurement of screening, measurement of optical, measurement of testing, measurement of vaccine, measurement of FOBT, measurement of group, measurement of recent, measurement of Asian]']\n",
      "['[measurement of celecoxib efficacy, measurement of exercise impact, measurement of radiotherapy effectiveness, measurement of portion size, measurement of bacteria response, measurement of learning outcomes, measurement of step count, measurement of influence, measurement of rectal treatment]']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['[measurement of imatinib efficacy, measurement of mesylate response, measurement of label effectiveness, measurement of open impact, measurement of stromal response, measurement of colectomy outcomes, measurement of resection outcomes, measurement of following impact, measurement of regorafenib efficacy]']\n",
      "['[measurement of mitomycin, measurement of modulated, measurement of failure, measurement of light, measurement of risk, measurement of scope, measurement of develop, measurement of decision, measurement of colonic]']\n",
      "['measurement of dose tolerance', 'measurement of tolerated combination', 'measurement of maximum dose', 'measurement of determine', 'measurement of irinotecan', 'measurement of phase', 'measurement of KRAS', 'measurement of recommended', 'measurement of concurrent']\n",
      "['measurement of fatigue', 'measurement of mfolfox efficacy', 'measurement of bleeding', 'measurement of symptoms', 'measurement of developing cancer', 'measurement of late effects', 'measurement of protection', 'measurement of identified women']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['[measurement of water leak, measurement of esophageal option, measurement of examination, measurement of anastomotic carcinomatosis, measurement of treated histologically localized]']\n",
      "['measurement of vitamin', 'measurement of pemetrexed', 'measurement of esophagus', 'measurement of barrett', 'measurement of chemoprevention', 'measurement of certain', 'measurement of observe', 'measurement of observation', 'measurement of procedure', 'measurement of finding']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[measurement of bevacizumab impact, measurement of group response, measurement of positive response, measurement of anesthesia, measurement of concentration, measurement of activity, measurement of female response, measurement of factor impact, measurement of improvement, measurement of gastric treatment]']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['[measurement of everolimus impact, measurement of navigator effectiveness, measurement of band impact, measurement of care effectiveness, measurement of narrow outcomes, measurement of white outcomes, measurement of financial outcomes, measurement of project outcomes, measurement of disparity outcomes, measurement of endomicroscopy]']\n",
      "['measurement of bowel preparation', 'measurement of plan', 'measurement of volume', 'measurement of histology', 'measurement of versus', 'measurement of colonoscopy', 'measurement of caused', 'measurement of self', 'measurement of perioperative']\n",
      "['[measurement of adenoma detection, measurement of robotic detection, measurement of under went detection, measurement of laparoscopic detection, measurement of rate detection, measurement of colonoscopy detection, measurement of compare detection, measurement of risk surgery]']\n",
      "['measurement of dysphagia', 'measurement of monotherapy', 'measurement of recurrent', 'measurement of duodenal', 'measurement of slow', 'measurement of interfere', 'measurement of device', 'measurement of esophagus', 'measurement of rectal', 'measurement of safety']\n",
      "['[measurement of esophagectomy, measurement of newly, measurement of vomiting, measurement of nausea, measurement of autologous, measurement of planned, measurement of diagnosed, measurement of month, measurement of evaluating, measurement of receiving]']\n",
      "['[measurement of gene response, measurement of BRAF response, measurement of vaccine efficacy, measurement of VEGFR response, measurement of mutant response, measurement of immune response, measurement of cell response, measurement of cetuximab impact, measurement of blood response, measurement of papillomavirus]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['measurement of gemcitabine', 'measurement of counseling', 'measurement of prevention', 'measurement of program', 'measurement of care', 'measurement of cost', 'measurement of thought', 'measurement of session', 'measurement of improves', 'measurement of anterior']\n",
      "['[measurement of pathological tumor growth, measurement of practice response, measurement of daily drug efficacy, measurement of CRC treatment, measurement of retrospectively screening effectiveness, measurement of dysplasia impact, measurement of multicentric chemotherapy effectiveness, measurement of retrospectively therapy outcomes, measurement of gastric treatment]']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of service effectiveness, measurement of member presence, measurement of cell presence, measurement of plasma presence, measurement of cetuximab impact]']\n",
      "['[measurement of treatment, measurement of panitumumab, measurement of progression]']\n",
      "['measurement of tumor growth, measurement of lung response, measurement of product efficacy, measurement of liver treatment, measurement of cell effectiveness, measurement of tablet impact, measurement of weekly chemotherapy effectiveness, measurement of sample outcomes, measurement of severity.']\n",
      "['[measurement of prediction, measurement of movement, measurement of define, measurement of blood, measurement of sampling, measurement of risk, measurement of invasive, measurement of advantage, measurement of screening, measurement of model]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of chemotherapy effectiveness]']\n",
      "['measurement of chemotherapy', 'measurement of predict', 'measurement of involves', 'measurement of researcher', 'measurement of polypectomy', 'measurement of implementation', 'measurement of response', 'measurement of positive', 'measurement of intervention', 'measurement of research']\n",
      "['[measurement of inoperable tumor, measurement of gastric tumor, measurement of identified tumor, measurement of related tumor, measurement of advanced tumor, measurement of chemotherapy, measurement of multicenter study, measurement of biomarkers, measurement of combination therapy, measurement of locally]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[preventing, optimal, untreated, doctor, screening, confocal, previously, learn, randomized, colorectal]']\n",
      "['[measurement of octreotide supplementation, measurement of detecting half oncology, measurement of screening efficacy, measurement of methylation, measurement of measurement]']\n",
      "['[measurement of fluorescence, measurement of extended, measurement of subgroup, measurement of flow, measurement of blood, measurement of malnutrition, measurement of retrospective, measurement of poor, measurement of major, measurement of detection]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[measurement of tumor growth, measurement of artery response, measurement of resected tissue, measurement of rectal tumor treatment, measurement of arm, measurement of placebo, measurement of surgery, measurement of selection]']\n",
      "['[measurement of induced screening, measurement of folinic ass, measurement of educational material, measurement of adult determine rectum acid]']\n",
      "['measurement of platinum', 'measurement of survivor', 'measurement of physical', 'measurement of relapsed', 'measurement of elective', 'measurement of breast', 'measurement of disorder', 'measurement of metabolic', 'measurement of activity', 'measurement of measure']\n",
      "['[measurement of stool, measurement of diarrhea, measurement of protein, measurement of specificity, measurement of vaccination, measurement of vaccine, measurement of existing, measurement of lynch, measurement of western, measurement of sensitivity]']\n",
      "['measurement of capecitabine region', 'measurement of survivor', 'measurement of radiation', 'measurement of tumor', 'measurement of treated', 'measurement of determine', 'measurement of colorectal', 'measurement of approved', 'measurement of treatment']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['measurement of prophylactic', 'measurement of complication', 'measurement of aflibercept', 'measurement of panitumumab', 'measurement of tolerance', 'measurement of hospital', 'measurement of university', 'measurement of melanoma', 'measurement of record', 'measurement of regimen']\n",
      "['[measurement of diet, measurement of pylorus, measurement of predicting, measurement of weight, measurement of eradication, measurement of serum, measurement of therapy, measurement of gastric, measurement of acid, measurement of arterial]']\n",
      "['[measurement of regimen effectiveness, measurement of scan response, measurement of agent efficacy, measurement of pancreatic treatment, measurement of adenocarcinoma treatment, measurement of esophagogastric treatment, measurement of anti-angiogenesis impact, measurement of possible outcomes, measurement of rectum treatment]']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['measurement of intervention, measurement of screening, measurement of outcome, measurement of bowel, measurement of colonoscopy, measurement of aim, measurement of caregiver, measurement of primary, measurement of telephone, measurement of related']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of bevacizumab impact', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "['[measurement of postoperative surgery, measurement of abdominal anesthesia, measurement of pain, measurement of complication, measurement of expressing, measurement of protocol, measurement of gastric, measurement of delivered]']\n",
      "['measurement of adenocarcinoma', 'measurement of squamous', 'measurement of pembrolizumab', 'measurement of extension', 'measurement of bevacizumab', 'measurement of single', 'measurement of elderly', 'measurement of death', 'measurement of expression', 'measurement of group']\n",
      "['[measurement of sunitinib dosing, measurement of interleukin dosing, measurement of magnetic intolerant resonance assessment, measurement of single measured treatment]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[measurement of neck, measurement of head, measurement of mucositis, measurement of mouth, measurement of called, measurement of lesion, measurement of radiation, measurement of nutritional, measurement of medicine, measurement of imatinib]']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of bevacizumab impact', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "['[measurement of colonoscopy, measurement of polyp, measurement of routine, measurement of rehabilitation, measurement of care, measurement of sedation, measurement of screening, measurement of starting, measurement of diagnosis, measurement of planning]']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of bevacizumab impact', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "[\"[measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of screening effectiveness, measurement of image detection, measurement of programme outcomes, measurement of carboplatin impact, measurement of endoscopists' performance, measurement of detection accuracy, measurement of intention]\"]\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of blocking effectiveness, measurement of growth, measurement of monoclonal impact, measurement of spread, measurement of work, measurement of antibody effectiveness, measurement of killing]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['measurement of neoadjuvant tolerability', 'measurement of rectal tolerability', 'measurement of gastric excision', 'measurement of paclitaxel', 'measurement of ultrasound', 'measurement of mesorectal', 'measurement locally', 'measurement feasibility']\n",
      "['measurement of placebo efficacy', 'measurement of oral efficacy', 'measurement of carcinoma growth', 'measurement of double-blind effectiveness', 'measurement of regorafenib impact', 'measurement of receiving outcomes', 'measurement of skin safety', 'measurement of participant safety']\n",
      "['[measurement of training, measurement of vessel, measurement of radiofrequency, measurement of performance, measurement of heart, measurement of ablation, measurement of intestine, measurement of disease, measurement of indication, measurement of outpatient]']\n",
      "[measurement of training, measurement of vessel, measurement of radiofrequency, measurement of performance, measurement of heart, measurement of ablation, measurement of intestine, measurement of disease, measurement of indication, measurement of outpatient]\n"
     ]
    }
   ],
   "source": [
    "# Set the OpenAI API key make sure to use your own key, or the notebook will not work\n",
    "openai.api_key = ################################\n",
    "import requests\n",
    "\n",
    "# Create empty lists to store the scores and measurements\n",
    "list_of_scores_tfidf=[]\n",
    "list_all_measurements_tfidf=[]\n",
    "\n",
    "\n",
    "for z in tfidf_list:\n",
    "    list_of_scores_tfidf=z\n",
    " # Define the user input query for TF-IDF\n",
    "    input_tfidf=' give all of the measurements found without scores for the topics below: '\n",
    "    URL_tfidf = \"https://api.openai.com/v1/chat/completions\"\n",
    "    query_tfidf=(input_tfidf + ', '.join(list_of_scores_tfidf))\n",
    "    payload_tfidf = {\n",
    "    \"model\": \"gpt-3.5-turbo-16k\",\n",
    "    \"messages\": [{'role': 'system','content':'you are a translation system. Your role is to get this type of input (Topic: 0.038* tumor  + 0.027*cell + 0.015*drug + 0.014*colorectal + 0.014*treatment + 0.013*growth + 0.013*screening + 0.010*bevacizumab + 0.009*chemotherapy + 0.009*therapy and reformat it into this type:[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]'},\n",
    "                {\"role\": \"user\", \"content\": query_tfidf}],\n",
    "    \"temperature\" : 0.8,\n",
    "    \"top_p\":0.87,\n",
    "    \"n\" : 1,\n",
    "    \"stream\": False,\n",
    "    \"presence_penalty\":0.03,\n",
    "    \"frequency_penalty\":0.5,\n",
    "    }\n",
    "\n",
    "    headers_tfidf = {\n",
    "    \"Content-Type\": \"application/json\",\n",
    "    \"Authorization\": f\"Bearer {openai.api_key}\"\n",
    "    }\n",
    "    try:\n",
    "         # Send a POST request to the OpenAI API for TF-IDF and get the response\n",
    "        response_tfidf = requests.post(URL_tfidf, headers=headers_tfidf, json=payload_tfidf, stream=False)\n",
    "        response_json_tfidf = response_tfidf.json()\n",
    "        chatbot_response_tfidf = response_json_tfidf['choices'][0]['message']['content']\n",
    "        # Split the chatbot response into a list of individual measurements\n",
    "        measurements_list_tfidf = chatbot_response_tfidf.strip().split('\\n')\n",
    "        print(chatbot_response_tfidf.strip().split('\\n'))\n",
    "        list_all_measurements_tfidf.append((chatbot_response_tfidf.strip().split('\\n')))\n",
    "    except:\n",
    "        continue\n",
    "#Print the list of measurements\n",
    "for measurement in measurements_list_tfidf:\n",
    "    print(measurement)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "fc82ab01",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['[measurement of treatment, measurement of gastric, measurement of response, measurement of tumor, measurement of chemotherapy, measurement of clinical, measurement of advanced, measurement of colorectal, measurement of combination, measurement of primary]']\n",
      "['measurement of surgery, measurement of group, measurement of treatment, measurement of colorectal, measurement of respiratory, measurement of pulmonary, measurement of compare, measurement of postoperative, measurement of performed, measurement of participant']\n",
      "['[measurement of treatment, measurement of gastric, measurement of screening, measurement of disease, measurement of immune, measurement of objective, measurement of tumor, measurement of related, measurement of clinical, measurement of great]']\n",
      "['measurement of tumor growth, measurement of palliative care, measurement of weekly treatment, measurement of placebo, measurement of randomized, measurement of receive, measurement of standard, measurement of visit, measurement of oral']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of growth', 'measurement of test', 'measurement of associated factors', 'measurement of blood', 'measurement of therapy outcomes']\n",
      "['measurement of cell response, measurement of drug efficacy, measurement of screening effectiveness, measurement of bevacizumab impact']\n",
      "['[measurement of treatment, measurement of imaging, measurement of rectal, measurement of biopsy, measurement of colon, measurement of disease, measurement of information, measurement of resection, measurement of surgery]']\n",
      "['measurement of chemotherapy', 'measurement of tumor', 'measurement of drug', 'measurement of phase', 'measurement of treatment', 'measurement of gastric', 'measurement of factor', 'measurement of randomized', 'measurement of participant', 'measurement of recurrence']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['measurement of treatment ', 'measurement of cell ', 'measurement of tumor ', 'measurement of death ', 'measurement of colorectal ', 'measurement of cause ', 'measurement of disease ', 'measurement of prognostic ', 'measurement of bevacizumab ', 'measurement of year']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of bevacizumab impact', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "['[measurement of gastric treatment, measurement of stomach acid, measurement of treatment, measurement of event, measurement of cell response, measurement of lining, measurement of effect, measurement of progression, measurement of colonic]']\n",
      "['measurement of treatment', 'measurement of individual', 'measurement of investigator', 'measurement of chemotherapy', 'measurement of outcome', 'measurement of care', 'measurement of improve', 'measurement of time', 'measurement of surgical', 'measurement of colon']\n",
      "['[measurement of colorectal treatment, measurement of screening effectiveness, measurement of drug efficacy, measurement of therapy outcomes]']\n",
      "['[measurement of gastric diagnosis, measurement of primary tissue, measurement of upper screening, measurement of objective rate, measurement of colorectal detection]']\n",
      "['measurement of colorectal treatment, measurement of group, measurement of outcome, measurement of compare, measurement of surgery, measurement of anastomosis, measurement of purpose, measurement of quality, measurement of hereditary, measurement of surgical']\n",
      "['[measurement of surgery rate, measurement of rectal surgery, measurement of local surgery, measurement of abdominal surgery, measurement of resection, measurement of pain, measurement of western treatment, measurement of postoperative therapy]']\n",
      "['measurement of screening', 'measurement of group', 'measurement of outcome', 'measurement of surgery', 'measurement of year', 'measurement of data', 'measurement of recovery', 'measurement of colonoscopy', 'measurement of hospital', 'measurement of method']\n",
      "['measurement of treatment', 'measurement of polyp', 'measurement of diagnosis', 'measurement of optical', 'measurement of phase', 'measurement of mcr', 'measurement of open', 'measurement of chemotherapy', 'measurement of trial', 'measurement of cell']\n",
      "['measurement of treatment', 'measurement of sunitinib', 'measurement of gist', 'measurement of regorafenib', 'measurement of tumor', 'measurement of kinase', 'measurement of purpose', 'measurement of advanced', 'measurement of imatinib', 'measurement of therapy']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "['measurement of node', 'measurement of lymph', 'measurement of surgery', 'measurement of trial', 'measurement of clinical', 'measurement of colorectal', 'measurement of treatment', 'measurement of cell', 'measurement of randomized', 'measurement of follow']\n",
      "['[measurement of care, measurement of colorectal, measurement of disease, measurement of pain, measurement of physician, measurement of health, measurement of life, measurement of undergoing, measurement of purpose, measurement of palliative]']\n",
      "['[measurement of treatment, measurement of secondary, measurement of symptom, measurement of chemotherapy, measurement of radiotherapy, measurement of procedure, measurement of surgery, measurement of primary, measurement of survival]']\n",
      "['measurement of chemotherapy', 'measurement of gastric', 'measurement of tumor', 'measurement of treatment', 'measurement of purpose', 'measurement of esophageal', 'measurement of colorectal', 'measurement of metastatic', 'measurement of dose', 'measurement of folfox']\n",
      "['[measurement of treatment, measurement of gastric, measurement of chemotherapy, measurement of esophageal, measurement of effect, measurement of stage, measurement of safety, measurement of adjuvant, measurement of phase, measurement of capecitabine]']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of treatment, measurement of chemotherapy, measurement of stop, measurement of growth, measurement of trial, measurement of capecitabine, measurement of everolimus']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of screening effectiveness, measurement of group, measurement of bowel, measurement of investigator, measurement of stent, measurement of colorectal, measurement of esophageal']\n",
      "['[measurement of chemotherapy purpose, measurement of trial, measurement of receiving, measurement of phase, measurement of combination, measurement of advanced, measurement of blood, measurement of tumor, measurement of efficacy]']\n",
      "['measurement of tumor growth', 'measurement of oxaliplatin efficacy', 'measurement of advanced treatment outcomes', 'measurement of regimen effectiveness', 'measurement of capsule impact', 'measurement of capecitabine effectiveness', 'measurement of perioperative outcomes', 'measurement of chemotherapy effectiveness', 'measurement of gastric therapy']\n",
      "['[measurement of risk, measurement of esophageal, measurement of molecular, measurement of barrett, measurement of anal, measurement of colorectal, measurement of investigator, measurement of treatment, measurement of imaging, measurement of esophagus]']\n",
      "['measurement of therapy', 'measurement of radiation', 'measurement of purpose', 'measurement of neck', 'measurement of head', 'measurement of trial', 'measurement of phase', 'measurement of mucositis', 'measurement of randomized', 'measurement of preventing']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['measurement of therapy', 'measurement of survival', 'measurement of rate', 'measurement of resection', 'measurement of treatment', 'measurement of surgical', 'measurement of year', 'measurement of efficacy', 'measurement of primary']\n",
      "['measurement of colorectal', 'measurement of blood', 'measurement of screening', 'measurement of gene', 'measurement of tumor', 'measurement of mutation', 'measurement of sample', 'measurement of cell', 'measurement of drug', 'measurement of laboratory']\n",
      "['[measurement of therapy, measurement of pemetrexed, measurement of gastric, measurement of factor, measurement of cisplatin, measurement of chemoradiation, measurement of tumor, measurement of response, measurement of mucositis, measurement of oral]']\n",
      "['measurement of imatinib efficacy', 'measurement of tumor growth', 'measurement of GIST treatment', 'measurement of colonoscopy effectiveness', 'measurement of high treatment outcomes', 'measurement of month therapy outcomes', 'measurement of cell response', 'measurement of day therapy outcomes', 'measurement of following therapy outcomes']\n",
      "['[measurement of treatment, measurement of capecitabine, measurement of combination, measurement of drug, measurement of approved, measurement of colorectal, measurement of irinotecan, measurement of standard, measurement of improve, measurement of metastatic]']\n",
      "['measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes']\n",
      "['measurement of gastric', 'measurement of postoperative', 'measurement of nutrition', 'measurement of complication', 'measurement of colorectal', 'measurement of survival', 'measurement of assess', 'measurement of year', 'measurement of surveillance', 'measurement of undergoing']\n",
      "['measurement of treatment', 'measurement of colorectal', 'measurement of safety', 'measurement of clinical', 'measurement of regorafenib', 'measurement of effect', 'measurement of prior', 'measurement of phase', 'measurement of efficacy', 'measurement of evaluate']\n",
      "['measurement of cohort', 'measurement of advanced', 'measurement of neoadjuvant', 'measurement of based', 'measurement of phase', 'measurement of locally', 'measurement of trial', 'measurement of treated', 'measurement of purpose', 'measurement of chemotherapy']\n",
      "['[measurement of treatment, measurement of chemotherapy, measurement of risk, measurement of model, measurement of based, measurement of ass, measurement of mucositis, measurement of dose, measurement of high, measurement of radiotherapy]']\n",
      "['measurement of treatment', 'measurement of endoscopic', 'measurement of acid', 'measurement of esophagus', 'measurement of gastric', 'measurement of barrett', 'measurement of lesion', 'measurement of response', 'measurement of investigator', 'measurement of resection']\n",
      "['measurement of tumor growth, measurement of screening effectiveness, measurement of colorectal, measurement of avastin, measurement of evaluate, measurement of objective, measurement of treatment, measurement of colonoscopy, measurement of disease, measurement of investigator']\n",
      "['[measurement of surgery effectiveness, measurement of diet impact, measurement of subject response, measurement of week outcomes, measurement of colorectal treatment, measurement of liver impact, measurement of exercise impact, measurement of resection effectiveness, measurement of blood levels, measurement of program effectiveness]']\n",
      "['measurement of surgery', 'measurement of gastric', 'measurement of laparoscopic', 'measurement of surgical', 'measurement of treatment', 'measurement of standard', 'measurement of survival', 'measurement of rectal', 'measurement of rate', 'measurement of therapy']\n",
      "['[measurement of colorectal combination therapy, measurement of advanced tumor, measurement of chemotherapy, measurement of metastatic colonoscopy, measurement of cell trial, measurement of paclitaxel]']\n",
      "['measurement of tumor growth', 'measurement of cell response', 'measurement of drug efficacy', 'measurement of colorectal treatment', 'measurement of screening effectiveness', 'measurement of chemotherapy effectiveness', 'measurement of therapy outcomes']\n",
      "['[measurement of risk, measurement of polyposis, measurement of colonoscopy, measurement of screening, measurement of factor, measurement of colorectal, measurement of treatment, measurement of survival, measurement of folfox, measurement of test]']\n",
      "['[measurement of dose, evaluate, objective, safety, response, tumor, advanced, determine, phase, treatment]']\n",
      "['[measurement of colorectal treatment, measurement of procedure, measurement of device, measurement of evaluate, measurement of rate, measurement of gastric, measurement of safety, measurement of time, measurement of purpose, measurement of high]']\n",
      "['measurement of tumor growth, measurement of stop, measurement of cell, measurement of drug, measurement of therapy, measurement of radiation, measurement of trial, measurement of treating, measurement of purpose']\n",
      "['measurement of tumor growth', 'measurement of stop', 'measurement of phase', 'measurement of drug', 'measurement of purpose', 'measurement of cell', 'measurement of treating', 'measurement of trial', 'measurement of gastric']\n",
      "['[measurement of treatment, measurement of chemotherapy, measurement of colon, measurement of tumor, measurement of combination, measurement of cell, measurement of effect, measurement of drug, measurement of rectal]']\n",
      "['measurement of colon treatment', 'measurement of colorectal treatment', 'measurement of early therapy', 'measurement of procedure', 'measurement of pain', 'measurement of metastatic', 'measurement of advanced', 'measurement of treatment', 'measurement of irinotecan']\n",
      "['[measurement of treatment, measurement of gastric, measurement of level, measurement of acid, measurement of tumor, measurement of safety, measurement of response, measurement of dosing, measurement of physical, measurement of rectal]']\n",
      "['measurement of tumor growth, measurement of endoscopic, measurement of phase, measurement of rate, measurement of submucosal, measurement of cell, measurement of trial, measurement of advanced, measurement of purpose, measurement of chemotherapy']\n",
      "['[measurement of clinical trial treatment, measurement of high effect, measurement of colorectal approach rate, measurement of purpose, measurement of surgical]']\n",
      "['measurement of safety', 'measurement of phase', 'measurement of combination', 'measurement of advanced', 'measurement of dose', 'measurement of tumor', 'measurement of line', 'measurement of cetuximab', 'measurement of evaluate', 'measurement of progression']\n",
      "['measurement of screening', 'measurement of colorectal', 'measurement of colonoscopy', 'measurement of effective', 'measurement of health', 'measurement of FOBt (fecal occult blood test)', 'measurement of risk', 'measurement of cost', 'measurement of colon', 'measurement of based']\n",
      "['measurement of gastric tumor growth, measurement of colorectal tumor growth, measurement of purpose, measurement of screening effectiveness, measurement of biomarkers, measurement of group, measurement of test, measurement of efficacy, measurement of surgery, measurement of recovery']\n",
      "['measurement of colorectal rate, measurement of detection, measurement of screening, measurement of colonoscopy, measurement of node, measurement of adenoma, measurement of treatment, measurement of response, measurement of lymph']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of chemotherapy, measurement of stop, measurement of treating, measurement of different, measurement of colorectal, measurement of way]']\n",
      "['[measurement of evaluate, measurement of capsule, measurement of purpose, measurement of allow, measurement of safety, measurement of efficacy, measurement of treatment, measurement of swallowing, measurement of neoplasm, measurement of unresectable]']\n",
      "['measurement of colorectal tumor size', 'measurement of surgery outcomes', 'measurement of colon size', 'measurement of high purpose', 'measurement of size', 'measurement of imatinib number', 'measurement of following']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['[measurement of participant combination, measurement of screening, measurement of receive, measurement of safety, measurement of survey, measurement of pembrolizumab, measurement of purpose, measurement of efficacy, measurement of week]']\n",
      "['[measurement of screening effectiveness, measurement of intervention, measurement of rate, measurement of care, measurement of health, measurement of group, measurement of clinic, measurement of colorectal, measurement of community, measurement of physician]']\n",
      "['[measurement of lesion, measurement of colonoscope, measurement of device, measurement of greater, measurement of therapeutic, measurement of performed, measurement of histological, measurement of physician, measurement of effect, measurement of polyp]']\n",
      "['measurement of program effectiveness, measurement of colorectal treatment, measurement of screening effectiveness, measurement of group outcomes, measurement of test results, measurement of individual outcomes, measurement of life outcomes, measurement of chemotherapy effectiveness, measurement of weekly outcomes, measurement of control outcomes']\n",
      "['measurement of colorectal treatment, measurement of cell response, measurement of factor, measurement of survival, measurement of phase, measurement of treatment, measurement of trial, measurement of metastasis, measurement of improve, measurement of response']\n",
      "['measurement of cell response, measurement of drug efficacy, measurement of treatment, measurement of clinical, measurement of tumor, measurement of carcinoma, measurement of acute, measurement of data, measurement of test, measurement of colorectal']\n",
      "['measurement of colorectal treatment, measurement of safety, measurement of treatment, measurement of panitumumab, measurement of phase, measurement of metastatic, measurement of surgery, measurement of clinical, measurement of leakage, measurement of anastomotic']\n",
      "['[measurement of accuracy, measurement of colonoscopy, measurement of diagnostic, measurement of result, measurement of symptom, measurement of imaging, measurement of test, measurement of lesion, measurement of pathway, measurement of value]']\n",
      "['measurement of colon surgery', 'measurement of treatment', 'measurement of procedure', 'measurement of screening', 'measurement of receive', 'measurement of trial', 'measurement of stage', 'measurement of lesion', 'measurement of intervention']\n",
      "['[measurement of immune response, measurement of surgery effectiveness, measurement of cell response, measurement of effect, measurement of laparoscopic procedure, measurement of tumor, measurement of gastric, measurement of investigator, measurement of recommendation, measurement of analgesia]']\n",
      "['[measurement of dose, measurement of treatment, measurement of effect, measurement of survival, measurement of cell, measurement of safety, measurement of disease, measurement of purpose, measurement of efficacy, measurement of drug]']\n",
      "['[measurement of colorectal treatment, measurement of screening effectiveness, measurement of primary treatment, measurement of resection outcomes, measurement of intervention outcomes, measurement of risk factors, measurement of patient group characteristics, measurement of survival rates, measurement of tumor response, measurement of testing effectiveness]']\n",
      "['[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]']\n",
      "[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]\n"
     ]
    }
   ],
   "source": [
    "openai.api_key = ################################\n",
    "import requests\n",
    "\n",
    "list_of_scores_lda=[]\n",
    "list_all_measurements_lda=[]\n",
    "\n",
    "for x in lda_list:\n",
    "    list_of_scores_lda=x\n",
    "\n",
    "    input_lda=' give all of the measurements found without scores for the topics below: '\n",
    "    URL_lda = \"https://api.openai.com/v1/chat/completions\"\n",
    "    query_lda=(input1 + ', '.join(list_of_scores_lda))\n",
    "    payload_lda = {\n",
    "    \"model\": \"gpt-3.5-turbo-16k\",\n",
    "    \"messages\": [{'role': 'system','content':'you are a translation system. Your role is to get this type of input (Topic: 0.038* tumor  + 0.027*cell + 0.015*drug + 0.014*colorectal + 0.014*treatment + 0.013*growth + 0.013*screening + 0.010*bevacizumab + 0.009*chemotherapy + 0.009*therapy and reformat it into this type:[measurement of tumor growth, measurement of cell response, measurement of drug efficacy, measurement of colorectal treatment, measurement of screening effectiveness, measurement of bevacizumab impact, measurement of chemotherapy effectiveness, measurement of therapy outcomes]'},\n",
    "            {\"role\": \"user\", \"content\": query_lda}],\n",
    "    \"temperature\" : 0.8,\n",
    "    \"top_p\":0.87,\n",
    "    \"n\" : 1,\n",
    "    \"stream\": False,\n",
    "    \"presence_penalty\":0.03,\n",
    "    \"frequency_penalty\":0.5,\n",
    "    }\n",
    "\n",
    "    headers_lda = {\n",
    "    \"Content-Type\": \"application/json\",\n",
    "    \"Authorization\": f\"Bearer {openai.api_key}\"\n",
    "    }\n",
    "    try:\n",
    "        response_lda = requests.post(URL_lda, headers=headers_lda, json=payload_lda, stream=False)\n",
    "        response_json_lda = response_lda.json()\n",
    "        chatbot_response_lda = response_json_lda['choices'][0]['message']['content']\n",
    "        # Split the chatbot response into a list of individual measurements\n",
    "        measurements_list_lda = chatbot_response_lda.strip().split('\\n')\n",
    "        print(chatbot_response_lda.strip().split('\\n'))\n",
    "        list_all_measurements_lda.append((chatbot_response_lda.strip().split('\\n'))),\n",
    "    except:\n",
    "        continue\n",
    "#Print the list of measurements\n",
    "for measurement in measurements_list_lda:\n",
    "    print(measurement)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "8937724e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this is lda/bow set for all gotten measruements also known as classes for our case\n",
      "['measurement of gastric diagnosis', 'measurement of effect', 'measurement of pain', 'measurement of cost', 'measurement of colonic', 'measurement of symptom', 'advanced', 'measurement of rectal', 'measurement of device', 'measurement of time', 'measurement of intervention outcomes', 'measurement of effective', 'measurement of regorafenib', 'measurement of subject response', 'measurement of visit', 'measurement of western treatment', 'measurement of related', 'measurement of method', 'measurement of life outcomes', 'measurement of tumor growth', 'measurement of optical', 'measurement of capecitabine effectiveness', 'measurement of cell trial', 'measurement of colon size', 'measurement of safety', 'measurement of test', 'measurement of surgery rate', 'measurement of mcr', 'measurement of recommendation', 'measurement of treated', 'measurement of gastric tumor growth', 'response', 'measurement of cohort', 'measurement of weekly treatment', 'measurement of progression', 'measurement of detection', 'measurement of laparoscopic', 'measurement of group', 'measurement of FOBt (fecal occult blood test)', 'measurement of pulmonary', 'measurement of purpose', 'measurement of preventing', 'measurement of objective', 'measurement of colorectal treatment', 'measurement of objective rate', 'measurement of week outcomes', 'measurement of rectal surgery', 'measurement of colorectal rate', 'measurement of advanced', 'measurement of response', 'measurement of immune', 'measurement of colon surgery', 'measurement of regimen effectiveness', 'measurement of unresectable', 'measurement of high purpose', 'measurement of screening effectiveness', 'measurement of stent', 'measurement of resection', 'measurement of prior', 'measurement of laboratory', 'measurement of liver impact', 'measurement of nutrition', 'measurement of ass', 'measurement of surgical', 'measurement of placebo', 'measurement of event', 'measurement of exercise impact', 'safety', 'measurement of metastasis', 'measurement of pembrolizumab', 'measurement of allow', 'measurement of neck', 'measurement of drug efficacy', 'measurement of surgery outcomes', 'measurement of capsule impact', 'measurement of stage', 'measurement of risk factors', 'measurement of colonoscopy effectiveness', 'measurement of bevacizumab impact', 'measurement of physician', 'measurement of stop', 'measurement of head', 'measurement of chemotherapy', 'measurement of growth', 'measurement of anastomosis', 'measurement of cetuximab', 'measurement of size', 'measurement of different', 'measurement of week', 'measurement of complication', 'measurement of diet impact', 'measurement of clinic', 'measurement of cell response', 'measurement of chemotherapy purpose', 'measurement of model', 'measurement of acute', 'measurement of drug', 'measurement of factor', 'measurement of polyposis', 'measurement of resection outcomes', 'measurement of result', 'measurement of bevacizumab', 'measurement of imaging', 'measurement of imatinib number', 'measurement of associated factors', 'measurement of oral', 'objective', 'measurement of cell', 'measurement of cisplatin', 'measurement of carcinoma', 'measurement of lesion', 'measurement of GIST treatment', 'measurement of survival rates', 'measurement of testing effectiveness', 'measurement of treatment', 'measurement of high effect', 'measurement of community', 'measurement of program effectiveness', 'measurement of pemetrexed', 'measurement of panitumumab', 'measurement of follow', 'measurement of locally', 'measurement of information', 'measurement of stomach acid', 'measurement of respiratory', 'measurement of survival', 'measurement of hereditary', 'measurement of participant combination', 'measurement of death', 'treatment', 'measurement of high treatment outcomes', 'measurement of endoscopic', 'measurement of imatinib efficacy', 'measurement of approved', 'measurement of gastric', 'measurement of chemoradiation', 'measurement of submucosal', 'measurement of colorectal detection', 'measurement of lymph', 'measurement of anal', 'measurement of weekly outcomes', 'measurement of lining', 'measurement of resection effectiveness', 'measurement of treating', 'measurement of abdominal surgery', 'phase', 'measurement of group outcomes', 'measurement of postoperative', 'measurement of assess', 'measurement of neoadjuvant', 'measurement of individual outcomes', 'measurement of colorectal tumor size', 'measurement of way', 'measurement of diagnosis', 'measurement of recovery', 'measurement of receiving', 'tumor', 'measurement of performed', 'measurement of data', 'measurement of therapy', 'measurement of kinase', 'measurement of control outcomes', 'measurement of life', 'measurement of metastatic colonoscopy', 'measurement of value', 'measurement of primary', 'measurement of molecular', 'evaluate', 'measurement of gastric therapy', 'measurement of following therapy outcomes', 'measurement of care', 'measurement of diagnostic', 'measurement of radiotherapy', 'measurement of barrett', 'measurement of tumor response', 'measurement of surveillance', 'measurement of esophageal', 'measurement of node', 'measurement of leakage', 'measurement of surgery', 'measurement of year', 'measurement of oxaliplatin efficacy', 'measurement of disease', 'measurement of evaluate', 'measurement of therapy outcomes', 'measurement of advanced tumor', 'measurement of esophagus', 'measurement of gene', 'measurement of colorectal approach rate', 'measurement of primary treatment', 'measurement of test results', 'measurement of gist', 'measurement of colon', 'measurement of day therapy outcomes', 'measurement of based', 'measurement of adjuvant', 'measurement of therapeutic', 'measurement of capsule', 'measurement of procedure', 'determine', 'measurement of undergoing', 'measurement of swallowing', 'measurement of combination', 'measurement of quality', 'measurement of perioperative outcomes', 'measurement of participant', 'measurement of early therapy', 'measurement of pathway', 'measurement of standard', 'measurement of tumor', 'measurement of primary tissue', 'measurement of mucositis', 'measurement of paclitaxel', 'measurement of colorectal', 'measurement of investigator', 'measurement of trial', 'measurement of avastin', 'measurement of colon treatment', 'measurement of improve', 'measurement of radiation', 'measurement of compare', 'measurement of line', 'measurement of efficacy', 'measurement of acid', 'measurement of analgesia', 'measurement of imatinib', 'measurement of clinical', 'measurement of mutation', 'measurement of capecitabine', 'measurement of blood', 'measurement of rate', 'measurement of irinotecan', 'measurement of sample', 'measurement of surgery effectiveness', 'measurement of biopsy', 'measurement of palliative care', 'measurement of advanced treatment outcomes', 'measurement of great', 'measurement of colorectal tumor growth', 'measurement of recurrence', 'measurement of cause', 'measurement of outcome', 'measurement of histological', 'measurement of immune response', 'measurement of laparoscopic procedure', 'measurement of metastatic', 'measurement of polyp', 'measurement of individual', 'measurement of physical', 'measurement of secondary', 'measurement of risk', 'measurement of phase', 'measurement of folfox', 'measurement of open', 'measurement of neoplasm', 'measurement of upper screening', 'measurement of colonoscopy', 'measurement of health', 'measurement of prognostic', 'measurement of clinical trial treatment', 'measurement of adenoma', 'measurement of colonoscope', 'measurement of biomarkers', 'measurement of postoperative therapy', 'measurement of month therapy outcomes', 'measurement of survey', 'measurement of local surgery', 'measurement of level', 'measurement of receive', 'measurement of following', 'measurement of patient group characteristics', 'measurement of sunitinib', 'measurement of palliative', 'measurement of colorectal combination therapy', 'measurement of hospital', 'measurement of high', 'measurement of accuracy', 'measurement of blood levels', 'measurement of greater', 'measurement of screening', 'measurement of chemotherapy effectiveness', 'measurement of randomized', 'measurement of gastric treatment', 'measurement of everolimus', 'measurement of dose', 'measurement of dosing', 'measurement of bowel', 'measurement of intervention', 'measurement of anastomotic']\n",
      "this is tfidf set for all gotten measruements also known as classes for our case\n",
      "['measurement of develop', 'measurement of cost', 'measurement of colonic', 'measurement of relapsed', 'measurement of rectal', 'measurement of sequence', 'measurement of tolerated combination', 'measurement of blood response', 'measurement of white outcomes', 'measurement of participant safety', 'measurement of capecitabine effectiveness', 'measurement of optical', 'measurement of flow', 'measurement of histology', 'measurement of polypectomy', 'measurement of session', 'measurement of investigate', 'measurement of detecting half oncology', 'measurement of colorectal treatment', 'measurement of single', 'measurement of gastric excision', 'measurement of protocol', 'measurement of recent', 'measurement of developing cancer', 'measurement of screening effectiveness', 'measurement of healthy', 'measurement of modulated', 'measurement of placebo', 'measurement of mutation effects', 'measurement of goal achievement', 'measurement of esophageal treatment', 'measurement of weekly chemotherapy effectiveness', 'measurement of following impact', 'measurement of postoperative surgery', 'measurement of decision', 'measurement of chemotherapy', 'measurement of thought', 'measurement of regorafenib impact', 'measurement of protein', 'measurement of elective', 'measurement of maximum dose', 'measurement of diagnosed', 'measurement of resection outcomes', 'measurement of good', 'measurement of cell', 'learn', 'measurement of esophagectomy', 'measurement of protection', 'measurement of pemetrexed', 'measurement of agent efficacy', 'measurement of cell effectiveness', 'measurement of causation', 'measurement of related tumor', 'measurement of arterial', 'measurement of navigation impact', 'measurement of approved', 'measurement of muscle', 'measurement of mouth', 'measurement of service effectiveness', 'measurement of positive response', 'measurement of stool', 'measurement of detection accuracy', 'measurement of beam impact', 'measurement of programme outcomes', 'measurement of record', 'measurement of vomiting', 'measurement of colon-based outcomes', 'measurement of program', 'measurement of barrett', 'measurement of referral effectiveness', 'measurement of image detection', 'measurement of vitamin', 'measurement of sedation', 'measurement of project outcomes', 'measurement of adding impact', 'measurement of extension', 'measurement of previously responded muscle reflux treated health screening intervention examine moderate', 'measurement of neoadjuvant tolerability', 'measurement of anastomotic carcinomatosis', 'measurement of VEGFR response', 'measurement of paclitaxel', 'measurement of vaccination', 'measurement of failure', 'measurement of radiation', 'measurement of receiving outcomes', 'measurement of sampling', 'measurement of giving', 'measurement of lynch', 'measurement of cetuximab impact', 'measurement of blood', 'measurement of testing', 'measurement of ablation', 'measurement of certain', 'measurement of measure', 'measurement of pancreatic treatment', 'measurement of small size', 'measurement of assistance provided', 'measurement of anterior', 'measurement of bowel preparation', 'measurement of phase', 'measurement of plan', 'measurement of chemoprevention', 'measurement of group response', 'measurement of radiation treatment', 'measurement of colonoscopy', 'measurement of gastrectomy', 'measurement of scope', 'measurement of measurement', 'measurement of fluid', 'measurement of chemotherapy effectiveness', 'measurement of screening', 'measurement of randomized', 'measurement of gastric tumor', 'measurement of pain', 'measurement of multicentric chemotherapy effectiveness', 'measurement of tolerance', 'measurement of indication', 'measurement of retrospectively therapy outcomes', 'measurement of resected tissue', 'measurement of device', 'measurement of capecitabine treatment', 'measurement of regorafenib efficacy', 'measurement of methylation', 'measurement of robotic detection', 'measurement of retrospectively screening effectiveness', 'measurement of starting', 'measurement of treated', 'measurement of single measured treatment', 'measurement of invasive', 'measurement of Asian', 'measurement of CRC treatment', 'measurement of progression', 'measurement of laparoscopic', 'measurement of vessel', 'measurement of adult determine rectum acid', 'measurement of care effectiveness', 'measurement of vaccine efficacy', 'measurement of bowel', 'measurement of response', 'measurement of regimen effectiveness', 'measurement of interleukin dosing', 'measurement of possible outcomes', 'measurement of inoperable tumor', 'measurement of artery response', 'measurement of prospective', 'measurement of practice response', 'measurement of neck', 'measurement of drug efficacy', 'measurement of operative outcomes', 'doctor', 'measurement of celecoxib efficacy', 'measurement of stoma', 'measurement of identified tumor', 'measurement of growth', 'measurement of scan response', 'measurement of complication', 'measurement of factor impact', 'measurement of anal recovery', 'measurement of rate detection', 'measurement of abdominal anesthesia', 'measurement of severity.', 'measurement of rectal treatment', 'measurement of caregiver', 'measurement of versus node type', 'measurement of major', 'optimal', 'measurement of completion', 'measurement of KRAS', 'measurement of adenocarcinoma treatment', 'measurement of activity', 'measurement of panitumumab', 'measurement of nurse effectiveness', 'measurement of crohns treatment', 'measurement of bleeding', 'measurement of tissue response', 'measurement of regimen', 'measurement of magnetic intolerant resonance assessment', 'measurement of gastric', 'measurement of soft treatment', 'measurement of gene response', 'measurement of lymph', 'measurement of stromal response', 'measurement of performance', 'measurement of prevention', 'measurement of planning', 'measurement of receiving', 'screening', 'measurement of bacteria response', 'measurement of docetaxel treatment', 'measurement of portion size', 'measurement of care', 'measurement of demonstration', 'measurement of nutritional', 'measurement of poor', 'measurement of narrow outcomes', 'measurement of neoplastic response', 'measurement of surgery', 'measurement feasibility', 'measurement of disease', 'measurement of malignancy', 'measurement of diet', 'measurement of squamous', 'preventing', 'measurement of stromal tumor malignancy', 'measurement of define', 'measurement of monotherapy', 'measurement of light', 'measurement of telephone', 'measurement of safe use', 'measurement of analgesia', 'measurement of near', 'measurement of intention', 'measurement of subgroup', 'measurement of planned', 'measurement of FOBT', 'measurement of induced screening', 'measurement of improves', 'measurement of immune response', 'measurement of radiofrequency', 'measurement of polyp', 'measurement of physical', 'measurement of carcinoma growth', 'measurement of oral efficacy', 'measurement of folinic ass', 'measurement of perioperative', 'measurement of extended', 'measurement of counseling', 'measurement of pylorus', 'measurement of elderly', 'measurement of tool', 'measurement of diarrhea', 'measurement of gastric treatment', 'measurement of intervention', 'measurement of strength', 'measurement of existing', 'measurement of recurrent', 'measurement of document analysis', 'measurement of effect', 'measurement of relationship effectiveness', 'measurement of clinical outcomes', 'measurement of duodenal', 'measurement of ultrasound', 'measurement of educational material', 'measurement of nausea', 'measurement of research impact', 'measurement of identified women', 'measurement of melanoma', 'measurement of tumor growth', 'measurement of safety', 'measurement of effectiveness', 'measurement of newly', 'measurement of sample outcomes', 'randomized', 'measurement of detection', 'measurement of fluorescence', 'measurement of group', 'measurement of liver treatment', 'measurement of evaluating', 'measurement of human', 'measurement of concentration', 'measurement of medicine', 'measurement of navigator effectiveness', 'measurement of surgery outcomes', 'measurement of gastric surgery', 'measurement of daily drug efficacy', 'measurement of member presence', 'measurement of rectum treatment', 'measurement of expressing', 'measurement of endomicroscopy', 'measurement of step count', 'measurement of rectal tolerability', 'measurement of model', 'measurement of called', 'measurement of loss', 'measurement of tablet impact', 'measurement of selection', 'measurement of university', 'measurement of killing', 'measurement of predict', 'measurement of training', 'measurement of month', 'measurement of familial adenomatous polyposis', 'measurement of treatment', 'measurement of program effectiveness', 'measurement of locally', 'measurement of band impact', 'measurement of highest group performance', 'measurement of cell presence', 'measurement of imatinib efficacy', 'measurement of lung response', 'measurement of expression', 'measurement of risk surgery', 'measurement of radiotherapy effectiveness', 'measurement of skin safety', 'measurement of sorafenib effectiveness', 'measurement of panitumumab efficacy', 'measurement of pathological tumor growth', 'measurement of diagnosis', 'measurement of everolimus impact', 'measurement of primary', 'measurement of delivered', 'measurement of pathway effectiveness', 'measurement of involves', 'measurement of multicenter study', 'measurement locally', 'measurement of apatinib', 'measurement of mitomycin', 'measurement of esophagus', 'measurement of examination', 'measurement of folfir', 'measurement of procedure', 'measurement of colonoscopy detection', 'measurement of studies conducted', 'measurement of dysplasia impact', 'measurement of researcher', 'measurement of esophageal option', 'measurement of tumor', 'measurement of colorectal', 'measurement of subsequent', 'measurement of anti-angiogenesis impact', 'measurement of prophylactic', 'measurement of plasma presence', 'measurement of aflibercept', 'measurement of efficacy', 'measurement of acid', 'measurement of female response', 'measurement of dose tolerance', 'measurement of arm', 'measurement of mesylate response', 'measurement of platinum', 'measurement of outcome', 'measurement of prevalence', 'measurement of intestine', 'measurement of human response', 'measurement of tested', 'measurement of carboplatin impact', 'untreated', 'colorectal', 'measurement of fixed', 'measurement of water leak', 'measurement of symptoms', 'measurement of caused', 'measurement of biomarkers', 'measurement of sunitinib dosing', 'measurement of investigates', 'measurement of young', 'measurement of metabolic', 'measurement of work', 'measurement of recommended', 'measurement of octreotide supplementation', 'measurement of gemcitabine', 'measurement of comparing lymph recovery', 'previously', 'measurement of label effectiveness', 'measurement of adenocarcinoma', 'measurement of vaccine', 'measurement of pilot', 'measurement of outpatient', 'measurement of endoscopists performance', 'measurement of incidence', 'measurement of combination therapy', 'measurement of related', 'measurement of targeting efficacy', 'measurement of heart', 'measurement of antibody effectiveness', 'measurement of open impact', 'measurement of clear outcomes', 'measurement of disorder', 'measurement of observe', 'measurement of spread', 'measurement of treated histologically localized', 'measurement of product efficacy', 'measurement of compare detection', 'measurement of laparoscopic detection', 'measurement of BRAF response', 'measurement of observed', 'measurement of versus', 'measurement of autologous', 'measurement of mutant response', 'measurement of biopsy outcomes', 'measurement of prediction', 'measurement of exercise impact', 'measurement of oral treatment', 'measurement of pembrolizumab', 'measurement of providing effectiveness', 'measurement of weight', 'measurement of antigen', 'measurement of serum', 'measurement of bevacizumab impact', 'measurement of mfolfox efficacy', 'measurement of head', 'measurement of fatigue', 'confocal', 'measurement of finding', 'measurement of cell response', 'measurement of factor', 'measurement of dysphagia', 'measurement of bevacizumab', 'measurement of retrospective', 'measurement of esophagogastric treatment', 'measurement of movement', 'measurement of lesion', 'measurement of observation', 'measurement of western', 'measurement of mesorectal', 'measurement of financial outcomes', 'measurement of death', 'measurement of volume', 'measurement of aim', 'measurement of anesthesia', 'measurement of monoclonal impact', 'measurement of chemoradiation', 'measurement of adenoma detection', 'measurement of eradication', 'measurement of papillomavirus', 'measurement of cisplatin treatment', 'measurement of disparity outcomes', 'measurement of therapy', 'measurement of stomach treatment', 'measurement of interfere', 'measurement of double-blind effectiveness', 'measurement of dissection', 'measurement of rehabilitation', 'measurement of laparoscopic surgery', 'measurement of determination', 'measurement of node', 'measurement of advanced tumor', 'measurement of therapy outcomes', 'measurement of polyp size', 'measurement of sentinel effectiveness', 'measurement of induction', 'measurement of under went detection', 'measurement of initiation', 'measurement of research', 'measurement of colectomy outcomes', 'measurement of improvement', 'measurement of mucositis', 'measurement of work effectiveness', 'measurement of satisfaction', 'measurement of slow', 'measurement of placebo efficacy', 'measurement of determine', 'measurement of median outcomes', 'measurement of imatinib', 'measurement of mutation', 'measurement of simultaneous', 'measurement of irinotecan', 'measurement of educational outcomes', 'measurement of learning outcomes', 'measurement of mucosa response', 'measurement of capecitabine region', 'measurement of palliative effect', 'measurement of healing', 'measurement of breast', 'measurement of positive', 'measurement of self', 'measurement of malnutrition', 'measurement of predicting', 'measurement of risk', 'measurement of dietary impact', 'measurement of advantage', 'measurement of implementation', 'measurement of survivor', 'measurement of sensitivity', 'measurement of influence', 'measurement of specificity', 'measurement of rectal tumor treatment', 'measurement of screening efficacy', 'measurement of blocking effectiveness', 'measurement of concurrent', 'measurement of hospital', 'measurement of child response', 'measurement of late effects', 'measurement of monitor', 'measurement of pelvic', 'measurement of routine', 'measurement of live performance']\n"
     ]
    }
   ],
   "source": [
    "import ast\n",
    "\n",
    "def clean_item(item):\n",
    "    # Remove square brackets, quotes, and extra white spaces\n",
    "    item = item.replace('[', '').replace(']', '').replace('\\'', '').strip()\n",
    "\n",
    "    # If the item contains commas, it was actually a list in string format\n",
    "    # Split it into a real list\n",
    "    if ',' in item:\n",
    "        item = item.split(', ')\n",
    "        \n",
    "    return item\n",
    "\n",
    "# Flatten the list and clean the items\n",
    "flat_list_lda = [clean_item(item) for sublist in list_all_measurements_lda for item in sublist]\n",
    "flat_list_tfidf=[clean_item(item) for sublist in list_all_measurements_tfidf for item in sublist]\n",
    "# In case there are any sublists remaining (from the string lists), flatten again\n",
    "flat_list_lda = [item for sublist in flat_list_lda for item in (sublist if isinstance(sublist, list) else [sublist])]\n",
    "flat_list_tfidf = [item for sublist in flat_list_tfidf for item in (sublist if isinstance(sublist, list) else [sublist])]\n",
    "# Convert to set to remove duplicates, and back to list\n",
    "unique_flat_list_lda = list(set(flat_list_lda))\n",
    "unique_flat_list_tfidf = list(set(flat_list_tfidf))\n",
    "print('this is lda/bow set for all gotten measruements also known as classes for our case')\n",
    "print(unique_flat_list_lda)\n",
    "print('this is tfidf set for all gotten measruements also known as classes for our case')\n",
    "print(unique_flat_list_tfidf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "836b9a63",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "measurement of develop\n",
      "measurement of cost\n",
      "measurement of colonic\n",
      "measurement of relapsed\n",
      "measurement of rectal\n",
      "measurement of sequence\n",
      "measurement of tolerated combination\n",
      "measurement of blood response\n",
      "measurement of white outcomes\n",
      "measurement of participant safety\n",
      "measurement of capecitabine effectiveness\n",
      "measurement of optical\n",
      "measurement of flow\n",
      "measurement of histology\n",
      "measurement of polypectomy\n",
      "measurement of session\n",
      "measurement of investigate\n",
      "measurement of detecting half oncology\n",
      "measurement of colorectal treatment\n",
      "measurement of single\n",
      "measurement of gastric excision\n",
      "measurement of protocol\n",
      "measurement of recent\n",
      "measurement of developing cancer\n",
      "measurement of screening effectiveness\n",
      "measurement of healthy\n",
      "measurement of modulated\n",
      "measurement of placebo\n",
      "measurement of mutation effects\n",
      "measurement of goal achievement\n",
      "measurement of esophageal treatment\n",
      "measurement of weekly chemotherapy effectiveness\n",
      "measurement of following impact\n",
      "measurement of postoperative surgery\n",
      "measurement of decision\n",
      "measurement of chemotherapy\n",
      "measurement of thought\n",
      "measurement of regorafenib impact\n",
      "measurement of protein\n",
      "measurement of elective\n",
      "measurement of maximum dose\n",
      "measurement of diagnosed\n",
      "measurement of resection outcomes\n",
      "measurement of good\n",
      "measurement of cell\n",
      "learn\n",
      "measurement of esophagectomy\n",
      "measurement of protection\n",
      "measurement of pemetrexed\n",
      "measurement of agent efficacy\n",
      "measurement of cell effectiveness\n",
      "measurement of causation\n",
      "measurement of related tumor\n",
      "measurement of arterial\n",
      "measurement of navigation impact\n",
      "measurement of approved\n",
      "measurement of muscle\n",
      "measurement of mouth\n",
      "measurement of service effectiveness\n",
      "measurement of positive response\n",
      "measurement of stool\n",
      "measurement of detection accuracy\n",
      "measurement of beam impact\n",
      "measurement of programme outcomes\n",
      "measurement of record\n",
      "measurement of vomiting\n",
      "measurement of colon-based outcomes\n",
      "measurement of program\n",
      "measurement of barrett\n",
      "measurement of referral effectiveness\n",
      "measurement of image detection\n",
      "measurement of vitamin\n",
      "measurement of sedation\n",
      "measurement of project outcomes\n",
      "measurement of adding impact\n",
      "measurement of extension\n",
      "measurement of previously responded muscle reflux treated health screening intervention examine moderate\n",
      "measurement of neoadjuvant tolerability\n",
      "measurement of anastomotic carcinomatosis\n",
      "measurement of VEGFR response\n",
      "measurement of paclitaxel\n",
      "measurement of vaccination\n",
      "measurement of failure\n",
      "measurement of radiation\n",
      "measurement of receiving outcomes\n",
      "measurement of sampling\n",
      "measurement of giving\n",
      "measurement of lynch\n",
      "measurement of cetuximab impact\n",
      "measurement of blood\n",
      "measurement of testing\n",
      "measurement of ablation\n",
      "measurement of certain\n",
      "measurement of measure\n",
      "measurement of pancreatic treatment\n",
      "measurement of small size\n",
      "measurement of assistance provided\n",
      "measurement of anterior\n",
      "measurement of bowel preparation\n",
      "measurement of phase\n",
      "measurement of plan\n",
      "measurement of chemoprevention\n",
      "measurement of group response\n",
      "measurement of radiation treatment\n",
      "measurement of colonoscopy\n",
      "measurement of gastrectomy\n",
      "measurement of scope\n",
      "measurement of measurement\n",
      "measurement of fluid\n",
      "measurement of chemotherapy effectiveness\n",
      "measurement of screening\n",
      "measurement of randomized\n",
      "measurement of gastric tumor\n",
      "measurement of pain\n",
      "measurement of multicentric chemotherapy effectiveness\n",
      "measurement of tolerance\n",
      "measurement of indication\n",
      "measurement of retrospectively therapy outcomes\n",
      "measurement of resected tissue\n",
      "measurement of device\n",
      "measurement of capecitabine treatment\n",
      "measurement of regorafenib efficacy\n",
      "measurement of methylation\n",
      "measurement of robotic detection\n",
      "measurement of retrospectively screening effectiveness\n",
      "measurement of starting\n",
      "measurement of treated\n",
      "measurement of single measured treatment\n",
      "measurement of invasive\n",
      "measurement of Asian\n",
      "measurement of CRC treatment\n",
      "measurement of progression\n",
      "measurement of laparoscopic\n",
      "measurement of vessel\n",
      "measurement of adult determine rectum acid\n",
      "measurement of care effectiveness\n",
      "measurement of vaccine efficacy\n",
      "measurement of bowel\n",
      "measurement of response\n",
      "measurement of regimen effectiveness\n",
      "measurement of interleukin dosing\n",
      "measurement of possible outcomes\n",
      "measurement of inoperable tumor\n",
      "measurement of artery response\n",
      "measurement of prospective\n",
      "measurement of practice response\n",
      "measurement of neck\n",
      "measurement of drug efficacy\n",
      "measurement of operative outcomes\n",
      "doctor\n",
      "measurement of celecoxib efficacy\n",
      "measurement of stoma\n",
      "measurement of identified tumor\n",
      "measurement of growth\n",
      "measurement of scan response\n",
      "measurement of complication\n",
      "measurement of factor impact\n",
      "measurement of anal recovery\n",
      "measurement of rate detection\n",
      "measurement of abdominal anesthesia\n",
      "measurement of severity.\n",
      "measurement of rectal treatment\n",
      "measurement of caregiver\n",
      "measurement of versus node type\n",
      "measurement of major\n",
      "optimal\n",
      "measurement of completion\n",
      "measurement of KRAS\n",
      "measurement of adenocarcinoma treatment\n",
      "measurement of activity\n",
      "measurement of panitumumab\n",
      "measurement of nurse effectiveness\n",
      "measurement of crohns treatment\n",
      "measurement of bleeding\n",
      "measurement of tissue response\n",
      "measurement of regimen\n",
      "measurement of magnetic intolerant resonance assessment\n",
      "measurement of gastric\n",
      "measurement of soft treatment\n",
      "measurement of gene response\n",
      "measurement of lymph\n",
      "measurement of stromal response\n",
      "measurement of performance\n",
      "measurement of prevention\n",
      "measurement of planning\n",
      "measurement of receiving\n",
      "screening\n",
      "measurement of bacteria response\n",
      "measurement of docetaxel treatment\n",
      "measurement of portion size\n",
      "measurement of care\n",
      "measurement of demonstration\n",
      "measurement of nutritional\n",
      "measurement of poor\n",
      "measurement of narrow outcomes\n",
      "measurement of neoplastic response\n",
      "measurement of surgery\n",
      "measurement feasibility\n",
      "measurement of disease\n",
      "measurement of malignancy\n",
      "measurement of diet\n",
      "measurement of squamous\n",
      "preventing\n",
      "measurement of stromal tumor malignancy\n",
      "measurement of define\n",
      "measurement of monotherapy\n",
      "measurement of light\n",
      "measurement of telephone\n",
      "measurement of safe use\n",
      "measurement of analgesia\n",
      "measurement of near\n",
      "measurement of intention\n",
      "measurement of subgroup\n",
      "measurement of planned\n",
      "measurement of FOBT\n",
      "measurement of induced screening\n",
      "measurement of improves\n",
      "measurement of immune response\n",
      "measurement of radiofrequency\n",
      "measurement of polyp\n",
      "measurement of physical\n",
      "measurement of carcinoma growth\n",
      "measurement of oral efficacy\n",
      "measurement of folinic ass\n",
      "measurement of perioperative\n",
      "measurement of extended\n",
      "measurement of counseling\n",
      "measurement of pylorus\n",
      "measurement of elderly\n",
      "measurement of tool\n",
      "measurement of diarrhea\n",
      "measurement of gastric treatment\n",
      "measurement of intervention\n",
      "measurement of strength\n",
      "measurement of existing\n",
      "measurement of recurrent\n",
      "measurement of document analysis\n",
      "measurement of effect\n",
      "measurement of relationship effectiveness\n",
      "measurement of clinical outcomes\n",
      "measurement of duodenal\n",
      "measurement of ultrasound\n",
      "measurement of educational material\n",
      "measurement of nausea\n",
      "measurement of research impact\n",
      "measurement of identified women\n",
      "measurement of melanoma\n",
      "measurement of tumor growth\n",
      "measurement of safety\n",
      "measurement of effectiveness\n",
      "measurement of newly\n",
      "measurement of sample outcomes\n",
      "randomized\n",
      "measurement of detection\n",
      "measurement of fluorescence\n",
      "measurement of group\n",
      "measurement of liver treatment\n",
      "measurement of evaluating\n",
      "measurement of human\n",
      "measurement of concentration\n",
      "measurement of medicine\n",
      "measurement of navigator effectiveness\n",
      "measurement of surgery outcomes\n",
      "measurement of gastric surgery\n",
      "measurement of daily drug efficacy\n",
      "measurement of member presence\n",
      "measurement of rectum treatment\n",
      "measurement of expressing\n",
      "measurement of endomicroscopy\n",
      "measurement of step count\n",
      "measurement of rectal tolerability\n",
      "measurement of model\n",
      "measurement of called\n",
      "measurement of loss\n",
      "measurement of tablet impact\n",
      "measurement of selection\n",
      "measurement of university\n",
      "measurement of killing\n",
      "measurement of predict\n",
      "measurement of training\n",
      "measurement of month\n",
      "measurement of familial adenomatous polyposis\n",
      "measurement of treatment\n",
      "measurement of program effectiveness\n",
      "measurement of locally\n",
      "measurement of band impact\n",
      "measurement of highest group performance\n",
      "measurement of cell presence\n",
      "measurement of imatinib efficacy\n",
      "measurement of lung response\n",
      "measurement of expression\n",
      "measurement of risk surgery\n",
      "measurement of radiotherapy effectiveness\n",
      "measurement of skin safety\n",
      "measurement of sorafenib effectiveness\n",
      "measurement of panitumumab efficacy\n",
      "measurement of pathological tumor growth\n",
      "measurement of diagnosis\n",
      "measurement of everolimus impact\n",
      "measurement of primary\n",
      "measurement of delivered\n",
      "measurement of pathway effectiveness\n",
      "measurement of involves\n",
      "measurement of multicenter study\n",
      "measurement locally\n",
      "measurement of apatinib\n",
      "measurement of mitomycin\n",
      "measurement of esophagus\n",
      "measurement of examination\n",
      "measurement of folfir\n",
      "measurement of procedure\n",
      "measurement of colonoscopy detection\n",
      "measurement of studies conducted\n",
      "measurement of dysplasia impact\n",
      "measurement of researcher\n",
      "measurement of esophageal option\n",
      "measurement of tumor\n",
      "measurement of colorectal\n",
      "measurement of subsequent\n",
      "measurement of anti-angiogenesis impact\n",
      "measurement of prophylactic\n",
      "measurement of plasma presence\n",
      "measurement of aflibercept\n",
      "measurement of efficacy\n",
      "measurement of acid\n",
      "measurement of female response\n",
      "measurement of dose tolerance\n",
      "measurement of arm\n",
      "measurement of mesylate response\n",
      "measurement of platinum\n",
      "measurement of outcome\n",
      "measurement of prevalence\n",
      "measurement of intestine\n",
      "measurement of human response\n",
      "measurement of tested\n",
      "measurement of carboplatin impact\n",
      "untreated\n",
      "colorectal\n",
      "measurement of fixed\n",
      "measurement of water leak\n",
      "measurement of symptoms\n",
      "measurement of caused\n",
      "measurement of biomarkers\n",
      "measurement of sunitinib dosing\n",
      "measurement of investigates\n",
      "measurement of young\n",
      "measurement of metabolic\n",
      "measurement of work\n",
      "measurement of recommended\n",
      "measurement of octreotide supplementation\n",
      "measurement of gemcitabine\n",
      "measurement of comparing lymph recovery\n",
      "previously\n",
      "measurement of label effectiveness\n",
      "measurement of adenocarcinoma\n",
      "measurement of vaccine\n",
      "measurement of pilot\n",
      "measurement of outpatient\n",
      "measurement of endoscopists performance\n",
      "measurement of incidence\n",
      "measurement of combination therapy\n",
      "measurement of related\n",
      "measurement of targeting efficacy\n",
      "measurement of heart\n",
      "measurement of antibody effectiveness\n",
      "measurement of open impact\n",
      "measurement of clear outcomes\n",
      "measurement of disorder\n",
      "measurement of observe\n",
      "measurement of spread\n",
      "measurement of treated histologically localized\n",
      "measurement of product efficacy\n",
      "measurement of compare detection\n",
      "measurement of laparoscopic detection\n",
      "measurement of BRAF response\n",
      "measurement of observed\n",
      "measurement of versus\n",
      "measurement of autologous\n",
      "measurement of mutant response\n",
      "measurement of biopsy outcomes\n",
      "measurement of prediction\n",
      "measurement of exercise impact\n",
      "measurement of oral treatment\n",
      "measurement of pembrolizumab\n",
      "measurement of providing effectiveness\n",
      "measurement of weight\n",
      "measurement of antigen\n",
      "measurement of serum\n",
      "measurement of bevacizumab impact\n",
      "measurement of mfolfox efficacy\n",
      "measurement of head\n",
      "measurement of fatigue\n",
      "confocal\n",
      "measurement of finding\n",
      "measurement of cell response\n",
      "measurement of factor\n",
      "measurement of dysphagia\n",
      "measurement of bevacizumab\n",
      "measurement of retrospective\n",
      "measurement of esophagogastric treatment\n",
      "measurement of movement\n",
      "measurement of lesion\n",
      "measurement of observation\n",
      "measurement of western\n",
      "measurement of mesorectal\n",
      "measurement of financial outcomes\n",
      "measurement of death\n",
      "measurement of volume\n",
      "measurement of aim\n",
      "measurement of anesthesia\n",
      "measurement of monoclonal impact\n",
      "measurement of chemoradiation\n",
      "measurement of adenoma detection\n",
      "measurement of eradication\n",
      "measurement of papillomavirus\n",
      "measurement of cisplatin treatment\n",
      "measurement of disparity outcomes\n",
      "measurement of therapy\n",
      "measurement of stomach treatment\n",
      "measurement of interfere\n",
      "measurement of double-blind effectiveness\n",
      "measurement of dissection\n",
      "measurement of rehabilitation\n",
      "measurement of laparoscopic surgery\n",
      "measurement of determination\n",
      "measurement of node\n",
      "measurement of advanced tumor\n",
      "measurement of therapy outcomes\n",
      "measurement of polyp size\n",
      "measurement of sentinel effectiveness\n",
      "measurement of induction\n",
      "measurement of under went detection\n",
      "measurement of initiation\n",
      "measurement of research\n",
      "measurement of colectomy outcomes\n",
      "measurement of improvement\n",
      "measurement of mucositis\n",
      "measurement of work effectiveness\n",
      "measurement of satisfaction\n",
      "measurement of slow\n",
      "measurement of placebo efficacy\n",
      "measurement of determine\n",
      "measurement of median outcomes\n",
      "measurement of imatinib\n",
      "measurement of mutation\n",
      "measurement of simultaneous\n",
      "measurement of irinotecan\n",
      "measurement of educational outcomes\n",
      "measurement of learning outcomes\n",
      "measurement of mucosa response\n",
      "measurement of capecitabine region\n",
      "measurement of palliative effect\n",
      "measurement of healing\n",
      "measurement of breast\n",
      "measurement of positive\n",
      "measurement of self\n",
      "measurement of malnutrition\n",
      "measurement of predicting\n",
      "measurement of risk\n",
      "measurement of dietary impact\n",
      "measurement of advantage\n",
      "measurement of implementation\n",
      "measurement of survivor\n",
      "measurement of sensitivity\n",
      "measurement of influence\n",
      "measurement of specificity\n",
      "measurement of rectal tumor treatment\n",
      "measurement of screening efficacy\n",
      "measurement of blocking effectiveness\n",
      "measurement of concurrent\n",
      "measurement of hospital\n",
      "measurement of child response\n",
      "measurement of late effects\n",
      "measurement of monitor\n",
      "measurement of pelvic\n",
      "measurement of routine\n",
      "measurement of live performance\n"
     ]
    }
   ],
   "source": [
    "#every outputted class/measurement for the TF-IDF model\n",
    "for elem in unique_flat_list_tfidf:\n",
    "    print (elem)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "77634068",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "measurement of gastric diagnosis\n",
      "measurement of effect\n",
      "measurement of pain\n",
      "measurement of cost\n",
      "measurement of colonic\n",
      "measurement of symptom\n",
      "advanced\n",
      "measurement of rectal\n",
      "measurement of device\n",
      "measurement of time\n",
      "measurement of intervention outcomes\n",
      "measurement of effective\n",
      "measurement of regorafenib\n",
      "measurement of subject response\n",
      "measurement of visit\n",
      "measurement of western treatment\n",
      "measurement of related\n",
      "measurement of method\n",
      "measurement of life outcomes\n",
      "measurement of tumor growth\n",
      "measurement of optical\n",
      "measurement of capecitabine effectiveness\n",
      "measurement of cell trial\n",
      "measurement of colon size\n",
      "measurement of safety\n",
      "measurement of test\n",
      "measurement of surgery rate\n",
      "measurement of mcr\n",
      "measurement of recommendation\n",
      "measurement of treated\n",
      "measurement of gastric tumor growth\n",
      "response\n",
      "measurement of cohort\n",
      "measurement of weekly treatment\n",
      "measurement of progression\n",
      "measurement of detection\n",
      "measurement of laparoscopic\n",
      "measurement of group\n",
      "measurement of FOBt (fecal occult blood test)\n",
      "measurement of pulmonary\n",
      "measurement of purpose\n",
      "measurement of preventing\n",
      "measurement of objective\n",
      "measurement of colorectal treatment\n",
      "measurement of objective rate\n",
      "measurement of week outcomes\n",
      "measurement of rectal surgery\n",
      "measurement of colorectal rate\n",
      "measurement of advanced\n",
      "measurement of response\n",
      "measurement of immune\n",
      "measurement of colon surgery\n",
      "measurement of regimen effectiveness\n",
      "measurement of unresectable\n",
      "measurement of high purpose\n",
      "measurement of screening effectiveness\n",
      "measurement of stent\n",
      "measurement of resection\n",
      "measurement of prior\n",
      "measurement of laboratory\n",
      "measurement of liver impact\n",
      "measurement of nutrition\n",
      "measurement of ass\n",
      "measurement of surgical\n",
      "measurement of placebo\n",
      "measurement of event\n",
      "measurement of exercise impact\n",
      "safety\n",
      "measurement of metastasis\n",
      "measurement of pembrolizumab\n",
      "measurement of allow\n",
      "measurement of neck\n",
      "measurement of drug efficacy\n",
      "measurement of surgery outcomes\n",
      "measurement of capsule impact\n",
      "measurement of stage\n",
      "measurement of risk factors\n",
      "measurement of colonoscopy effectiveness\n",
      "measurement of bevacizumab impact\n",
      "measurement of physician\n",
      "measurement of stop\n",
      "measurement of head\n",
      "measurement of chemotherapy\n",
      "measurement of growth\n",
      "measurement of anastomosis\n",
      "measurement of cetuximab\n",
      "measurement of size\n",
      "measurement of different\n",
      "measurement of week\n",
      "measurement of complication\n",
      "measurement of diet impact\n",
      "measurement of clinic\n",
      "measurement of cell response\n",
      "measurement of chemotherapy purpose\n",
      "measurement of model\n",
      "measurement of acute\n",
      "measurement of drug\n",
      "measurement of factor\n",
      "measurement of polyposis\n",
      "measurement of resection outcomes\n",
      "measurement of result\n",
      "measurement of bevacizumab\n",
      "measurement of imaging\n",
      "measurement of imatinib number\n",
      "measurement of associated factors\n",
      "measurement of oral\n",
      "objective\n",
      "measurement of cell\n",
      "measurement of cisplatin\n",
      "measurement of carcinoma\n",
      "measurement of lesion\n",
      "measurement of GIST treatment\n",
      "measurement of survival rates\n",
      "measurement of testing effectiveness\n",
      "measurement of treatment\n",
      "measurement of high effect\n",
      "measurement of community\n",
      "measurement of program effectiveness\n",
      "measurement of pemetrexed\n",
      "measurement of panitumumab\n",
      "measurement of follow\n",
      "measurement of locally\n",
      "measurement of information\n",
      "measurement of stomach acid\n",
      "measurement of respiratory\n",
      "measurement of survival\n",
      "measurement of hereditary\n",
      "measurement of participant combination\n",
      "measurement of death\n",
      "treatment\n",
      "measurement of high treatment outcomes\n",
      "measurement of endoscopic\n",
      "measurement of imatinib efficacy\n",
      "measurement of approved\n",
      "measurement of gastric\n",
      "measurement of chemoradiation\n",
      "measurement of submucosal\n",
      "measurement of colorectal detection\n",
      "measurement of lymph\n",
      "measurement of anal\n",
      "measurement of weekly outcomes\n",
      "measurement of lining\n",
      "measurement of resection effectiveness\n",
      "measurement of treating\n",
      "measurement of abdominal surgery\n",
      "phase\n",
      "measurement of group outcomes\n",
      "measurement of postoperative\n",
      "measurement of assess\n",
      "measurement of neoadjuvant\n",
      "measurement of individual outcomes\n",
      "measurement of colorectal tumor size\n",
      "measurement of way\n",
      "measurement of diagnosis\n",
      "measurement of recovery\n",
      "measurement of receiving\n",
      "tumor\n",
      "measurement of performed\n",
      "measurement of data\n",
      "measurement of therapy\n",
      "measurement of kinase\n",
      "measurement of control outcomes\n",
      "measurement of life\n",
      "measurement of metastatic colonoscopy\n",
      "measurement of value\n",
      "measurement of primary\n",
      "measurement of molecular\n",
      "evaluate\n",
      "measurement of gastric therapy\n",
      "measurement of following therapy outcomes\n",
      "measurement of care\n",
      "measurement of diagnostic\n",
      "measurement of radiotherapy\n",
      "measurement of barrett\n",
      "measurement of tumor response\n",
      "measurement of surveillance\n",
      "measurement of esophageal\n",
      "measurement of node\n",
      "measurement of leakage\n",
      "measurement of surgery\n",
      "measurement of year\n",
      "measurement of oxaliplatin efficacy\n",
      "measurement of disease\n",
      "measurement of evaluate\n",
      "measurement of therapy outcomes\n",
      "measurement of advanced tumor\n",
      "measurement of esophagus\n",
      "measurement of gene\n",
      "measurement of colorectal approach rate\n",
      "measurement of primary treatment\n",
      "measurement of test results\n",
      "measurement of gist\n",
      "measurement of colon\n",
      "measurement of day therapy outcomes\n",
      "measurement of based\n",
      "measurement of adjuvant\n",
      "measurement of therapeutic\n",
      "measurement of capsule\n",
      "measurement of procedure\n",
      "determine\n",
      "measurement of undergoing\n",
      "measurement of swallowing\n",
      "measurement of combination\n",
      "measurement of quality\n",
      "measurement of perioperative outcomes\n",
      "measurement of participant\n",
      "measurement of early therapy\n",
      "measurement of pathway\n",
      "measurement of standard\n",
      "measurement of tumor\n",
      "measurement of primary tissue\n",
      "measurement of mucositis\n",
      "measurement of paclitaxel\n",
      "measurement of colorectal\n",
      "measurement of investigator\n",
      "measurement of trial\n",
      "measurement of avastin\n",
      "measurement of colon treatment\n",
      "measurement of improve\n",
      "measurement of radiation\n",
      "measurement of compare\n",
      "measurement of line\n",
      "measurement of efficacy\n",
      "measurement of acid\n",
      "measurement of analgesia\n",
      "measurement of imatinib\n",
      "measurement of clinical\n",
      "measurement of mutation\n",
      "measurement of capecitabine\n",
      "measurement of blood\n",
      "measurement of rate\n",
      "measurement of irinotecan\n",
      "measurement of sample\n",
      "measurement of surgery effectiveness\n",
      "measurement of biopsy\n",
      "measurement of palliative care\n",
      "measurement of advanced treatment outcomes\n",
      "measurement of great\n",
      "measurement of colorectal tumor growth\n",
      "measurement of recurrence\n",
      "measurement of cause\n",
      "measurement of outcome\n",
      "measurement of histological\n",
      "measurement of immune response\n",
      "measurement of laparoscopic procedure\n",
      "measurement of metastatic\n",
      "measurement of polyp\n",
      "measurement of individual\n",
      "measurement of physical\n",
      "measurement of secondary\n",
      "measurement of risk\n",
      "measurement of phase\n",
      "measurement of folfox\n",
      "measurement of open\n",
      "measurement of neoplasm\n",
      "measurement of upper screening\n",
      "measurement of colonoscopy\n",
      "measurement of health\n",
      "measurement of prognostic\n",
      "measurement of clinical trial treatment\n",
      "measurement of adenoma\n",
      "measurement of colonoscope\n",
      "measurement of biomarkers\n",
      "measurement of postoperative therapy\n",
      "measurement of month therapy outcomes\n",
      "measurement of survey\n",
      "measurement of local surgery\n",
      "measurement of level\n",
      "measurement of receive\n",
      "measurement of following\n",
      "measurement of patient group characteristics\n",
      "measurement of sunitinib\n",
      "measurement of palliative\n",
      "measurement of colorectal combination therapy\n",
      "measurement of hospital\n",
      "measurement of high\n",
      "measurement of accuracy\n",
      "measurement of blood levels\n",
      "measurement of greater\n",
      "measurement of screening\n",
      "measurement of chemotherapy effectiveness\n",
      "measurement of randomized\n",
      "measurement of gastric treatment\n",
      "measurement of everolimus\n",
      "measurement of dose\n",
      "measurement of dosing\n",
      "measurement of bowel\n",
      "measurement of intervention\n",
      "measurement of anastomotic\n"
     ]
    }
   ],
   "source": [
    "#every outputted class/measurement for the BOW model\n",
    "for elem in unique_flat_list_lda:\n",
    "    print (elem)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "5410bfa3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "477"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#amount of classes\n",
    "len(unique_flat_list_tfidf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "55f927c4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "289"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(unique_flat_list_lda)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "604f8d85",
   "metadata": {},
   "outputs": [],
   "source": [
    "from owlready2 import *\n",
    "onto_path=(r\"C:\\Users\\PC\\Downloads\\lab_sessions\\lab6\\ontology.owl\")\n",
    "onto=get_ontology(onto_path).load()\n",
    "# Access classes in the ontology\n",
    "golden_ontology_measurements_list=[]\n",
    "for cls in onto.classes():\n",
    "    class_name = cls.label.first() if cls.label else cls.name\n",
    "    golden_ontology_measurements_list.append(class_name)\n",
    "    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "c186d06e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['clinical measurement',\n",
       " 'cardiovascular measurement',\n",
       " 'blood pressure measurement',\n",
       " 'calculated blood pressure',\n",
       " 'whole body morphological measurement',\n",
       " 'body morphological measurement',\n",
       " 'body weight',\n",
       " 'body length',\n",
       " 'hip circumference',\n",
       " 'body temperature',\n",
       " 'proximal hind limb circumference',\n",
       " 'hind limb morphological measurement',\n",
       " 'waist to hip ratio (WHR)',\n",
       " 'calculated body morphological measurement',\n",
       " 'blood chemistry measurement',\n",
       " 'blood measurement',\n",
       " 'red blood cell count',\n",
       " 'red blood cell morphological measurement',\n",
       " 'blood hemoglobin level',\n",
       " 'hemoglobin measurement',\n",
       " 'white blood cell count',\n",
       " 'immune cell count',\n",
       " 'white blood cell measurement',\n",
       " 'blood protein measurement',\n",
       " 'platelet count',\n",
       " 'platelet morphological measurement',\n",
       " 'hematocrit',\n",
       " 'blood viscosity measurement',\n",
       " 'mean corpuscular volume',\n",
       " 'plasma glucose level',\n",
       " 'blood glucose level',\n",
       " 'plasma alanine aminotransferase activity level',\n",
       " 'blood alanine aminotransferase activity level',\n",
       " 'blood urea nitrogen level',\n",
       " 'blood urea level',\n",
       " 'blood lipid measurement',\n",
       " 'plasma total protein level',\n",
       " 'plasma globulin level',\n",
       " 'plasma albumin level',\n",
       " 'blood albumin level',\n",
       " 'plasma phosphate level',\n",
       " 'blood phosphate level',\n",
       " 'plasma chloride level',\n",
       " 'blood chloride level',\n",
       " 'plasma sodium level',\n",
       " 'blood sodium level',\n",
       " 'plasma potassium level',\n",
       " 'blood potassium level',\n",
       " 'blood electrolyte measurement',\n",
       " 'blood enzyme activity level',\n",
       " 'blood enzyme measurement',\n",
       " 'plasma calcium level',\n",
       " 'blood calcium level',\n",
       " 'organ morphological measurement',\n",
       " 'organ measurement',\n",
       " 'heart weight as percentage of body weight',\n",
       " 'blood vessel measurement',\n",
       " 'body length, nose to tail',\n",
       " 'body length, nose to rump',\n",
       " 'abdominal fat pad weight',\n",
       " 'abdominal fat morphological measurement',\n",
       " 'body fat morphological measurement',\n",
       " 'liver/biliary morphological measurement',\n",
       " 'renal/urinary morphological measurement',\n",
       " 'abdominal fat pad weight to body weight ratio',\n",
       " 'calculated abdominal fat pad weight',\n",
       " 'body mass index (BMI)',\n",
       " 'calculated body weight measurement',\n",
       " 'body height',\n",
       " 'plasma angiotensin I converting enzyme activity level',\n",
       " 'blood angiotensin I converting enzyme activity level',\n",
       " 'blood free fatty acids level',\n",
       " 'blood triglyceride level',\n",
       " 'mean corpuscular hemoglobin level',\n",
       " 'mean corpuscular hemoglobin',\n",
       " 'blood sex steroid level',\n",
       " 'blood steroid hormone level',\n",
       " 'muscle morphological measurement',\n",
       " 'muscle measurement',\n",
       " 'muscle weight',\n",
       " 'both kidneys wet weight as percentage of body weight',\n",
       " 'liver weight as percentage of body weight',\n",
       " 'lung weight, single',\n",
       " 'head morphological measurement',\n",
       " 'head circumference',\n",
       " 'skull volume',\n",
       " 'limb morphological measurement',\n",
       " 'distal hind limb circumference',\n",
       " 'distal forelimb circumference',\n",
       " 'forelimb morphological measurement',\n",
       " 'forelimb length',\n",
       " 'hind limb length',\n",
       " 'tail morphological measurement',\n",
       " 'tail length',\n",
       " 'blood viscoelasticity',\n",
       " 'plasma magnesium level',\n",
       " 'blood magnesium level',\n",
       " 'body region fat morphological measurement',\n",
       " 'arterial blood gas measurement',\n",
       " 'blood gas measurement',\n",
       " 'body fat percentage, Lukaski equation',\n",
       " 'body fat percentage',\n",
       " 'cell measurement',\n",
       " 'waist circumference',\n",
       " 'abdominal morphological measurement',\n",
       " 'total abdominal fat area',\n",
       " 'abdominal visceral fat area',\n",
       " 'abdominal subcutaneous fat area',\n",
       " 'partial pressure of blood carbon dioxide (Pco2)',\n",
       " 'serum carboxyhemoglobin level',\n",
       " 'blood carboxyhemoglobin level',\n",
       " 'blood peptide hormone level',\n",
       " 'blood hormone level',\n",
       " 'calculated blood hemoglobin level',\n",
       " 'red blood cell molecular composition measurement',\n",
       " 'mean corpuscular hemoglobin concentration',\n",
       " 'pulse pressure',\n",
       " 'pulse',\n",
       " 'elbow breadth',\n",
       " 'upright sagittal abdominal diameter',\n",
       " 'supine abdominal height',\n",
       " 'absolute change in partial pressure of blood carbon dioxide',\n",
       " 'absolute change in partial pressure of blood oxygen',\n",
       " 'absolute change in blood pH',\n",
       " 'blood pH',\n",
       " 'body density',\n",
       " 'calculated body fat morphological measurement',\n",
       " 'body fat percentage, Siri equation',\n",
       " 'fat mass index (FMI)',\n",
       " 'total body fat weight',\n",
       " 'fat free mass index (FFMI)',\n",
       " 'body fat percentage, Lohman equation',\n",
       " 'body fat percentage, Schutte equation',\n",
       " 'body fat percentage, Ortiz equation',\n",
       " 'abdominal fat weight',\n",
       " 'central abdominal fat pad weight',\n",
       " 'arm span',\n",
       " 'chest circumference',\n",
       " 'proximal forelimb circumference',\n",
       " 'retina cell count',\n",
       " 'intestine morphological measurement',\n",
       " 'gastrointestinal tract morphological measurement',\n",
       " 'intestine measurement',\n",
       " 'intestine length',\n",
       " 'intestine weight',\n",
       " 'tumor measurement',\n",
       " 'blood insulin level',\n",
       " 'blood glucose level area under curve (AUC)',\n",
       " 'calculated blood glucose level',\n",
       " 'blood insulin level area under curve (AUC)',\n",
       " 'calculated blood insulin level',\n",
       " 'change in blood insulin level',\n",
       " 'mesenteric fat pad weight',\n",
       " 'retroperitoneal fat pad weight',\n",
       " 'epididymal fat pad weight',\n",
       " 'epididymal fat pad morphological measurement',\n",
       " 'serum triglyceride level',\n",
       " 'complete blood cell count',\n",
       " 'total white blood cell count',\n",
       " 'calculated white blood cell measurement',\n",
       " 'total plasma calcium level',\n",
       " 'partial pressure of blood oxygen',\n",
       " 'growth measurement',\n",
       " 'average daily body weight gain',\n",
       " 'body weight gain',\n",
       " 'change in body weight',\n",
       " 'carcass morphological measurement',\n",
       " 'carcass length',\n",
       " 'forelimb weight',\n",
       " 'wing weight',\n",
       " 'consumption measurement',\n",
       " 'back fat morphological measurement',\n",
       " 'back fat weight',\n",
       " 'calculated back fat morphological measurement',\n",
       " 'calculated body region fat morphological measurement',\n",
       " 'back fat percentage',\n",
       " 'back fat thickness',\n",
       " 'back fat thickness, 10th rib',\n",
       " 'back fat thickness, midpoint',\n",
       " 'back fat thickness, 3rd lumbar vertebra',\n",
       " 'back fat thickness, 1st rib',\n",
       " 'skeleton morphological measurement',\n",
       " 'skeletal system measurement',\n",
       " 'tail weight',\n",
       " 'bone morphological measurement',\n",
       " 'bone measurement',\n",
       " 'total muscle weight',\n",
       " 'carcass circumference, butt',\n",
       " 'carcass weight',\n",
       " 'total skeletal weight',\n",
       " 'carcass skeletal weight',\n",
       " 'carcass width',\n",
       " 'horn number',\n",
       " 'small intestine weight',\n",
       " 'large intestine weight',\n",
       " 'carcass length, first cervical vertebra to pelvis',\n",
       " 'carcass length, first rib to pelvis',\n",
       " 'plasma antibody level',\n",
       " 'blood antibody level',\n",
       " 'adipose tissue molecular composition measurement',\n",
       " 'adipose tissue adiponectin level',\n",
       " 'serum sodium level',\n",
       " 'hemoglobin concentration',\n",
       " 'hemoglobin absorbance',\n",
       " 'blood testosterone level',\n",
       " 'blood estradiol level',\n",
       " 'blood progesterone level',\n",
       " 'plasma creatinine level',\n",
       " 'blood creatinine level',\n",
       " 'blood creatinine measurement',\n",
       " 'heart left ventricle weight as a percentage of body weight',\n",
       " 'plasma lipid level',\n",
       " 'serum lipid level',\n",
       " 'plasma free fatty acids level',\n",
       " 'serum free fatty acids level',\n",
       " 'plasma triglyceride level',\n",
       " 'serum albumin level',\n",
       " 'blood apolipoprotein level',\n",
       " 'plasma estradiol level',\n",
       " 'plasma progesterone level',\n",
       " 'plasma testosterone level',\n",
       " 'serum alanine aminotransferase activity level',\n",
       " 'plasma urea nitrogen level',\n",
       " 'serum urea nitrogen level',\n",
       " 'plasma hemoglobin level',\n",
       " 'plasma carboxyhemoglobin level',\n",
       " 'CD25+ cell count',\n",
       " 'CD4+ cell count',\n",
       " 'single adrenal gland weight to body weight ratio',\n",
       " 'both adrenal glands weight as percentage of body weight',\n",
       " 'single kidney wet weight as percentage of body weight',\n",
       " 'heart right ventricle wet weight',\n",
       " 'lung weight',\n",
       " 'calculated retroperitoneal fat pad weight',\n",
       " 'retroperitoneal fat pad weight to body weight ratio',\n",
       " 'sperm count',\n",
       " 'calculated mesenteric fat pad weight',\n",
       " 'mesenteric fat pad weight to body weight ratio',\n",
       " 'heart left ventricle wet weight',\n",
       " 'epididymal fat pad weight to body weight ratio',\n",
       " 'calculated epididymal fat pad weight',\n",
       " 'blood globulin measurement',\n",
       " 'serum globulin level',\n",
       " 'blood lactate dehydrogenase activity level',\n",
       " 'plasma lactate dehydrogenase activity level',\n",
       " 'organ lesion measurement',\n",
       " 'infarction measurement',\n",
       " 'organ non-tumorous lesion measurement',\n",
       " 'organ infarction size measurement',\n",
       " 'calculated heart left ventricle infarction size',\n",
       " 'heart left ventricle infarction size to total heart left ventricle size ratio',\n",
       " 'organ infarction weight',\n",
       " 'organ infarction area',\n",
       " 'absolute change in body temperature',\n",
       " 'blood vessel resistance measurement',\n",
       " 'pulmonary vascular resistance (PVR)',\n",
       " 'calculated pulmonary vascular resistance',\n",
       " 'chemical response/sensitivity measurement',\n",
       " 'concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)',\n",
       " 'sodium nitroprusside response/sensitivity measurement',\n",
       " 'change in calculated blood pressure',\n",
       " 'blood metabolite measurement',\n",
       " 'calculated plasma creatinine level',\n",
       " 'organ tumorous lesion measurement',\n",
       " 'musculoskeletal system measurement',\n",
       " 'joint measurement',\n",
       " 'joint inflammation measurement',\n",
       " 'joint inflammation composite score',\n",
       " 'platelet measurement',\n",
       " 'platelet intracellular calcium level',\n",
       " 'platelet physiological measurement',\n",
       " 'platelet function measurement',\n",
       " 'organ tumorous lesion incidence/prevalence measurement',\n",
       " 'organ non-tumorous lesion incidence/prevalence measurement',\n",
       " 'body movement measurement',\n",
       " 'body movement/balance measurement',\n",
       " 'heart left ventricle end-diastolic relative wall thickness',\n",
       " 'alimentary/gastrointestinal measurement',\n",
       " 'organ infarction volume',\n",
       " 'mortality/survival measurement',\n",
       " 'survival measurement',\n",
       " 'mortality measurement',\n",
       " 'ratio of deaths to total study population during a period of time',\n",
       " 'percentage of deaths in a study population during a period of time',\n",
       " 'head temperature',\n",
       " 'core body temperature',\n",
       " 'number of prompted entries into a discrete space in an experimental apparatus',\n",
       " 'number of unprompted entries into a discrete space in an experimental apparatus',\n",
       " 'pancreatic islet area to total pancreatic area ratio',\n",
       " 'beta cell area to total pancreatic islet area ratio',\n",
       " 'liver tumorous lesion measurement',\n",
       " 'area of liver occupied by tumorous lesions as percentage of total liver area',\n",
       " 'volume of liver occupied by tumorous lesions as percentage of total liver volume',\n",
       " 'liver fibrotic lesion area to total liver area ratio',\n",
       " 'blood Th1 cell to Th2 cell ratio as percentage',\n",
       " 'disease process measurement',\n",
       " 'disease onset/diagnosis measurement',\n",
       " 'disease severity measurement',\n",
       " 'disease progression measurement',\n",
       " 'calculated skeletal muscle morphological measurement',\n",
       " 'skeletal muscle morphological measurement',\n",
       " 'skeletal muscle weight',\n",
       " 'blood phospholipid level',\n",
       " 'plasma phospholipid level',\n",
       " 'serum phospholipid level',\n",
       " 'kidney glomerulosclerotic lesion count to total glomeruli count ratio',\n",
       " 'age at time of death',\n",
       " 'white adipose tissue weight to body weight ratio',\n",
       " 'epididymal plus perirenal white adipose tissue weight to body weight ratio',\n",
       " 'body weight to tibia length ratio',\n",
       " 'epididymal fat pad weight to tibia length ratio',\n",
       " 'small intestine length',\n",
       " 'large intestine length',\n",
       " 'bone mineral density',\n",
       " 'bone mineral morphological measurement',\n",
       " 'blood growth hormone level',\n",
       " 'plasma growth hormone level',\n",
       " 'cubic root of body weight to nasoanal length ratio',\n",
       " 'blood thyroid stimulating hormone level',\n",
       " 'plasma thyroid stimulating hormone level',\n",
       " 'inguinal fat morphological measurement',\n",
       " 'calculated inguinal fat pad weight',\n",
       " 'inguinal fat pad weight',\n",
       " 'inguinal fat pad weight to body weight ratio',\n",
       " 'blood troponin level',\n",
       " 'blood troponin T level',\n",
       " 'serum troponin T level',\n",
       " 'plasma troponin T level',\n",
       " 'blood thyroid hormone level',\n",
       " 'blood thyroxine level',\n",
       " 'plasma thyroxine level',\n",
       " 'serum thyroxine level',\n",
       " 'blood triiodothyronine level',\n",
       " 'plasma triiodothyronine level',\n",
       " 'serum triiodothyronine level',\n",
       " 'feed conversion ratio',\n",
       " 'blood carbon dioxide level',\n",
       " 'blood oxygen measurement',\n",
       " 'oxygen saturation',\n",
       " 'base excess',\n",
       " 'body height at withers',\n",
       " 'body height at hip',\n",
       " 'mean platelet volume',\n",
       " 'plateletcrit',\n",
       " 'platelet distribution width',\n",
       " 'calculated platelet morphological measurement',\n",
       " 'red blood cell measurement',\n",
       " 'red blood cell Na+/K+ ATPase activity',\n",
       " 'red blood cell physiological measurement',\n",
       " 'calculated blood thyroid hormone level',\n",
       " 'blood triiodothyronine to thyroxine ratio',\n",
       " 'skin measurement',\n",
       " 'back fat thickness, last rib',\n",
       " 'back fat thickness, last lumbar vertebra',\n",
       " 'body weight loss',\n",
       " 'maximum body weight loss to initial body weight ratio',\n",
       " 'joint mobility measurement',\n",
       " 'time to first movement outside a discrete space in a an experimental apparatus following a stimulus',\n",
       " 'hind limb weight',\n",
       " 'involuntary body movement measurement',\n",
       " 'acoustic startle response measurement',\n",
       " 'serum globulin measurement',\n",
       " 'plasma globulin measurement',\n",
       " 'blood immunoglobulin measurement',\n",
       " 'immunoglobulin measurement',\n",
       " 'blood globulin measurement',\n",
       " 'plasma E. coli specific antibody measurement',\n",
       " 'bone physiological measurement',\n",
       " 'bone mineral content',\n",
       " 'calculated bone mineral content measurement',\n",
       " 'bone mineral content to body weight ratio',\n",
       " 'calculated bone biomechanical measurement',\n",
       " 'immune system measurement',\n",
       " 'single inguinal fat pad weight to body weight ratio',\n",
       " 'both inguinal fat pads weight to body weight ratio',\n",
       " 'bone area measurement',\n",
       " 'bone cross-sectional area measurement',\n",
       " 'balance measurement',\n",
       " 'colorectal tumor measurement',\n",
       " 'colorectal tumor number',\n",
       " 'benign colorectal tumor number',\n",
       " 'malignant colorectal tumor number',\n",
       " 'colorectal tumor surface area measurement',\n",
       " 'malignant colorectal tumor surface area measurement',\n",
       " 'colorectal tumor incidence/prevalence measurement',\n",
       " 'percentage of study population developing colorectal tumors during a period of time',\n",
       " 'coat/hair morphological measurement',\n",
       " 'coat/hair color measurement',\n",
       " 'calculated coat/hair color measurement',\n",
       " 'pigmented coat/hair area to total coat/hair area ratio',\n",
       " 'pigmented dorsal coat/hair area to total dorsal coat/hair area ratio',\n",
       " 'pigmented ventral coat/hair area to total ventral coat/hair area ratio',\n",
       " 'infection severity measurement',\n",
       " 'parasitic infection severity measurement',\n",
       " 'parasite count',\n",
       " 'antibody measurement',\n",
       " 'blood anti-parasite antibody measurement',\n",
       " 'immune cell measurement',\n",
       " 'absolute change in pulse pressure',\n",
       " 'stomach measurement',\n",
       " 'stomach lesion measurement',\n",
       " 'stomach tumorous lesion measurement',\n",
       " 'stomach non-tumorous lesion measurement',\n",
       " 'stomach tumor measurement',\n",
       " 'stomach tumor depth of invasion',\n",
       " 'stomach tumor diameter',\n",
       " 'stomach tumor number',\n",
       " 'moribundity measurement',\n",
       " 'post-insult time to onset of moribundity',\n",
       " 'blood cytokine measurement',\n",
       " 'blood interleukin measurement',\n",
       " 'front foot morphological measurement',\n",
       " 'front foot phalanges count',\n",
       " 'hind foot morphological measurement',\n",
       " 'hind foot phalanges count',\n",
       " 'post-insult time of death',\n",
       " 'absolute change in blood glucose level area under curve',\n",
       " 'calculated serum triglyceride level',\n",
       " 'stomach tumor susceptibility score',\n",
       " 'absolute change in body weight',\n",
       " 'serum sterol level',\n",
       " 'plasma sterol level',\n",
       " 'abdominal subcutaneous fat pad weight',\n",
       " 'blood autoantibody level',\n",
       " 'calculated plasma albumin level',\n",
       " 'plasma albumin to plasma non-albumin protein ratio',\n",
       " 'joint morphological measurement',\n",
       " 'joint diameter',\n",
       " 'liver disease severity measurement',\n",
       " 'calculated plasma insulin level',\n",
       " 'body fat volume',\n",
       " 'total body fat volume',\n",
       " 'whole body subcutaneous fat volume',\n",
       " 'whole body visceral fat volume',\n",
       " 'lean tissue morphological measurement',\n",
       " 'lean tissue volume',\n",
       " 'whole body lean tissue volume',\n",
       " 'renal fat pad morphological measurement',\n",
       " 'renal fat pad volume',\n",
       " 'renal fat pad weight',\n",
       " 'left renal fat pad weight',\n",
       " 'right renal fat pad weight',\n",
       " 'left renal fat pad weight to body weight ratio',\n",
       " 'change in body weight to body weight ratio',\n",
       " 'change in body weight to final body weight ratio',\n",
       " 'change in body weight to initial body weight ratio',\n",
       " 'blood creatine kinase activity level',\n",
       " 'plasma creatine kinase activity level',\n",
       " 'serum creatine kinase activity level',\n",
       " 'calorie intake measurement',\n",
       " 'liver non-tumorous lesion incidence/prevalence measurement',\n",
       " 'kidney non-tumorous lesion incidence/prevalence measurement',\n",
       " 'spleen non-tumorous lesion incidence/prevalence measurement',\n",
       " 'liver edema incidence/prevalence measurement',\n",
       " 'percentage of study population developing liver edema during a period of time',\n",
       " 'percentage of study population displaying liver edema at a point in time',\n",
       " 'percentage of study population displaying liver hyperemia at a point in time',\n",
       " 'liver hyperemia incidence/prevalence measurement',\n",
       " 'percentage of study population developing liver hyperemia during a period of time',\n",
       " 'percentage of study population displaying liver parenchymal degeneration at a point in time',\n",
       " 'liver parenchymal degeneration incidence/prevalence measurement',\n",
       " 'percentage of study population developing liver parenchymal degeneration during a period of time',\n",
       " 'percentage of study population displaying kidney edema at a point in time',\n",
       " 'kidney edema incidence/prevalence measurement',\n",
       " 'percentage of study population developing kidney edema during a period of time',\n",
       " 'percentage of study population displaying kidney tubular degeneration at a point in time',\n",
       " 'kidney tubular degeneration incidence/prevalence measurement',\n",
       " 'percentage of study population developing kidney tubular degeneration during a period of time',\n",
       " 'kidney tubulointerstitial damage incidence/prevalence measurement',\n",
       " 'percentage of study population displaying spleen fibrosis at a point in time',\n",
       " 'spleen fibrosis incidence/prevalence measurement',\n",
       " 'percentage of study population developing spleen fibrosis during a period of time',\n",
       " 'stomach tumor incidence/prevalence measurement',\n",
       " 'calculated balance measurement',\n",
       " 'calculated body weight estimate',\n",
       " 'plasma albumin to plasma total protein ratio',\n",
       " 'alimentary/gastrointestinal disease incidence/prevalence measurement',\n",
       " 'anogenital distance',\n",
       " 'stomach tumor histology grade',\n",
       " 'blood globulin level',\n",
       " 'plasma globulin level',\n",
       " 'calculated blood globulin level',\n",
       " 'blood superoxide dismutase activity level',\n",
       " 'plasma superoxide dismutase activity level',\n",
       " 'blood malondialdehyde level',\n",
       " 'plasma malondialdehyde level',\n",
       " 'serum retinol level',\n",
       " 'blood retinol level',\n",
       " 'plasma retinol level',\n",
       " 'blood vitamin level',\n",
       " 'potassium chloride response/sensitivity measurement',\n",
       " 'concentration of potassium chloride at which the force of blood vessel contraction is half the maximum value (EC50)',\n",
       " 'blood glutamate dehydrogenase activity level',\n",
       " 'serum glutamate dehydrogenase activity level',\n",
       " 'plasma glutamate dehydrogenase activity level',\n",
       " 'parasite size measurement',\n",
       " 'parasite length',\n",
       " 'skeletal muscle fiber density',\n",
       " 'skeletal muscle length',\n",
       " 'muscle length',\n",
       " 'white blood cell radioactive nucleoside incorporation',\n",
       " 'blood haptoglobin level',\n",
       " 'plasma haptoglobin level',\n",
       " 'absolute change in hematocrit',\n",
       " 'percent change in hematocrit',\n",
       " 'adult parasite count',\n",
       " 'parasite egg/oocyst count',\n",
       " 'fecal parasite egg count',\n",
       " 'fecal parasite oocyst count',\n",
       " 'basal white blood cell radioactive nucleoside incorporation',\n",
       " 'blood pressure time series calculated parameter',\n",
       " 'blood pressure time series',\n",
       " 'blood anti-DNA antibody level',\n",
       " 'blood anti-collagen antibody level',\n",
       " 'blood anti-laminin antibody level',\n",
       " 'blood antibody titer',\n",
       " 'bone ash content',\n",
       " 'bone calcium content',\n",
       " 'bone phosphorus content',\n",
       " 'total calorie intake level',\n",
       " 'bacterial infection severity measurement',\n",
       " 'bacterial infection severity score',\n",
       " 'bacterial infection severity score based on mucosal leukocyte infiltration',\n",
       " 'bacterial infection severity score based on inflammatory foci in exudate',\n",
       " 'bacteria count',\n",
       " 'total number of bacterial colony forming units recovered',\n",
       " 'logarithm of the total number of bacterial colony forming units recovered',\n",
       " 'logarithm of the total number of Haemophilus influenzae bacterial colony forming units recovered',\n",
       " 'logarithm of the total number of Streptococcus pneumoniae bacterial colony forming units recovered',\n",
       " 'logarithm of the total number of nontypeable Haemophilus influenzae bacterial colony forming units recovered',\n",
       " 'blood glycerol level',\n",
       " 'plasma glycerol level',\n",
       " 'percent change in pulse pressure',\n",
       " 'calculated pulse pressure measurement',\n",
       " 'serum hemoglobin level',\n",
       " 'ratio of survivors to total study population during a period of time',\n",
       " 'anogenital distance to cube root of body weight ratio',\n",
       " 'nose to tail body mass index',\n",
       " 'nose to rump body mass index',\n",
       " 'blood hemoglobin A1c level',\n",
       " 'kidney ribonucleic acid composition measurement',\n",
       " 'body weight to body length (nose to rump) ratio',\n",
       " 'body weight to body length (nose to tail) ratio',\n",
       " 'body weight area under curve (AUC)',\n",
       " 'body weight growth curve measurement',\n",
       " 'calculated whole body visceral fat weight',\n",
       " 'whole body visceral fat weight to body length (nose to rump) ratio',\n",
       " 'systolic blood pressure variability',\n",
       " 'blood glycated albumin level',\n",
       " 'blood glycated albumin level to blood albumin level ratio',\n",
       " 'calculated blood glycated albumin level',\n",
       " 'blood hemoglobin A1c level level to blood hemoglobin level ratio',\n",
       " 'blood parathyroid hormone level',\n",
       " 'plasma parathyroid hormone level',\n",
       " 'arteriolar resistance',\n",
       " 'blood insulin level AUC to blood glucose level AUC ratio',\n",
       " 'whole body insulin sensitivity index',\n",
       " 'gastrointestinal tract weight',\n",
       " 'total reticulocyte count',\n",
       " 'reticulocyte count to total red blood cell count ratio',\n",
       " 'hemoglobin distribution width',\n",
       " 'serum total bile acid',\n",
       " 'blood vascular endothelial growth factor A (VEGF-a)',\n",
       " 'serum vascular endothelial growth factor A (VEGF-a)',\n",
       " 'blood interleukin-4 level',\n",
       " 'intestine protein/peptide measurement',\n",
       " 'intestine enzyme measurement',\n",
       " 'intestine trypsin level',\n",
       " 'initial nifedipine concentration in the plasma',\n",
       " 'the first 120min of plasma nifedipine level area under curve',\n",
       " 'blood reactive oxygen metabolite level',\n",
       " 'serum reactive oxygen metabolite level',\n",
       " 'Myocardial interstitial angiotensin II level',\n",
       " 'myocardial interstitial bradykinin level',\n",
       " 'Myocardial interstitial norepinephrine',\n",
       " 'Myocardial interstitial epinephrine',\n",
       " 'glucose disappearance constant',\n",
       " 'heart left ventricle weight to right ventricle weight ratio',\n",
       " 'serum pyrophosphate level',\n",
       " 'blood pyrophosphate level',\n",
       " 'platelet-large cell ratio',\n",
       " 'calculated platelet count',\n",
       " 'white blood cell ribonucleic acid composition measurement',\n",
       " 'adipose tissue ribonucleic acid composition measurement',\n",
       " 'kidney fractional mesangial volume',\n",
       " 'serum eicosanoid level',\n",
       " 'serum 8-epi-prostaglandin F2alpha level',\n",
       " 'plasma 8-epi-prostaglandin F2alpha level',\n",
       " 'plasma eicosanoid level',\n",
       " 'maximum slope of body weight growth curve',\n",
       " 'blood mineral measurement',\n",
       " 'blood copper level',\n",
       " 'plasma copper level',\n",
       " 'serum copper level',\n",
       " 'plasma insulin level to plasma glucose level ratio',\n",
       " 'calculated plasma glucose level',\n",
       " 'measurement of minimal stimulus needed to elicit evasive reaction',\n",
       " 'measurement of minimal mechanical stimulus needed to elicit evasive reaction',\n",
       " 'liver adult Schistosoma mansoni worm count',\n",
       " 'intestine tumor incidence/prevalence measurement',\n",
       " 'intestine tumor measurement',\n",
       " 'percentage of study population developing intestine tumors during a period of time',\n",
       " 'percentage of study population displaying intestine tumors at a point in time',\n",
       " 'calculated plasma triglyceride level',\n",
       " 'plasma triglyceride level area under curve',\n",
       " 'ileocecal immunocytoma latency period',\n",
       " 'blood gastric inhibitory polypeptide level',\n",
       " 'plasma gastric inhibitory polypeptide level',\n",
       " 'percentage of study population developing kidney tubulointerstitial damage during a period of time',\n",
       " 'percentage of study population developing kidney tubulointerstitial damage at a point in  time',\n",
       " 'blood volume measurement',\n",
       " 'calculated blood volume',\n",
       " 'calculated measurement of mechanical stimulus needed to elicit evasive reaction',\n",
       " 'measurement of the 50% threshold of mechanical stimulus needed to elicit evasive reaction',\n",
       " 'dose of whole thorax lung irradiation at which breathing rate increases for 50% of the total study population',\n",
       " 'pulse wave velocity',\n",
       " 'blood amino acid measurement',\n",
       " 'blood arginine level',\n",
       " 'plasma arginine level',\n",
       " 'calculated plasma arginine level',\n",
       " 'blood lipase activity level',\n",
       " 'plasma lipase activity level',\n",
       " 'intestine physiological measurement',\n",
       " 'calculated anorectal physiological measurement',\n",
       " 'area under the anorectal pressure curve',\n",
       " 'red blood cell sodium level',\n",
       " 'red blood cell potassium level',\n",
       " 'red blood cell ATP level',\n",
       " 'red blood cell Na-K-Cl cotransport activity',\n",
       " 'red blood cell sodium/potassium passive permeability',\n",
       " 'hepatic extraction fraction',\n",
       " 'body length, crown to rump',\n",
       " 'calculated red blood cell Na+/K+ ATPase activity',\n",
       " 'rate constant of red blood cell Na+/K+ ATPase activity',\n",
       " 'calculated red blood cell Na-K-Cl cotransport activity',\n",
       " 'rate constant of red blood cell Na-K-Cl cotransport activity',\n",
       " 'ouabain-sensitive red blood cell Na+ export rate',\n",
       " 'ouabain-sensitive red blood cell K+ import rate',\n",
       " 'bumetanide-sensitive red blood cell Na+ export rate',\n",
       " 'bumetanide-sensitive red blood cell K+ import rate',\n",
       " 'ouabain- and bumetanide-resistant red blood cell Na+ import rate',\n",
       " 'calculated red blood cell sodium/potassium passive permeability',\n",
       " 'ouabain- and bumetanide-resistant red blood cell K+ import rate',\n",
       " 'rate constant of red blood cell sodium/potassium passive permeability',\n",
       " 'serum urea level',\n",
       " 'plasma urea level',\n",
       " 'serum carbon dioxide level',\n",
       " 'serum glucose level area under curve (AUC)',\n",
       " 'serum insulin level area under curve (AUC)',\n",
       " 'combined renal and gonadal fat pad weight',\n",
       " 'calculated bone mineral density measurement',\n",
       " 'total bone mineral density',\n",
       " 'erythrocyte sedimentation rate',\n",
       " 'cell composition measurement',\n",
       " 'MESH_D000073640',\n",
       " 'MESH_D017934',\n",
       " 'MESH_D045473',\n",
       " 'MESH_D065207',\n",
       " 'bowel tumor measurement']"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "golden_ontology_measurements_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "e3fbbd00",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create TF-IDF ontology from parsed classes\n",
    "TFIDF_ontology = get_ontology(\"http://test.org/onto.owl\")\n",
    "TFIDF_list=[]\n",
    "with TFIDF_ontology:\n",
    "    # Define a list of classes\n",
    "    for elem in unique_flat_list_tfidf:\n",
    "        TFIDF_list.append(elem)\n",
    "\n",
    "    # Loop through the list and create classes in the ontology\n",
    "    for class_name in TFIDF_list:\n",
    "        types.new_class(class_name, (Thing,))\n",
    "        \n",
    "#Please make sure to change the directory       \n",
    "directory = os.path.expanduser(r\"C:\\Users\\PC\\Downloads\\lab_sessions\\lab6\")\n",
    "file_path = os.path.join(directory, \"TFIDF.owl\")\n",
    "# Save the ontology to a file\n",
    "TFIDF_ontology.save(file = file_path, format = \"rdfxml\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "dfa23f85",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create BOW ontology from parsed classes\n",
    "BOW_ontology = get_ontology(\"http://test1.org/onto1.owl\")\n",
    "Bow_list=[]\n",
    "with BOW_ontology:\n",
    "    # Define a list of classes\n",
    "    for elem1 in unique_flat_list_lda:\n",
    "        Bow_list.append(elem1)\n",
    "\n",
    "    # Loop through the list and create classes in the ontology\n",
    "    for class_name1 in Bow_list:\n",
    "        types.new_class(class_name1, (Thing,))\n",
    "\n",
    "#Please make sure to change the directory\n",
    "directory = os.path.expanduser(r\"C:\\Users\\PC\\Downloads\\lab_sessions\\lab6\")\n",
    "file_path1 = os.path.join(directory, \"BOW.owl\")\n",
    "# Save the ontology to a file\n",
    "BOW_ontology.save(file = file_path1, format = \"rdfxml\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "1330acf8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 99 matching elements in the two sets.\n"
     ]
    }
   ],
   "source": [
    "def hash_list(lst):\n",
    "    \"\"\"Hash a list by creating a sorted tuple of its unique elements\"\"\"\n",
    "    return tuple(sorted(set(lst)))\n",
    "\n",
    "def count_matching_lists(list_of_lists1, list_of_lists2):\n",
    "    hash_set1 = {hash_list(lst) for lst in list_of_lists1}\n",
    "    hash_set2 = {hash_list(lst) for lst in list_of_lists2}\n",
    "\n",
    "    matches = hash_set1.intersection(hash_set2)\n",
    "\n",
    "    return len(matches)\n",
    "\n",
    "count = count_matching_lists(unique_flat_list_tfidf, unique_flat_list_lda)\n",
    "\n",
    "print(f\"There are {count} matching elements in the two sets.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "a30749f1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "659"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#number of classes in golden ontology\n",
    "len(golden_ontology_measurements_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "ba57a057",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Dataset names and sizes\n",
    "dataset_names = ['Bag_Of_Words', 'TF_IDF', 'Golden']\n",
    "dataset_sizes = [len(unique_flat_list_lda), len(unique_flat_list_tfidf), len(golden_ontology_measurements_list)]\n",
    "\n",
    "# Define colors for each dataset\n",
    "dataset_colors = ['blue', 'green', 'orange']\n",
    "\n",
    "# Create bar chart\n",
    "plt.bar(dataset_names, dataset_sizes, color=dataset_colors)\n",
    "\n",
    "# Add labels and title\n",
    "plt.xlabel('Dataset')\n",
    "plt.ylabel('Size')\n",
    "plt.title('Number of classes by method')\n",
    "\n",
    "# Display the bar chart\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "5b6eeaeb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Total number of classes\n",
    "total_classes = [len(unique_flat_list_lda),len(unique_flat_list_tfidf) ]\n",
    "\n",
    "# Number of overlapping classes\n",
    "overlapping_classes = [111,111]\n",
    "\n",
    "# Dataset names\n",
    "dataset_names = ['Bag_Of_Words', 'TF_IDF']\n",
    "\n",
    "\n",
    "# Define colors for each dataset\n",
    "dataset_colors = ['blue', 'green']\n",
    "\n",
    "# Create bar chart for total classes\n",
    "plt.bar(dataset_names, total_classes, color=dataset_colors, label='Total Classes')\n",
    "\n",
    "# Create bar chart for overlapping classes\n",
    "plt.bar(dataset_names, overlapping_classes, color='purple', label=' absolute Overlapping Classes')\n",
    "\n",
    "# Add labels and title\n",
    "plt.xlabel('Ontologies')\n",
    "plt.ylabel('Number of Classes')\n",
    "plt.title('Number of Classes in automated ontologies and their coverage between each other  ')\n",
    "\n",
    "\n",
    "\n",
    "# Add legend\n",
    "plt.legend()\n",
    "\n",
    "\n",
    "\n",
    "# Display the bar chart\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "1eebcb57",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\PC\\anaconda3\\lib\\site-packages\\seaborn\\_decorators.py:36: FutureWarning: Pass the following variables as keyword args: x, y. From version 0.12, the only valid positional argument will be `data`, and passing other arguments without an explicit keyword will result in an error or misinterpretation.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1500x927.07 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Load the library with the CountVectorizer method\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "import numpy as np\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "sns.set_style('whitegrid')\n",
    "%matplotlib inline\n",
    "\n",
    "# Helper function\n",
    "def plot_20_most_common_words(count_data, count_vectorizer):\n",
    "    import matplotlib.pyplot as plt\n",
    "    words = count_vectorizer.get_feature_names_out()\n",
    "    total_counts = np.zeros(len(words))\n",
    "    for t in count_data:\n",
    "        total_counts+=t.toarray()[0]\n",
    "    \n",
    "    count_dict = (zip(words, total_counts))\n",
    "    count_dict = sorted(count_dict, key=lambda x:x[1], reverse=True)[0:20]\n",
    "    words = [w[0] for w in count_dict]\n",
    "    counts = [w[1] for w in count_dict]\n",
    "    x_pos = np.arange(len(words)) \n",
    "    \n",
    "    plt.figure(2, figsize=(15, 15/1.6180))\n",
    "    plt.subplot(title='20 most common words')\n",
    "    sns.set_context(\"notebook\", font_scale=1.25, rc={\"lines.linewidth\": 2.5})\n",
    "    sns.barplot(x_pos, counts, palette='husl')\n",
    "    plt.xticks(x_pos, words, rotation=90) \n",
    "    plt.xlabel('words')\n",
    "    plt.ylabel('counts')\n",
    "    plt.show()\n",
    "\n",
    "# Initialise the count vectorizer with the English stop words\n",
    "count_vectorizer = CountVectorizer(stop_words='english')\n",
    "\n",
    "# Fit and transform the processed titles\n",
    "summary_data = count_vectorizer.fit_transform(papers2['Summary'])\n",
    "\n",
    "\n",
    "# Visualise the 10 most common words\n",
    "plot_20_most_common_words(summary_data, count_vectorizer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9c3c6173",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "ae82bd24",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\PC\\anaconda3\\lib\\site-packages\\seaborn\\_decorators.py:36: FutureWarning: Pass the following variables as keyword args: x, y. From version 0.12, the only valid positional argument will be `data`, and passing other arguments without an explicit keyword will result in an error or misinterpretation.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1500x927.07 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "def plot_20_most_common_words_avg2(count_data, count_vectorizer, total_papers):\n",
    "    import matplotlib.pyplot as plt\n",
    "    words = count_vectorizer.get_feature_names_out()\n",
    "    total_counts = np.zeros(len(words))\n",
    "    for t in count_data:\n",
    "        total_counts+=t.toarray()[0]\n",
    "    \n",
    "    # calculate average counts\n",
    "    avg_counts = total_counts/total_papers\n",
    "    \n",
    "    count_dict = (zip(words, avg_counts))\n",
    "    count_dict = sorted(count_dict, key=lambda x:x[1], reverse=True)[0:20]\n",
    "    words = [w[0] for w in count_dict]\n",
    "    counts = [w[1] for w in count_dict]\n",
    "    x_pos = np.arange(len(words)) \n",
    "    \n",
    "    plt.figure(2, figsize=(15, 15/1.6180))\n",
    "    plt.subplot(title='frequency of words per paper')\n",
    "    sns.set_context(\"notebook\", font_scale=1.25, rc={\"lines.linewidth\": 2.5})\n",
    "    sns.barplot(x_pos, counts, palette='husl')\n",
    "    plt.xticks(x_pos, words, rotation=90) \n",
    "    plt.xlabel('words')\n",
    "    #plt.ylabel('average counts per paper')\n",
    "    plt.show()\n",
    "\n",
    "# Initialise the count vectorizer with the English stop words\n",
    "count_vectorizer = CountVectorizer(stop_words='english')\n",
    "\n",
    "# Fit and transform the processed titles\n",
    "summary_data = count_vectorizer.fit_transform(papers2['Summary'])\n",
    "\n",
    "# Total number of papers\n",
    "total_papers = 4763\n",
    "\n",
    "# Visualise the 10 most common words\n",
    "plot_20_most_common_words_avg2(summary_data, count_vectorizer, total_papers)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ee18bfa8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e88dd9f2",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4e7f37f8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "84a4abfd",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
